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Abstract  
 
 
 
Parkinson’s disease (PD) is one of the most common neurodegenerative 
diseases. It is characterized by the presence of intracellular inclusions termed 
Lewy bodies (LBs) and Lewy neuritis (LNs) in the brain, in which α-Syn 
aggregates constitute the main component. Therefore, α-Syn aggregation was 
implicated in the pathogenesis of PD. Structurally α-Syn is a disordered protein 
with little ordered structure under physiological conditions. However, research of 
α-Syn has provided substantial information about its structural properties. The 
precise function of α-Syn is still under investigation. Research has also shown 
that metals, such as copper and iron, accelerate α-Syn aggregation and 
fibrillation in vitro and are proposed to play an important role in vitro. In this study, 
isothermal titration calorimetry was used to determine iron binding properties to 
α-Syn revealing the presence of two binding sites for iron with an affinity of 1.06 x 
105 M-1 and a dissociation constant of ~ 10µM which is physiologically relevant to 
iron content in the brain. In addition, α-Syn was found to reduce iron in the 
presence of copper. This property was demonstrated via ferrozine based assay. 
In vitro, thoflavin-T fluorescence assay was used to investigate the mechanism 
by which metals induce α-Syn aggregation and whether it is related to metal 
binding. Metals, mainly copper and iron, caused 2-fold increase in the 
aggregation rate of WT α-Syn and its metal binding mutants. Linking that to the 
increased metal content in the brain, α-Syn aggregation can cause changes in 
tissue composition, thus altering the normal functional environment in the brain. 
Moreover, western blotting analysis showed that copper increases the aggregate 
formation in mammalian dopaminergic cells over-expressing α-Syn. 
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Chapter One: Introduction 
 
 
 
1.1  Background of Parkinson’s Disease 
 
 
Parkinson’s disease (PD) is one of the most common neurodegenerative 
diseases. It has been defined as a movement illness accompanied by neuronal 
loss of dopaminergic neurons in the nigrostriatal system, in particular neurons in 
the substantia nigra pars compacta (SNpc) (Forno 1996; Dauer and Przedborski 
2003). Parkinson’s disease is classified as non-genetic disease, since the 
majority of cases occur sporadically and for unknown reasons. Epidemiological 
studies suggest that environmental factors may play an important role in most 
sporadic cases of the disease (Tanner 2003; Wirdefeldt, Adami et al. 2011) 
where no apparent genetic linkage was established (Dauer and Przedborski 
2003). In concept, cases of sporadic appearance (ie, not inherited) is referred to 
as idiopathic PD (IPD). Nevertheless, some of the late onset cases of sporadic 
PD have been shown to result from and associate with genetic changes (Gilks, 
Abou-Sleiman et al. 2005) or a complex interaction between genetic and 
environmental factors (Maraganore, Farrer et al. 2003).  
 
 
The aetiology of PD is not well known and regardless of the abundancy of 
sporadic cases of the disease, approximately 10% of the cases are thought to 
have genetic origin. The identification of inherited forms of PD is considered to be 
a crucial step forward in understanding the mechanisms behind the disease 
pathology. Mendelian inheritance of the disease trait or the presence of the 
disease among patients with familial relations introduced the term, familial PD. 
Several gene mutations have been described in patients with familial forms of the 
disease, including mutations in alpha synuclein gene and Parkin gene (Hardy, 
Cai et al. 2006).  
 15 
 
 
Specific clinical criteria has been established for IPD based on late age of 
disease onset, typically in the seventh decade, the absence of a family history 
and is confirmed by a post-mortem analysis showing neuronal loss in the brain 
and the presence of Lewy bodies (LBs) and Lewy neuritis (LNs) in the surviving 
neurons (Figure 1.1). The presence of the classical symptom triad of the disease, 
such as resting tremor, rigidity, bradykinesia in addition to good response to 
levodopa therapy (Gibb 1988; Gibb and Lees 1988) are also included in the 
clinical criteria of PD. Both familial and idiopathic PD is almost clinically 
indistinguishable. Nevertheless, patients with familial disease can display some 
features that are not found in patients with IPD, such as early age of disease 
onset which ranges between 30-60 years (Olanow and McNaught 2006).  
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Fig. 1.1 α-Syn-positive inclusions in patients with neurodegenerative disease. 
Inclusions in patients with Dementia with Lewy body (DLB) (a and b), and with PD 
(c) immunostained for alpha synuclein. a, α-Syn-positive Lewy neurites in the 
SNpc. b, α-Syn-positive Lewy body (arrow) in pigmented nerve cell of the SN 
(Spillantini, Schmidt et al. 1997). c, Lewy bodies in the SNpc of PD brain. 
 
 
1.2 Familial Parkinson’s disease 
              
Several gene mutations have been described in patients with familial form of the 
disease (Hardy, Cai et al. 2006). 
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1.2.1 Alpha-synuclein gene  
 
Alpha-synuclein gene (SNCA) was the first gene to be associated with familial 
PD. Three point mutations, as well as duplications and triplications in the SNCA 
gene, have been described in affected individuals with the disease. The first point 
mutation, causing alanine to threonine substitution at position 53 of the alpha-
synuclein (α-Syn) protein (Ala53Thr), has been first reported in Italian-American 
family known as the Contursi kindred and in another three unrelated families of 
Greek origin (Polymeropoulos, Lavedan et al. 1997). This was followed by the 
recognition of another form of α-Syn mediated familial PD within patients of 
German origin with a second point mutation resulting in the substitution of alanine 
to proline at residue 30 (Ala30Pro) (Kruger, Kuhn et al. 1998). More recently, a 
third point mutation in SNCA gene causing the substitution of glutamate with 
lysine at residue 46 (Glu46Lys) was discovered in a Spanish kindred (Zarranz, 
Alegre et al. 2004). PD patients carrying the Ala30Pro mutation display 
symptoms that clinically overlap with IPD (Kruger, Kuhn et al. 2001). In contrast, 
carriers of the Ala53Thre mutation have a more rapid disease progression with 
an early age of disease onset (Schiesling, Kieper et al. 2008), while carriers of 
the Glu46Lys mutations have a higher occurrence of dementia (Zarranz, Alegre 
et al. 2004). Patients with duplications and triplications in SNCA are clinically 
similar to IPD patients, however, there is increasing severity with increasing gene 
multiplication, for example more rapid disease progression and early dementia in 
carriers of the gene triplications (Fuchs, Nilsson et al. 2007). Moreover, a 
polymorphism in the promoter region of SNCA has been identified as a risk factor 
for the disease in patients of different ethnic origins (Maraganore, de Andrade et 
al. 2006). These observations along with the discovery of full length α-Syn 
protein in LBs from post-mortem brain samples of patients with sporadic PD as 
well as familial PD (Spillantini, Schmidt et al. 1997; Wakabayashi, Matsumoto et 
al. 1997; Baba, Nakajo et al. 1998) strongly suggest that -Syn plays an 
important role in the pathogenesis of Parkinson’s disease. 
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1.2.2 Other forms of familial Parkinson’s disease 
 
Genes other than SNCA have been linked and classified as potential causes or 
risk factors in familial PD. Mutations in the Parkin gene (PARK2) have been 
identified in Japanese families, as well as in patients of different ethnic origins, as 
the likely cause of early-onset Parkinsonism (Klein, Lohmann-Hedrich et al. 
2007). Patients with mutations in the Parkin gene share similar clinical symptoms 
with IPD patients, but have earlier age of onset and slower disease progression 
(Lohmann, Periquet et al. 2003). The ubiquitin C-terminal hydrolase-1 (UCH-L1) 
gene (PARK5), coding for the multifunctional ubiquitin C-terminal hydrolase-1, 
has been classified as the third gene to be associated with familial PD in a 
German family. Patients with the mutation in the PARK5 gene, although rare, 
display the clinical features of IPD (Leroy, Boyer et al. 1998). Other studies have 
shown that modifications of the peptide sequence of UCH-L1, due to oxidative 
damage, are linked to neurodegeneration found in brains of patients with 
Alzheimer’s disease (AD) and PD (Castegna, Aksenov et al. 2002; Choi, Levey et 
al. 2004). In addition to Parkin (PARK2) and UCH-L1 (PARK5) genes, familial PD 
has also been linked to mutations in other genes such as the PINK1 gene 
(PARK6) (Valente, Brancati et al. 2002; Valente, Abou-Sleiman et al. 2004), the 
DJ-1 gene (PARK7) (Bonifati, Rizzu et al. 2003), the LRRK2 gene (PARK8) 
(Mata, Wedemeyer et al. 2006) and more recently the ATP13A2 gene (PARK9) 
(Ramirez, Heimbach et al. 2006). 
 
 
1.3 Parkinson’s Disease Pathology and Lewy 
Bodies  
 
Neurodegeneration in PD is characterized by neuronal loss mainly in the 
dopaminergic neurons in the Substantia nigra pars compacta (SNpc) in the 
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central nervous system (CNS). The neuronal loss is accompanied by the 
presence of cytoplasmic intraneuronal protein aggregates inclusions known as 
LBs and LNs. LBs and LNs are considered to be the pathological hallmarks of 
PD, where α-Syn constitutes the major component of these neuronal inclusions 
in both familial and sporadic PD (Spillantini, Crowther et al. 1998b). Other 
neurodegenerative diseases have also been found to have the characteristic α-
Syn positive inclusions in neuronal or glial cells, and therefore collectively 
referred to as synucleinopathies. This group of diseases includes Multiple 
System Atrophy (MSA) (Spillantini, Crowther et al. 1998a; Duda, Giasson et al. 
2000), dementias with Lewy bodies (DLB) (Spillantini, Schmidt et al. 1997) and 
LB variant of AD (Goedert 2001). In addition, some non-neurodegenerative 
diseases have been reported to contain a considerable percentage of α-Syn 
positive neuronal inclusions, such as brain iron accumulation type-1 (Arawaka, 
Saito et al. 1998) and Down’s syndrome (Lippa, Schmidt et al. 1999). 
 
 
The process of neurodegeneration in PD patients occurs initially in other regions 
of the brainstem, reaching dopaminergic neurons in the substantia nigra at later 
stages. It starts in the olfactory bulb, dorsal motor vagal nucleus and the locus 
coeruleus (Braak, Del Tredici et al. 2003). Neurodegeneration may also occur in 
nerve cells in the peripheral autonomic ganglia (Wakabayashi, Matsumoto et al. 
1997). LBs were initially described in 1912 by Frederich Lewy as rounded 
cytoplasmic inclusions consisting of a translucent glassy core that stains brightly 
for eosin, surrounded by a pale staining peripheral halo of radiating fibrils of α-
Syn and other proteins (Bennett 2005), such as chymotrypsin A, elements of 
proteasome (Ii, Ito et al. 1997), ubiquitin ligase (E3) parkin (Choi, Golts et al. 
2001) and some cytoskeletal protein such as tubulin (Galloway, Grundke-Iqbal et 
al. 1988). Prior to the discovery that α-Syn is the major component of LBs, these 
proteinaceous inclusions have been marked using ubiquitin antigenicity (Lennox, 
Lowe et al. 1989).  
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1.4 Parkinson’s Disease Symptoms 
 
PD is a neurological disorder characterized by a large number of motor and non-
motor features that have impact on individual’s everyday function to varying 
degree. Resting tremor, bradykinesia, rigidity and loss of postural reflexes are 
generally considered the cardinal signs of the disease. Other clinical features 
include secondary motor symptoms such as hypomimia, dysarthria, dysphagia, 
sialorrhoea, micrographia, shuffling gait, festination, freezing, dystonia and 
glabellar reflexes. In addition, some non-motor symptoms have been described 
such as autonomic dysfunction, neurobehavioral abnormalities, sleep disorders 
and sensory abnormalities like anosmia, paresthesias and pain. The absence of 
resting tremor along with early occurrence of gait difficulty, postural instability, 
dementia, hallucinations and the presence of dysautonomia, ophthalmoparesis, 
ataxia and other atypical features, coupled with poor or no response to levodopa, 
suggest diagnosis other than PD (Jankovic 2008).  
 
 
1.5 Alpha Synuclein and Parkinson’s Disease 
 
1.5.1     Alpha Synuclein Family and Disease Mutants 
 
1.5.1.1 The Synuclein family 
 
Alpha-synuclein (α-Syn) belongs to a protein family known as the Synuclein 
family, which includes two other proteins named beta-synuclein (β-Syn) and 
gamma-synuclein (γ-Syn). α-Syn was first discovered when a protein named 
synuclein was isolated from the electric organ of Torpedo californica using an 
antiserum against cholinergic vesicles. It was given the name synuclein because 
of its localization in the presynaptic nerve terminals and also close to the nuclear 
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envelope of neurons (Maroteaux, Campanelli et al. 1988). A highly homologous 
protein was later found in rat brains (Maroteaux and Scheller 1991). Subsequent 
research of AD led to the identification of a peptide called NAC (non-A beta 
component) in the amyloid plaques of brains from AD patients. The precursor 
protein of that peptide (NACP) has been shown to be homologous to the rat 
synuclein protein (Ueda, Fukushima et al. 1993). Furthermore, Jakes and co-
workers (Jakes, Spillantini et al. 1994) identified two synuclein-related proteins of 
140 and 134 amino acids in length from a cytosolic extract of human brain. The 
human 140 amino acid protein was found to be identical to the previously 
reported precursor protein of NAC peptide (NACP) in AD amyloid plaques, and 
shares high similarity with synuclein from Torpedo and rat brains. This was 
named α-Syn. Two other isoforms of α-Syn have subsequently been discovered. 
The 112 and 126 amino acid isoforms are produced by alternative splicing of the 
gene encoding α-Syn leading to in-frame deletions of exon 5 and exon 3 
respectively (Xia, Saitoh et al. 2001; Uversky 2007). The 134 amino acid protein 
was found to be a homologue of the bovine phosphoneuroprotein 14 (Nakajo, 
Tsukada et al. 1993) and was named β-Syn (Jakes, Spillantini et al. 1994). The 
most recently discovered member of the synuclein family, γ-Syn, was isolated 
and characterized in 1997 (Ji, Liu et al. 1997; Lavedan, Leroy et al. 1998). γ-Syn 
is a 127 amino acid protein and was found 75.3% similar to the previously 
described Torpedo protein mainly at the amino-terminal part (Lavedan 1998). 
 
 
1.5.1.2 Localization and expression of synuclein proteins 
 
The synuclein family members, α-Syn, β-Syn and γ-Syn are encoded by three 
different genes, SNCA, SNCB and SNCG, which map to chromosomes 4q21.3-
q22, 5q35 and 10q23, respectively. All three synucleins are predominantly 
expressed in the brain. -Syn and β-Syn expression has been detected primarily 
in the CNS, particularly in presynaptic nerve terminals in the neocortex, 
hippocampus, striatum, thalamus, cerebellum, cerebellar cortex, substantia nigra 
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and brain stem (Jakes, Spillantini et al. 1994; Iwai, Masliah et al. 1995; Irizarry, 
Kim et al. 1996). Both α-Syn and β-Syn have been shown to be found in the 
cytosol. γ-Syn is primarily expressed in cell bodies and axons of primary sensory 
neurons, sympathetic neurons and motor sensory neurons of the peripheral 
nervous system (Buchman, Hunter et al. 1998). γ-Syn expression has also been 
reported at moderate levels in the heart, skeletal muscles, and much lower levels 
in the kidney, liver and pancreas with no expression observed in the lung and 
placenta (Lavedan, Leroy et al. 1998). It is important to mention that abnormally 
high expression of γ-Syn has been associated with many types of cancers, such 
as breast tumours (Jia, Liu et al. 1999), where it has been considered as a 
marker of tumour progression (Lavedan 1998; Jia, Liu et al. 1999), as well as 
ovarian tumours (Bruening, Giasson et al. 2000). However, it is not known what 
role γ-Syn can have in normal breast or ovary tissues, as levels of γ-Syn are 
almost undetectable at the surface epithelial cells of a normal ovary.  
 
 
1.5.2 Alpha synuclein structure  
 
Generally speaking, all synucleins are small proteins with calculated molecular 
mass close to 14kDa, however when run on SDS-PAGE gels synucleins have 
displayed an apparent molecular mass of 19-20kDa, with α-Syn at 16-17kDa 
running slightly faster than the others (Jakes, Spillantini et al. 1994). 
 
 
Several spectroscopic and structural studies, such as NMR, have shown that α-
Syn is a disordered protein that belongs to the rapidly growing family of natively 
unfolded proteins that have little or no ordered structure under physiological 
conditions (Weinreb, Zhen et al. 1996; Uversky, Li et al. 2001b). The primary 
sequence of human α-Syn can be divided to three distinct regions: 1) an amino 
terminal region (residues 1-60) containing four 11-amino acid imperfect repeats 
with a highly conserved motif KTKEGV, which is responsible for lipid binding 
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(Perrin, Woods et al. 2000); 2) a hydrophobic centre domain (residues 61-95), 
also referred to as the non-amyloid component NAC, which contains two 
additional repeats and is believed to be responsible for α-Syn’s ability to form 
beta-sheet rich fibrils and 3) a highly negatively charged carboxy-terminal region 
(residues 96-140) (Figure 1.2).  
 
 
N-terminal                                                NAC domain                                           C-terminal 
 
   1                                                   60                          95                                      140 
                          a   b c  
Fig. 1.2 Alpha synuclein schematic representation 
α-Syn contains three main domains namely, the amphipathic N-terminal domain, 
the hydrophobic NAC central domain and the acidic C-terminal domain. Arrows a, 
b and c represent the three disease related mutations in α-Syn, Ala30Pro, 
Glu46Lys and Ala53Thr, respectively.  
 
 
The highly conserved N-terminal domain is a common feature to all synucleins. 
For α-Syn, this region has been predicted to form amphipathic α-helices structure 
when associated with lipid membranes (Davidson, Jonas et al. 1998; Perrin, 
Woods et al. 2000; Eliezer, Kutluay et al. 2001). This conformation is 
characterized by two helical domains interrupted by a short non helical turn 
(Davidson, Jonas et al. 1998). This is due to the presence of the consensus 
imperfect repeats (KTKEGV) in α-Syn that resembles an 11-residue repeating 
motif found in lipid binding domain of apolipoproteins (George, Jin et al. 1995). It 
has been suggested that α-Syn adopts α-helical rich structure in vivo as well, 
particularly the membrane- and synaptic vesicles-associated states (Sung and 
Eliezer 2006). Furthermore, the presence of these repeats in α-Syn, which have 
unknown function, has also been proposed to play a role in protein-protein 
interactions (Jakes, Spillantini et al. 1994). These repeats contain clusters of 
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basic and acidic amino acids and such clusters have been proposed to mediate 
binding between structural proteins (Weinreb, Zhen et al. 1996; Davidson, Jonas 
et al. 1998) and dimerization (Jensen, Hojrup et al. 1997). 
 
 
The central hydrophobic region (NAC) of α-Syn has been implicated in α-Syn 
aggregation and fibrillation (Giasson, Murray et al. 2001; Uversky, Li et al. 
2002b). NAC is one of the main components of amyloid plaques in Alzheimer’s 
brains (Ueda, Fukushima et al. 1993) and can form ordered fibrils in vitro (Iwai, 
Masliah et al. 1995). Moreover, NAC has been shown to seed Aβ (1-40) 
amyloidogenesis (Han, Weinreb et al. 1995). In addition, the substitution of amino 
acid residue at position 76 (Ala) with a charged amino acid (Glu or Arg) results in 
a decrease in α-Syn association, whereas deletion of amino acid residues 71-82 
in human α-Syn prevents protein aggregation (Giasson, Murray et al. 2001). 
Finally, the N-terminal region of the NAC sequence has been shown to exhibit 
similarity to the amino acid sequence crucial for aggregation of other 
amyloidogenic polypeptides such as Aβ, and prion protein (Gly-Ala-X-X), where 
X is an amino acid with aliphatic side chain (El-Agnaf, Bodles et al. 1998). These 
observations together suggest the possible direct involvement of the NAC 
domain in the pathologic aggregation of α-Syn in neurodegenerative diseases. 
The C-terminal region of α-Syn has been characterized by its enrichment in 
acidic amino acid residues (Asp and Glu) and prolines. It also contains three out 
of four tyrosine residues (positions 125, 133 and 136). The fourth tyrosine is 
found at position 39. There are no tryptophan residues in α-Syn. The highly 
acidic C-terminal region has been suggested to possess chaperone like activity 
(Kim, Paik et al. 2002), and also to regulate α-Syn aggregation (Murray, Giasson 
et al. 2003). In fact, it has been shown that C-terminally truncated α-Syn 
assembled into fibrils more rapidly than the full length protein (Crowther, Jakes et 
al. 1998).  
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Both β-Syn and -Syn share high homology with -Syn at the amino acid 
sequence level. Spectroscopic studies have shown that both β-Syn and γ-Syn, in 
their free state, behave similarly to α-Syn and both are unfolded proteins 
(Uversky, Li et al. 2002b). Using amino acid sequence alignment, β-Syn has 
been found to be 61% identical to α-Syn. Most of this homology is observed in 
the amino terminal half, suggesting that this may serve a function shared 
between α-Syn and β-Syn (Jakes, Spillantini et al. 1994). γ-Syn has been found 
to be 50% identical to α-Syn  (Figure 1.3).  
 
                   1                      10                          20                       30                         40 
(α-Syn)      MDVEMKGL SKAKEGVVAAA EKTKQGVAEAA GKTKEGVLYVG         
(β-Syn)      MDVEMKGL SMAKEGVVAAA EKTKQGVTEAA EKTKEGVLYVG  
(γ-Syn)      MDVEKKGF SIAKEGVVGAV EKTKQGVTEAA EKTKEGVMYVG 
                       50                                  60                         70                         80  
      SKTKEGVVHGV   ATVA EKTKEQVTNVG GAVVTGVTAVA QKTVEGAGSIA  
      SKTREGVVQGV   ASVA EKTKEQASHLG GAVFSG--------- --AGNIA  
      AKTKENVVQSV   TSVA EKTKEQANAVS EAVVSSVNTVA TKTVEEAENIA  
90                     100                                          110                    120                     130                     140    
AATGFVKKDQLGKN--------EEGAPQEGILEDMPVDPDNEAYEMPSEEGYQDYEPEA      
AATGLVKREEFPTDLKPEEVAQEAAEEPLIEPLMEPEGESYEDPPQEEYQEYEPEA 
VTSGVVRKEDLRPSAPQQEGVASKEKEEVAEEAQSGGD 
Fig. 1.3 Sequence alignment of human α-Syn, β-Syn and γ-Syn. 
Underlined is the consensus imperfect hexameric repeat (KTKEGV) presence in 
the N-terminal region of the synucleins. Spaces (-) represents the 11 amino acids 
absence from β-Syn sequence in the NAC domain. Bold characters indicate a 
differences from the α-Syn sequence. 
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Compared to α-Syn and γ-Syn, β-Syn lacks 11 amino acid residues in the central 
highly hydrophobic region, and has an increased helical propensity which might 
stabilize its disordered native state and explain why β-Syn has been found to 
have reduced propensity to self-aggregate and form oligomers and fibrils 
(Hashimoto, Rockenstein et al. 2001; Uversky, Li et al. 2002b; Bertoncini, Rasia 
et al. 2007). However, at its C-terminal region, β-Syn has three tyrosine residues 
located identically to α-Syn (Uversky, Li et al. 2002b).  
 
 
In this regard, it is important to mention that two of the disease-related mutants of 
α-Syn (Ala30Pro and Ala53Thr) were found to have no effect on the 
conformational and structural properties of the monomeric protein (Conway, 
Harper et al. 1998; Li, Uversky et al. 2001). Moreover, it has been shown that the 
propensity of α-Syn to form α-helical structures was reduced by both mutants 
(Ala30Pro and Ala53Thr), whereas the beta-sheet content was predicted to be 
slightly enhanced (Li, Uversky et al. 2001). 
 
 
1.5.3 Alpha synuclein function 
              
α-Syn has been estimated to account for as much as 1% of total protein in 
soluble cytosolic brain fractions (Iwai, Masliah et al. 1995). It is surprising that the 
function of such a highly abundant protein is poorly understood. It has been 
shown that in presynaptic terminals, monomeric α-Syn exists in equilibrium 
between two forms, free and plasma membrane- or vesicle-bound (McLean, 
Ribich et al. 2000). Approximately 15% of α-Syn has been revealed to be 
membrane-bound (Lee, Choi et al. 2002). Based on that association with 
vesicular structures, several studies suggested a role of α-Syn in membrane-
associated processes at the presynaptic terminals, such as regulation of synaptic 
neurotransmission and dopamine (DA) release (Abeliovich, Schmitz et al. 2000). 
In addition, α-Syn may regulate the size of synaptic vesicle pool in mature 
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neurons, as deletion of α-Syn from cultured hippocampal neurons resulted in 
decreased synaptic vesicle pool as demonstrated by electron microscopy 
(Murphy, Rueter et al. 2000). α-Syn also interacts with synaptic phospholipid 
vesicles that contain acidic phospholipids (Davidson, Jonas et al. 1998), as well 
as various phospholipid membranes (Jo, McLaurin et al. 2000) and biological and 
general cellular membranes (Jensen, Nielsen et al. 1998; McLean, Kawamata et 
al. 2000). Moreover, α-Syn has been suggested to modulate the organization of 
membrane lipid components by affecting the integrity of the membranes’ bilayers 
and causing the formation of non-bilayer or small vesicular structures (Madine, 
Doig et al. 2006). α-Syn has been shown to inhibit lipid oxidation when bound to 
lipid membranes, which has been attributed to its easy oxidation via the formation 
of methionine sulfoxide (Zhu, Qin et al. 2006).  
 
 
One of the first physiological functions anticipated for α-Syn is to regulate the 
activity of several enzymes. For example, α-Syn has been shown to act as 
selective inhibitor of phospholipase D2 (PLD2), which is an active isoform of the 
phospholipase D enzymes, and is localized primarily along plasma membrane 
and hydrolyses phosphatidylcholine to phosphatidic acid  (Jenco, Rawlingson et 
al. 1998). In addition, α-Syn has also been shown to inhibit tyrosine hydroxylase 
(TH), which is the rate limiting enzyme in dopamine synthesis, thus supporting 
the hypothesis that α-Syn is involved in the regulation of synaptic 
neurotransmission (Perez, Waymire et al. 2002). However, the precise function of 
α-Syn is not yet determined and research on α-Syn continues to propose 
possible functions of the protein in biological processes. Indeed, α-Syn has been 
suggested to interact with many proteins and ligands, and to act as a molecular 
chaperone assisting in the process of folding and refolding of synaptic proteins 
(Chandra, Gallardo et al. 2005). This proposed function was further emphasized 
when α-Syn was shown to bind to the cytoplasmic chaperone 14-3-3, which was 
reported to bind and activate TH (Ostrerova, Petrucelli et al. 1999; Perez, 
Waymire et al. 2002). In addition, α-Syn has been suggested to play a role in the 
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protection of the nerve terminals via its cooperation with CSPα, an abundant 
synaptic vesicle protein, which possesses a co-chaperone function and is 
essential for neuronal survival (Chandra, Gallardo et al. 2005). The 
accomplishment of this cooperation was suggested to require phospholipid 
binding by α-Syn (Chandra, Gallardo et al. 2005). Finally, a role of α-Syn in 
inhibiting the endoplasmic reticulum to Golgi vesicular trafficking has been 
shown, with an impairment of endoplasmic reticulum-associated degradation 
(Cooper, Gitler et al. 2006). 
 
 
1.5.4 Metal binding 
              
PD is thought to be of multi-factorial aetiology, suggesting both genetic and 
environmental factors. Taking into account the potential role of α-Syn in the 
disease pathology, many studies have addressed the possible involvement of α-
Syn in the environmental causation theory. A range of environmental factors and 
neurotoxins have been associated with PD, which directly interact with α-Syn, 
including metal ions, pesticides, herbicides and organic solvents. Interaction of α-
Syn with these neurotoxins provoked the aggregation of α-Syn in vitro (Uversky, 
Li et al. 2001c; Uversky, Cooper et al. 2002) and was associated with increased 
α-Syn positive inclusions in animal models (Betarbet, Sherer et al. 2000; Sherer, 
Kim et al. 2003). In this respect, metals have been recognized as risk factors in 
several neurodegenerative diseases, such as AD (Huang, Atwood et al. 2004) 
and Prion disease (Brown, Guantieri et al. 2004). Less information is known 
about the relationship between metals and PD (Zayed, Ducic et al. 1990; Gorell, 
Johnson et al. 1997). Most recent studies propose a correlation between the 
exposure to heavy metals and PD development (Gorell et al. 1997; Gorell et al. 
1999; Weisskopf et al. 2010; Bonilla-Ramirez et al. 2011).  
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Metals serve vital roles in many biological systems. They do not only represent 
factors that can stabilize and modulate protein structures, but are also essential 
survival elements as they participate in various biologically important reactions, 
such as DNA and RNA synthesis, redox reactions and act as co-factors to many 
enzymes (Regan 1995; Sayre, Moreira et al. 2005). The latter property is 
exhibited by both redox active (copper and iron) and redox inactive (zinc) metal 
ions. Therefore, disruption of metal ion homeostasis can be harmful as their 
deficiency can lead to disturbances in central nervous system and other organs’ 
function, while their accumulation can be toxic (Sayre, Moreira et al. 2005). Due 
to the general acceptance that oxidative stress might be involved in the 
pathogenesis of neurodegenerative diseases such as AD and PD (Paik, Shin et 
al. 2000), redox active metal ions such as copper and iron are of interest. These 
metals are implicated in the disease pathology affecting areas of the brain in both 
PD and AD. The brains of patients suffering with these diseases have been 
shown to contain abnormally high levels of such metals, particularly iron (Sayre, 
Moreira et al. 2005). Post-mortem analysis of PD brains provided information 
about the involvement of metals in PD, where increased levels of copper have 
been reported in cerebrospinal fluid of PD patients (Pall, Williams et al. 1987). 
High levels of zinc were found in the substantia nigra of PD brains (Dexter, Wells 
et al. 1989). Moreover, iron deposits have also been identified as components of 
Lewy bodies (LBs), in addition to elevated levels of alumimium in the 
Parkinsonian substantia nigra (Hirsch, Brandel et al. 1991). An understanding of 
the outcome of increased levels of metals in the brain come from animal 
experiments, for example an injection of FeCl3 into the substantia nigra of adult 
rats caused a selective decrease in the level of dopamine, and resulted in 
impaired dopamine-related behavioural responses (Youdim, Ben-Shachar et al. 
1991).  
 
 
In vitro experiments have shown that a number of mono-, di- and trivalent metal 
ions can facilitate α-Syn oligomerization and aggregation, particularly copper 
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(Cu2+), as assessed by laddering on SDS-PAGE gels (Paik, Shin et al. 1999) and 
using the Thioflavin-T based fluorometric assay (Uversky, Li et al. 2001b). For 
example, aluminium has been shown to cause alterations in α-Syn structure, 
such as transition into a secondary structure with 33% more α-helical content 
(Paik, Lee et al. 1997) and induced fibril formation (Uversky, Li et al. 2001b). 
Given the effect of metals on accelerating α-Syn aggregation and fibril formation, 
much research has been conducted to assess the ability of the protein to bind 
metals. Although it remained controversial for a long time, it is becoming clear 
how and where metals (especially copper and iron) can bind to α-Syn. Early 
studies have shown that Cu2+ binds to the C-terminal domain of α-Syn and 
induces its oligomerization (Paik, Shin et al. 1999). A single molecule of α-Syn 
can bind 10 molecules of copper with a dissociation constant of 59µM. However, 
subsequent studies have revealed that the primary Cu2+ binding site is located at 
the N-terminal domain involving residues 1-9 and residues 48-52, with the 
Histidine residue at position 50 being an anchoring residue (Rasia, Bertoncini et 
al. 2005; Binolfi, Rasia et al. 2006). Rasia et al. 2005 have shown that α-Syn 
strongly binds two Cu2+ ions per monomer at its N-terminal copper-binding 
interface with dissociation constant of 0.1-50µM and that this binding is 
independent of the presence of the C-terminal interface. They also suggested 
that the C-terminal interface involving residues 119-123 is able to coordinate 
more Cu2+ but with significantly lower affinity. A similar result has also been 
reported showing a high affinity binding site (0.1µM) at the N-terminal of α-Syn, 
and a low affinity metal binding site at the C-terminal (Binolfi, Rasia et al. 2006). 
Finally, in a more recent study convincing evidence suggests that there are two 
independent, non-interacting copper-binding sites with significantly different 
binding affinities at the N-terminal region of α-Syn (Binolfi, Lamberto et al. 2008). 
They demonstrated the involvement of the Methionine residue at position 1 as 
the primary anchoring residue for Cu2+ binding. While a second Cu2+ binding site 
with lower affinity is centred at the Histidine residue at position 50. The presence 
of two copper binding sites in α-Syn has also been reported by a different group 
(Bharathi and Rao 2007), where they also showed that α-Syn has a single Fe3+ 
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binding site. The specificity of iron binding to α-Syn is still elusive. However, the 
C-terminal domain of α-Syn, specifically residues 110-140 centring on Asp121, 
has been proposed to be able to bind Fe2+, in addition to other divalent metal 
ions such as Mn2+, Co2+ and Ni2+ (Binolfi, Rasia et al. 2006). 
 
 
The mechanisms by which metals interact with the proposed metal-binding sites 
are still not clear. Nevertheless, the preferential interaction with the acidic C-
terminus is suggested to be due to the negatively charged surface (Paik, Shin et 
al. 1999). It has also been hypothesized that copper binding to the N-terminus of 
α-Syn would perturb the long range interactions critical for stabilizing a soluble 
auto-inhibited conformation of α-Syn (Rasia, Bertoncini et al. 2005).  
 
 
1.5.5 Alpha synuclein aggregation  
              
Since fibrillar α-Syn is the hallmark of PD and other synucleinopathies, it is likely 
that fibrillation plays a critical role in the disease aetiology and progress. 
Identifying conditions that lead to α-Syn fibrillation are fundamentally important 
for the design of novel therapies. It has been established that recombinant α-Syn 
and its disease mutant forms are able to assemble into filaments with 
morphologies and staining properties similar to those extracted from disease 
affected brains (El-Agnaf, Jakes et al. 1998b; Uversky, Li et al. 2001b; 
Fredenburg, Rospigliosi et al. 2007). This is important as it verifies the use of 
recombinant protein as a model system for analysing α-Syn aggregation in vitro. 
Different final products with distinct morphologies may occur from α-Syn 
aggregation depending on the experimental conditions, and this includes fibrils, 
soluble oligomers and insoluble amorphous aggregates (Fink 2006). Research 
has aimed to identify conditions that would induce the formation of the pathologic 
insoluble aggregates of α-Syn. It has been shown that α-Syn has a strong 
tendency to aggregate and it does so spontaneously (Hashimoto, Hsu et al. 
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1998). Monomeric α-Syn, when incubated at 37°C and neutral pH, has been 
shown to form fibrils in a condition-dependent manner with agitation greatly 
enhancing the process (Fink 2006). On the other hand, incubating α-Syn at acidic 
pH leads to a shift in the resultant aggregate morphology towards the formation 
of amorphous aggregates rather than fibrils (Hoyer, Antony et al. 2002). 
 
 
α-Syn aggregation kinetics in vitro show sigmoidal curves defined by an initial lag 
phase, followed by exponential phase (fibril growth phase) and final plateau after 
fibrils are completely formed. α-Syn aggregation has been proposed to display a 
nucleation dependent mechanism where a partially folded intermediate is thought 
to be critical for α-Syn oligomerization and fibrillation (Uversky, Li et al. 2001a; 
Rasia, Bertoncini et al. 2005). However, it remains a fundamental question as to 
what forces and factors causing α-Syn transformation from random coiled to a 
structured form with predominantly β-pleated sheet structure (Uversky, Li et al. 
2001a). A model has been proposed for α-Syn fibrillation pathway. The 
monomeric unfolded protein undergoes a conformational change into an 
aggregation-prone intermediate, which can then lead to the formation of one of 
the final end products mentioned earlier (fibrils, amorphous aggregates and 
soluble oligomers) (Uversky, Li et al. 2001a; Fink 2006). This model is further 
supported by research which showed a correlation between partial folding and 
fibrillation (Uversky, Li et al. 2001a). Consequently, factors that favour the 
formation of the partially folded intermediate will facilitate fibril formation.  
 
 
It has been well demonstrated that a variety of different endogenous and 
exogenous factors and ligands, as well as certain in vitro conditions, stimulate a 
conformational change that results in modulation of α-Syn aggregates 
morphology and kinetics. Partial folding has been considered and shown to 
represent the main mechanism by which α-Syn aggregation is induced. In this 
respect, several commonly used pesticides (rotenone, paraquat) and some di- 
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and trivalent metal ions (Cu2+, Fe3+ and Al3+) have been shown to cause 
significant alterations in the rate of α-Syn fibril formation (Paik, Shin et al. 1999; 
Uversky, Li et al. 2002a). Their effectiveness has been shown to be correlated 
with their ability to induce and stabilize a fibrillation-prone partially folded 
intermediate, and with increased ion charge density in the case of metals 
(Uversky, Li et al. 2001b; Uversky, Li et al. 2001c; Uversky, Li et al. 2002a). 
However, the mechanism by which metals act has been further proposed to 
involve metal binding to the negatively charged carboxylates, thus masking the 
electrostatic repulsion and facilitating collapse to partially folded conformation. 
The identification of specific metal binding sites for some metals supports this 
mechanism of action (Uversky, Li et al. 2001b; Uversky, Li et al. 2002a). Protein 
concentration and molecular crowding also enhance α-Syn fibril formation via the 
partial folding mechanism (Uversky, Cooper et al. 2002). α-Syn has been 
proposed to be present in an equilibrium between its unfolded and partially folded 
states (Uversky 2007), and in vitro experiments have shown that high 
concentrations of α-Syn result in increased fibrillation rate which is likely to be 
due to elevated intermediate concentration (Uversky, Li et al. 2001b). This is 
important in the understanding of the pathogenesis of Parkinson’s disease, 
particularly in the case of patients with the triplication of the α-Syn locus, which 
leads potentially to an elevated to level of α-Syn formation (Singleton, Farrer et 
al. 2003; Pals, Lincoln et al. 2004) and therefore increasing protein concentration 
and partial folding. In addition, the presence of high concentration of 
macromolecules is a common property of cells where 25% of the volume of a 
standard cell consists of macromolecules such as inert proteins, nucleic acids 
and carbohydrates (Minton 2001; Fink 2006). This can have major consequences 
on the properties of macromolecules, such as protein-protein interactions. In 
relation to α-Syn aggregation, this was investigated in vitro with high 
concentration of various types of biopolymers causing acceleration of α-Syn 
fibrillation in a concentration dependant manner (Shtilerman, Ding et al. 2002; 
Uversky, Cooper et al. 2002). Finally, C-terminally truncated α-Syn was found in 
Lewy bodies (LBs) along with full length protein and was found to be more prone 
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to fibrillate (Murray, Giasson et al. 2003). The effect of post-translational 
modification on α-Syn fibrillation has also been investigated. Pathogenic 
inclusions have also been shown to have extensively phosphorylated α-Syn at 
Ser129 (Fujiwara, Hasegawa et al. 2002; Nishie, Mori et al. 2004). Although α-
Syn under normal conditions has been reported to be non-phosphorylated, 
specific phosphorylation of α-Syn at residue Serine at position 129 resulted in 
accelerated oligomerization and fibrillation (Fujiwara, Hasegawa et al. 2002).   
 
 
Besides the continuous interest in identifying factors contributing to increased α-
Syn aggregation, extensive research has been also directed towards specifying 
factors that can inhibit α-Syn aggregation. Modifying α-Syn by methionine 
oxidation or tyrosine nitration has been shown to completely inhibit α-Syn fibril 
formation due to the formation of stable oligomers (Uversky, Yamin et al. 2002; 
Yamin, Uversky et al. 2003; Uversky, Yamin et al. 2005). This is crucial as the 
existence of nitrated α-Syn in Lewy bodies (LBs) has been demonstrated (Duda, 
Giasson et al. 2000; Giasson, Duda et al. 2000). Oxidative stress has also been 
implicated in Parkinson’s disease, particularly taking into consideration alteration 
in iron homeostasis. Increased iron levels, which is a redox active metal, can 
cause increased generation of free radicals via Fenton reaction which in turn can 
oxidatively damage proteins including α-Syn (Hashimoto, Hsu et al. 1999).  
 
 
In contrast to α-Syn, β-Syn does not fibrillate when incubated under the same 
conditions as α-Syn (Uversky, Li et al. 2002b). However, it has been shown that 
β-Syn can be forced to fibrillate under specific conditions, such as presence of 
metals, pesticides, molecular crowding (Yamin, Munishkina et al. 2005). 
Interestingly, fibrillation of α-Syn was completely inhibited at 4:1 molar excess of 
β-Syn or γ-Syn over α-Syn (Uversky, Li et al. 2002b). This suggests that both β-
Syn and γ-Syn may behave as negative regulators of α-Syn fibrillation (Uversky, 
Li et al. 2002b). β-Syn was also shown to inhibit α-Syn fibrillation in animal 
 35 
models (Hashimoto, Rockenstein et al. 2001). The mechanism is not clear yet, 
but it was suggested to be mediated by stabilizing α-Syn aggregates via direct 
interaction (Uversky, Li et al. 2002b) or even via affecting and modulating α-Syn 
expression level (Fan, Limprasert et al. 2006). Importantly, these observations 
suggest that the balance in the levels of the synuclein family members may be 
essential for disease prevention. Finally, since dopaminergic neurons in the 
substantia nigra are the most susceptible to neurodegeneration in PD, and 
dopamine is being sensitive to oxidation, this has led to the suggestion that 
dopamine is linked in a way to the disease pathology (Uversky 2007). It has been 
shown that dopamine can inhibit α-Syn fibril formation in vitro (Conway, Rochet 
et al. 2001; Li, Zhu et al. 2004). The mechanism is not well known, but it was 
attributed to the covalent modification of α-Syn by o-quinones derived from 
dopamine leading to the production of modified proto-fibrils that are unable to 
fibrillate (Conway, Rochet et al. 2001).  
 
 
1.5.6 Toxicity of Alpha Synuclein 
 
The presence of α-Syn aggregates in LBs is a common feature of many 
neurodegenerative diseases, including PD. It is still not clear whether cell death 
is the result of α-Syn aggregation. This prompted investigations towards the 
assessment of α-Syn toxicity both in vitro cell-culture and animal models, and it 
was shown to be toxic in many studies (El-Agnaf, Jakes et al. 1998a; Sung, Kim 
et al. 2001). The mechanism underlying α-Syn toxicity and which species are 
responsible for the neuronal death are still not clear. As surviving neurons in the 
brain contain aggregates (fibrils), then this could be an indication that other 
aggregate species might be involved. Therefore, specific populations of α-Syn 
may be responsible for the toxicity, and a growing body of evidence suggest that 
prefibrillar oligomers and proto-fibrils rather than mature fibrils are the toxic 
species (Lashuel, Petre et al. 2002; Danzer, Schnack et al. 2007; Wright, Wang 
et al. 2009). Evidence for this hypothesis has been confirmed using an in vitro 
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cell model of human dopaminergic neurons, wherein toxicity was observed with 
non-fibrillar, small α-Syn aggregates, suggesting that soluble species mediate 
toxicity (Xu, Kao et al. 2002). This has also been proposed to be the case with 
intermediates formed during amyloid assembly of Aβ-peptide in Alzheimer’s 
disease (Lashuel, Hartley et al. 2002).  
 
 
The mechanism of oligomer toxicity is not clear, however, there are many 
hypotheses. The formation of oligomers has been shown to increase leakiness of 
synthetic lipid vesicles (Volles, Lee et al. 2001) and therefore might cause 
damage to cellular membranes in vivo. The mechanism by which α-Syn 
oligomers damage cellular membranes is not characterized, but it could be 
mediated by integrating to the membrane and forming pore-like structures which 
could cause membrane permeability (Volles and Lansbury 2002). This might lead 
to altered ion balance such as elevation of intracellular calcium levels (Danzer, 
Haasen et al. 2007). Calcium disruption induced-toxicity was a common 
proposed mechanism caused by other amyloidogenic peptides (amyloid β 
peptide, prion) (Demuro, Mina et al. 2005). However, cell culture studies of α-Syn 
toxicity are still controversial. Some studies have shown that expression of α-Syn 
or its disease mutants is associated with aggregate formation (Ostrerova-Golts, 
Petrucelli et al. 2000; Lee, Hyun et al. 2001) and inducing the cells to be more 
vulnerable to cellular changes (Zhou, Yap et al. 2006). On the other hand, other 
studies have shown that α-Syn expression can be protective against cellular 
stresses (Hashimoto, Hsu et al. 2002). Also, α-Syn oligomers generated in vitro 
and added extra-cellularly to cultured cells have been shown to cause toxicity 
(Liu, Giasson et al. 2005; Wright, Wang et al. 2009). Finally, expression of α-Syn 
in yeast has also been reported to form cytoplasmic inclusions that are 
associated with toxicity (Soper, Roy et al. 2008). 
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1.6 Regulation of Alpha Synuclein Expression  
 
Several lines of evidence suggest the involvement of α-Syn gene SNCA in 
Parkinson’s disease. Multiple point mutations (Polymeropoulos, Lavedan et al. 
1997; Kruger, Kuhn et al. 1998) as well as gene multiplications in the α-Syn gene 
SNCA (Singleton, Farrer et al. 2003; Pals, Lincoln et al. 2004), have been 
associated with cases of familial and sporadic PD. However, the majority of PD 
patients do not have gene mutations or multiplications, yet they show α-Syn 
deposits in Lewy bodies (LBs) (Mezey, Dehejia et al. 1998). Therefore, it can be 
assumed that there are other mechanisms contributing to α-Syn role in PD 
pathogenesis. Studies have demonstrated that over-expression of WT α-Syn, in 
cases of SNCA multiplications, is sufficient to cause Parkinsonism in a dose 
dependent manner (Singleton, Farrer et al. 2003; Pals, Lincoln et al. 2004). For 
example, carriers of the three SNCA copies (patient with gene duplication) were 
shown to have 1.5-fold increase in α-Syn mRNA and protein levels, whereas 
carriers of the four SNCA copies (patients with gene triplication) were shown to 
have 2-fold increase (Pals, Lincoln et al. 2004). To some degree, this is 
consistent with the observation that molecular crowding leads to dramatic 
acceleration of α-Syn aggregation and fibrillation in vitro (Shtilerman, Ding et al. 
2002; Uversky, Cooper et al. 2002; Fink 2006). Also, several model systems 
have been studied in order to better illustrate the role of α-Syn in PD progression. 
For instance, transgenic mice over-expressing α-Syn were shown to display 
neuronal inclusions that are similar to Lewy bodies LBs, increased degradation of 
dopaminergic neurons and motor deficits (Masliah, Rockenstein et al. 2000). In 
addition, the expression of WT, A53T and A30P α-Syn in transgenic flies resulted 
in similar effects such as neuronal inclusions and motor deficits (Feany and 
Bender 2000). Hence, over-expression of α-Syn could play a similar role in 
disease aetiology and it is important to understand the regulation of α-Syn 
expression and factors that can affect it.  
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Differences in the expression levels of α-Syn might not only be dependent on 
disease status but also might be modified by genetic variability (Fuchs, Tichopad 
et al. 2008). Several studies have shown that genetic variability in α-Syn gene 
(promoter and 3’ region) can modulate the risk to develop sporadic PD by 
affecting α-Syn expression level (Pals, Lincoln et al. 2004; Fuchs, Tichopad et al. 
2008). The best characterised genetic variation associated with PD is the NACP-
Rep1 polymorphic alleles (Kruger, Vieira-Saecker et al. 1999; Maraganore, de 
Andrade et al. 2006). NACP-Rep1 is a polymorphic nucleotide complex repeat 
site located ~10kb upstream of the transcription start site of α-Syn gene SNCA 
(Xia, Rohan de Silva et al. 1996; Touchman, Dehejia et al. 2001). It has been 
demonstrated that NACP-Rep1 has a reproducible effect on regulating 
transcriptional activity, where a fragment of SNCA promoter including different 
alleles of NACP-Rep1 repeat, led to differences in expression levels (Chiba-Falek 
and Nussbaum 2001; Chiba-Falek, Touchman et al. 2003). Five alleles of NACP-
Rep1 have been identified which differ in size and length by two nucleotides (Xia, 
Rohan de Silva et al. 1996). Three of those alleles were found to be the most 
common alleles, (257,259,261bp as measured by length), and allele length 
variability has been shown to be associated with altered expression of α-Syn 
gene SNCA (Chiba-Falek and Nussbaum 2001; Chiba-Falek, Touchman et al. 
2003). Since the level of α-Syn is directly linked to disease progression, it is 
important to characterise and identify the α-Syn promoter (enhancer) region.  
 
 
Importantly, it was reported that levels of α-Syn mRNA increases and β-Syn 
mRNA decreases in PD brains compared to controls (Rockenstein, Hansen et al. 
2001), which is the opposite to normal aging brains (Li, Lesuisse et al. 2004). In 
vitro studies confirming the inhibitory effect of β-Syn over α-Syn, suggest that 
both α-Syn and β-Syn transcription is regulated to ensure that β-Syn will prevent 
α-Syn aggregation and disease progression. Therefore, these observations 
emphasize the importance of a balanced regulation of both α-Syn and β-Syn. 
Moreover, α-Syn was found to bind metals (Binolfi, Rasia et al. 2006). Metals 
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such as copper and iron were found to accelerate its aggregation in vitro 
(Uversky, Li et al. 2001b). This is also likely to occur in vivo, as metals (zinc, 
aluminium and copper) were also reported to have elevated levels in brains with 
normal aging and patients with PD (Pall, Williams et al. 1987; Dexter, Wells et al. 
1989; Hirsch, Brandel et al. 1991). Since metals, such as copper, have been 
found to regulate the expression of other proteins involved in neurodegenerative 
diseases, such as PrP in Prion disease (Varela-Nallar, Toledo et al. 2006a), 
metals may have a role in regulating α-Syn expression.  
 
 
1.7 Aims of project 
 
This project examined the role of alpha synuclein in PD in terms of its relation to 
metals such as copper and iron. This work aims to: 
 
1. Determine the ferric iron (Fe3+) binding properties to α-Syn including 
number of binding sites and affinity values. 
2. Assess the ability of α-Syn to reduce ferric iron in the presence of copper, 
based on the protein’s binding properties to both metals. 
3. Assess the effect of metals on inducing the aggregation of α-Syn and its 
metal-binding mutants.  
4. Explore any effects of metals on regulating α-Syn expression by looking at 
changes in promoter activity. 
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Chapter two:  Material and Methods 
 
 
    2.1 Materials 
 
 
All media and reagents were purchased from Sigma-Aldrich (Poole, UK) 
laboratories unless otherwise stated.  
 
 
Plasmid Constructs 
Plasmid vectors used in recombinant protein production are pET15b and pTrcHis 
vectors supplied by Novagen and Invitrogen, respectively. The coding sequence 
of human α-Syn and its mutants were cloned into XhoI /KpnI in pTricHis vector 
and into XhoI /BamHI in pET15b vector. pET15b was used for expression of N-
terminal (His)6-tagged proteins in E.Coli followed by a thrombin cleavage site. 
pTrcHis was used for expression of N-terminal (His)6-tagged proteins in E.Coli 
followed by an enterokinase cleavage site. pET11a and pET3a were used for 
expression of untagged proteins in E.Coli.  
pcDNA3.1(-) was obtained from Invitrogen. It is a vector used for transfections to 
express untagged proteins in mammalian neuroblastoma SHSY-5Y cells. The 
open reading frame of α-Syn was cloned between KpnI /XhoI sites in the 
plasmid. Site directed mutagenesis using PCR and paired oligonucleotide 
primers was used to introduce point mutations into the plasmid. 
pGL3-Basic vector was obtained from Promega. It is a Luciferase Reporter 
Vector that was used for quantitative analysis of factors that regulate mammalian 
gene expression. 
Genomic α-Syn and β-Syn were obtained from cDNA libraries (RPI-27M7 and 
RZPD 1.0, respectively) (ImaGenes).   
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Oligonucleotide primers Used 
Oligonucleotides used to produce His-tagged and untagged forms of both WT 
and disease mutant and metal binding mutants of α-Syn, were already available 
in the laboratory. Oligonucleotides used to introduce mutations in α-Syn and 
produce proteins used in this project include: 
 
 
His-tagged Δ1-9 α-Syn: 
F 5’ CGC GGC AGC CAT ATG AAG GCC AAG GAG GGA G- 3’  
R 5’ CTC CCT CCT TGG CCT TCA TAT GGC TGC CGC G- 3’    
 
Ala30Pro α-Syn: 
F 5’ GGC AGA AGC ACC AGG AAA GAC 3’ 
R 5’ GTC TTT CCT GGT GCT TCT GCC 3’ 
 
Ala53Thr α-Syn: 
F 5’ GTG GTG CAT GGT GTG ACA ACA GTG GCT GAG AAG 3’ 
R 5’ CTT CTC AGC CAC TGT TGT CAC ACC ATG CAC CAC 3’ 
 
Glu46Lys α-Syn: 
F 5’ GCT CCA AAA CCA AGA AGG GAG TGG TGC ATG 3’ 
R 5’ CAT GCA CCA CTC CCT TCT TGG TTT TGG AGC 3’ 
 
Δ2-9 α-Syn: 
F 5’ GAAGGAGATATACATATGAAGGCCAAGGAGGGAGTTG 3’ 
R 5’ CAACTCCCTCCTTGGCCTTCATATGTATATCTCCTTC 3’ 
 
Δ119-126 α-Syn: 
F 5’ CTGGAAGATATGCCTGTGATGCCTTCTGAGGAAGGG 3’ 
R 5’ CCCTTCCTCAGAAGGCATCACAGGCATATCTTCCAG 3’ 
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Promoter fragment β-Syn (-3.7/1)  
F 5’ –ATA TCT CGA GGC ACG CAC CTG TAG TCT C- 3’ 
R 5’ –TAA AGG ATC CGA ACA CGT CCA TCC TGG C- 3’ 
 
PCR Mutagenesis 
PCR enzymes such as Pwo polymerase (Roche applied science, Burgess Hill, 
UK) or Prime Star DNA polymerase (TaKaRa), dNTP’s and assay buffers were 
supplied by New England Biolabs Inc (Hertfordshire, UK). 
Primers were produced by MWG (Germany). 
 
Transformations  
E.Coli XL-2 blue cells were supplied from Stratagene (Oxford, UK). The pET 
plasmid DNA was used to transform XL-2 blue competent cells, from which 
permanent bacterial stocks were prepared in 15% sterile glycerol. Protein 
expression was conducted by DNA transformation into BL21 cells (Promega Ltd, 
Hampshire, UK). 
 
DNA Purification 
DNA purification kits were purchased from QIAGEN and Fermentas Molecular 
Bio (York, UK). 
 
Agarose Gel Electrophoresis 
10X Bluejuice loading dye and 1kb gene ladder were obtained from Invitrogen. 
Agarose and ethidium bromide were supplied by Melford Laboratories Ltd 
(Ipswich). 
 
Protein Expression and Purification 
LB broth and Carbenicillin were obtained from Melford Laboratories Ltd (Ipswich).  
Isopropyl β-D-1-thiogalactopyranoside (IPTG) was obtained from Apollo 
Scientific. 
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Chelating sepharose was purchased from GE healthcare. 
Ultra filtration equipment, including filters, was purchased from Millipore.  
Dialysis membrane was obtained from Medicell and EDTA from Fisher Scientific 
(Loughborough). 
Tris and Sodium Chloride were obtained from Fisher Scientific. 
MOPS was obtained from Sigma-Aldrich. 
Phenylmethanesulphonylfluoride (PMSF) was purchased from Melford 
Laboratories Ltd (Ipswich). 
 
Protein Determination 
Biorad reagent was obtained from BioRad Laboratories (Hercules, CA, USA). 
Bovine Serum Albumin BSA was obtained from Fisher Scientific. 
 
 Protein Purity 
SDS gels: 30% acrylamide protogel was purchased from Fisher Scientific. 
Ammonium Persulphate (APS) was purchased from Melford Laboratories Ltd 
(Ipswich). 
N,N,N,N-Tetramethylethylene-diamine (TEMED) 
Sodium Dodecyl Sulphate (SDS) was obtained from Melford Laboratories Ltd 
(Ipswich). 
Glycine, Coomassie brilliant blue, Methanol and glacial acetic acid were obtained 
from Fisher Scientific. 
 
Western Blotting 
Marvel dry semi-skimmed milk. 
PVDF membrane was purchased from Millipore (Bedford, MA, USA). 
Blotting paper was purchased from Fisher Scientific. 
Tween 20 was purchased from Fisher Scientific. 
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Antibodies for α-Syn:  
Mouse primary antibody directed against the C-terminus of α-Syn (Zymed 
laboratories). 
Sheep primary α-Syn antibody (Abcam) directed against amino acids 11-26 of α-
Syn sequence. 
 
Cell Culture 
Dulbecco’s modified eagles media (DMEM) was obtained from Lonza. 
Fetal Bovine Serum (FBS) was obtained from Lonza. 
Trypsin-EDTA was obtained from Lonza. 
 
 
    2.2 Methods 
 
 
2.2.1 Site-directed mutagenesis 
 
Site directed mutagenesis was performed to create mutant form of α-Syn lacking 
the potential metal binding sites. The mutation was introduced to the plasmid 
(pET15b) containing α-Syn coding sequence using PCR. The following reactions 
were set up in 0.5ml thin-wall PCR tubes: 1µl template DNA (50-100ng), 1.2µl of 
25µM of each primer, 0.5µl of 25mM of dNTPs, 5µl 10x buffer (-MgSO4), 0.5µl 
Pwo Polymerase, 2.5mM MgSO4 and up to 50µl sterilised MilliQ water.  
The PCR programme, utilising a Thermo Hybaid PCR Sprint thermal cycler, was 
as follows: one cycle: 95°C for 30 seconds; 5 cycles: 95°C for 30 seconds, 50°C 
for 1 minute, 72°C for 7 minutes; followed by 15 cycles: 95°C for 30 seconds, 
55°C for 1 minute, 72°C for 7 minutes; finally, one cycle: 72°C for 10 minutes. 
Temperature was held at 4°C. PCR samples were then Dpn1 treated for one 
hour at 37°C to remove the remaining parental DNA and transformed afterwards 
into competent cells (XL-2 blue competent cells). The following are the primer 
sequences used to create the N-terminal mutation deleting amino acids 1 to 9: 
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Forward primer: 5’ cgcggcagccatatgaaggccaaggagggag 3' 
Reverse primer: 5' ctccctccttggccttcatatggctgccgcg 3' 
After transformation, single colonies were picked individually and grown in 5ml 
LB with relevant antibiotic (50µg/ml Carbenicillin). DNA was extracted and 15µl 
was sent to Geneservice for sequencing.  
 
 
2.2.2 Preparation of Bacterial Competent Cells 
 
XL-2 Blue Ultra competent cells (Stratagene) and BL21 (DE) competent cells 
(Promega) were plated on two separate LB agar plates and incubated overnight 
at 37°C. A single colony from each plate was inoculated into 10ml LB medium 
and incubated overnight at 37°C. The 10ml overnight culture was then added to 
200ml LB medium and incubated at 37°C shaking at 200rpm until it reached an 
optical density of 0.6 at 600nm. After that, the culture was centrifuged at 4000rpm 
at 4°C for 10min. Cell pellets were then resuspended in 200ml ice cold 0.1M 
sterile MgCl2. The mixture was then centrifuged as mentioned earlier and the 
cells pellets were resuspended in 100ml ice cold 0.1M CaCl2. The mixture was 
incubated on ice for 20min and centrifuged as previous. The cell were 
resuspended in 10ml ice cold 0.1M MgCl2 with 15% glycerol and dispensed into 
200µl aliquots in 1.5ml tubes sitting on dry ice. The cells were stored at -80°C. All 
the work was performed next to the flame and all the solutions and tubes were 
sterilized by autoclaving. 
 
 
 2.2.3 Transformation 
  
XL-2 blue, JM109 and BL21 competent cells were used. Cells were thawed on 
ice by gently flicking the tube. 3µl of DNA was then added to 50µl of competent 
cells in pre-chilled tubes and incubated on ice for 30 minutes. Cells were then 
heat shocked at 42°C for one minute and then placed back on ice for another two 
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minutes. 300µl LB broth was added to the cells/DNA mixture and incubated for 
30-60 minutes at 37°C, shaking at 200 rpm. The mixture was centrifuged for 
5minutes at 4000rpm. The cell pellet was then resuspended in 150µl supernatant 
and plated on LB agar plates supplemented with appropriate antibiotic and then 
incubated at 37°C, overnight. This will allow the selection of transformed 
colonies.  
 
 
2.2.4 DNA Purification 
 
Single colonies from transformation plates were picked up and added individually 
to 10ml LB broth in 25ml Falcon tube containing 50µg/ml carbenicillin. Cultures 
were incubated at 37°C, shaking at 200rpm overnight. Next day, the cultures 
were centrifuged 4000rpm for 7 minutes to pellet the cells, and the supernatants 
were discarded. Plasmid DNA was then purified using the QIAprep Spin Miniprep 
kit according to the manufacturers protocols (QIAGEN). The DNA concentration 
was then determined by diluting the DNA in MilliQ water at 1:200 and then 
measuring the absorbance at 260nm in a UV spectrophotometer (Cary UV Vis 
Spectrophotometer).    
DNA purified following mutagenesis or cloning process was run on 1% 
agarose/TAE gel with 0.5µg/ml ethidium bromide to confirm the DNA purification. 
Gels were run for 100V for 1hr using a BioRad mini-sub®cell GT gel tank and 
BioRad power pack 300. Gels were photographed under long wave UV light. 
DNA concentration was determined using absorbance at 260nm in a UV 
spectrophotometer. DNA was sent to check for sequence analysis (Geneservice).  
 
 
2.2.5 Cloning  
 
Fragments of alpha or beta synuclein promoters were cloned into a plasmid 
reporter system. BAC clones containing the genomic sequences of alpha and 
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beta synuclein genes were purchased from RZPD (RPI-27M7 and RZPD1.0). 
This process included three steps, starting with PCR, then ligation and finally 
transformation, and was used to clone β-Syn (-3742/1) into pGL3basic plasmid 
vector.  
 
2.2.5.1 PCR Amplification 
 
PCR reactions were set up in 200µl thin wall PCR tubes; 1µl DNA (100ng/µl); 
0.6µl 25µM forward primer; 0.6µl 25µM reverse primer; 1µl 10mM dNTPs; 10µl 
5X buffer (Prime star buffer); 0.5µl Prime star DNA polymerase (TAKARA) and 
the volume made up to 50µl with nuclease-free water. Tubes were tapped to mix, 
spun briefly, and placed in Thermo Hybaid PCR Sprint thermo cycler. PCR 
programme was set as follows: 1 cycle: 98°C for 1 minutes; 35 cycles: 98°C for 
10 seconds, followed by 68°C for 4 minutes; 1 cycle: 72°C for 12 minutes. 
Temperature was hold at 4°C. Samples were then digested by restriction 
enzymes. 
 
2.2.5.2 Restriction enzyme digestion 
 
The digestion reactions were set up for both PCR product (insert) and plasmid 
vector (pGL3-basic) as follows: 3µg of plasmid vector, 5µl of 10X buffer and 1µl 
of each restriction enzyme (Xhol, BamHI and Bgl II) in a 1.5ml tube and made up 
to 50µl with nuclease-free water. The mixture was vortexed gently and spun 
down and then at the appropriate temperature for 2-4 hours or overnight. The 
digestion product was then gel-purified using the manufacturers protocols 
(QIAquick Gel Extraction Kit, QIAGEN) (2.2.5.4). Amplified DNA was digested by 
using ¾ of the PCR product volume (35µl) with 1µ of each restriction enzyme 
(XhoI /BamHI), 5µl of 10x buffer and made up to 50µl with nuclease-free water. 
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2.2.5.3 Dephosphorylation of Vector DNA 
 
The digested DNA vector was dephosphorylated by treatment with shrimp 
alkaline phosphatase SAP (Roche) to prevent the self-ligation of the plasmid. The 
mixture of 3µg digested vector and 3µl shrimp alkaline phosphatase with 3µl 10x 
SAO buffer were incubated at 37°C for 15 minutes. The enzyme was then 
inactivated at 65°C for 15 minutes. 
 
2.2.5.4 DNA Extraction 
 
This was performed by agarose gel electrophoresis. 2µl of the digested mixtures 
with 3µl loading dye, were loaded onto 1% agarose gel/TAE with 0.5µg/ml 
ethidium bromide. Agarose gel was run at 100V, 400mA for 45 minutes with 1Kb 
DNA ladder. The separated DNA was then visualised using a UV light source to 
detect DNA bands corresponding to the expected sizes of the products. The total 
volume of the digested mixtures was run then to extract the DNA. Fragments of 
interest were cut off using a clean, sharp razor blade. The DNA was extracted 
from the gel slices using the QIAquick Gel Extraction Kit according to the 
manufacturer’s protocol. In brief, each gel slice was weighed in colourless tube. 
Three volumes of buffer QG (supplied within the kit) was added to one volume of 
gel (100mg ~ 100µl) followed by incubation at 50ºC for 10min until gel slice was 
completely dissolved. One volume of isopropanol was then added to the sample, 
mixed and applied to QIAquick spin column to bind DNA. Several buffer washes 
were applied before eluting DNA with nuclease free water. The purified DNA was 
stored at -20°C.  
 
2.2.5.5 Ligation 
 
2µl of each of the DNA vector and DNA insert were run on 1% agarose gel to 
estimate the concentrations of both DNA samples. 5µl 0.1µg/µl DNA Ladder 
(GeneRuler™ 1kb DNA Ladder, 250-10,000bp) was run next to fragments on gel. 
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DNA Ladder was used for DNA sizing and approximate quantification as provided 
by manufacturer (Fermentas Molecular Biology Tools). The aim was to use 50ng 
plasmid vector and 150ng of DNA insert (1:3 ratio) in a total reaction volume of 
20µl. The ligation reaction was carried out in 1.5ml tube by adding DNA plasmid 
and DNA insert, 1µl T4DNA ligase (Promega), 2µl 10X ligation buffer and up to 
20µl with nuclease-free water. The reaction mix was incubated at 16°C overnight. 
 
2.2.5.6 Transformation 
 
The product from the ligation reaction was then transformed into XL-2 blue or 
JM109 competent cells as described previously in 2.2.3.  
 
 
2.2.6 Protein Expression and Purification 
 
2.2.6.1 Transformation 
 
The alpha synuclein open reading frame was previously cloned into pET15b (for 
His-tag protein) and pET11a (for untagged protein). Plasmid DNA was 
transformed into BL-21 competent cells as described previously in 2.2.3.  
 
2.2.6.2 Protein Expression 
 
A single colony was picked from a transformation plate and added to 100ml flask 
tube with 50ml LB broth with 50µg/ml carbenicillin. The culture was grown 
overnight at 37°C. The next day, the 50mls were added to a litre of LB with 
50µg/ml carbenicillin and incubated at 37°C, 200 rpm, until the cells reached an 
optical density at 600nm of 0.5-0.8. 1ml of 1M IPTG is used to induce protein 
expression for 3-4 hours. Cells were pelleted by centrifugation at 6000rpm for 10 
minutes and pellets were stored at -20°C prior to protein purification. 1ml of 
culture was taken out before starting the induction with IPTG and another ml of 
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culture was taken out before pelleting the cells by centrifuging at 6000rpm as un-
induced and induced samples, respectively, to check the protein expression later 
by running the samples on SDS-PAGE gels.  
 
2.2.6.3 Protein Purification 
 
a. Purification of His-tag protein 
IMAC column (Immobilized Metal Affinity Chromatography) was used to purify 
His-tag proteins. It included two steps, starting with preparing the lysate and then 
loading it onto the column. Cell pellets were resuspended in 2ml buffer (50mM 
Tris pH7.5, 10mM MgCl2) per gram of cell pellet. 4µl of 100mM PMSF 
(Phenylmethyl Sulphonyl Fluoride) per ml lysate was then added, followed by 
sonicating (4X 1 minute each) at 75% power. Sonication of lysate was performed 
on ice. After that, 50µg DNAse1 per ml lysate was added and samples were 
incubated shaking at 37°C, 200rpm for 30 minutes to one hour. Finally, 4ml of 8M 
Urea buffer pH 7.5 per gram of cell pellet was added (48g Urea, 11.6g NaCl, 
10.55g Tris-HCl and dH2O up to 1L pH7.5), followed by sonicating (3X 1 minute 
each) at 75% power. The lysate was then centrifuged at 12000rpm, 20 minutes, 
at 4°C. The next step was to filter the lysate through a 0.45µm filter before 
applying it onto a nickel affinity column, which had been packed with a bed of 5ml 
chelating sepharose (GE healthcare). The column was first washed with 5 
volumes of Milli Q water (pH7.5), 5 volumes of 0.3M nickel sulphate, 5 volumes 
of MilliQ water pH7 and equilibrated with 5 volumes urea buffer pH7.5. After the 
filtrate had been loaded, the column was washed with 25ml of 8M urea buffer 
pH7.5, 150ml of 25mM imidazole in urea buffer, 25ml of 40mM imidazole in urea 
buffer and the protein was finally eluted with 300mM imidazole in urea buffer. 
Proteins were then dialysed in chelex-treated MilliQ water pH7.5 prior to use in 
aggregation assays. 
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b. Purification of untagged proteins 
Ion Exchange Chromatography IEC was used to purify the untagged synuclein 
proteins. IEC separates proteins based on their net charge which is dependent 
on the composition of the buffer used. By adjusting the pH or the ionic 
concentration of the buffer, various protein molecules can be separated. IEC can 
be either anion or cation exchange chromatography. In anion exchange 
chromatography, negatively charged ions bind to positively charged resins, while 
it is the opposite case in cation exchange chromatography. Then, by increasing 
ionic strength of the elution buffer, the bound molecules will come off the column 
and will be eluted.   
 
 
Cell pellets were resuspended in buffer A (50mM Tris, pH8) with 1mM PMSF, 
50µg/ml DNAse1 and 50µg/ml Lysozyme. The cells were then lysed by 
sonication (3X 1 minute each) on ice and 1% (w/v) of streptomycin sulphate was 
added to precipitate ribosomal proteins. The cell lysate was centrifuged at 8000g 
for 20 minutes at 4°C and the supernatant was retained. 30% (w/v) ammonium 
sulphate was then added to the supernatant and stirred at 4°C overnight to 
precipitate the protein. Next day the mixture was centrifuged at 10000g for 20 
minutes at 4°C and the cell pellets were retained. At this stage, the cell pellet was 
resuspended with buffer A and filtered through a 0.22µM filter (Millipore) before it 
was loaded onto Q-Sepharose Fast Flow column pre-equilibrated with 2CV of 
buffer A and connected to a fast protein liquid chromatography (FPLC) system 
(AKTA FPLC) (Amersham Biosciences). The column was then washed with 
another 2CV of buffer A. Proteins were eluted using a linear gradient of buffer B 
(50mM Tris, 1M NaCl pH8). It started with 2CV of 0-20% buffer B, followed by a 
2CV wash of 20% buffer B. Finally, 2CV of 20-100% buffer B wash (2CV) was 
used to elute bound proteins. Fractions containing proteins were identified by 
size analysis using SDS-PAGE gel electrophoresis with Coomassie staining. This 
method was used to purify untagged Wild Type α-Syn and all its metal binding 
mutants used in this project. 
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2.2.6.4 Dialysis of Protein Fractions 
 
The dialysis tubing was prepared as follows: boiled in 2% (w/v) NaHCO3 with 
1mM EDTA for 5 minutes and rinsed in dH2O. Protein samples were dialysed in 
the tubing (MW12-14KDa for His-tagged proteins and MW7KDa for untagged 
proteins, against chelex-treated MilliQ water pH7. 1gram of chelex was added to 
5 liters of MilliQ water and stirred for a minimum of 2hours. Then the water was 
filtered through filtering paper to get rid of the chelex and pH was adjusted to 7 
using 1M NaOH or 1M HCl solutions.  
 
2.2.6.5 Determination of Protein Concentration 
 
a. Bradford Assay  
Bradford assay was used to determine protein concentration where protein 
standards of 0 to 1mg/ml Bovine Serum Albumin (BSA) with 0.2mg/ml intervals 
were prepared using MilliQ water. 10µl of each of the standards and of the 
protein samples as well were prepared. Bradford reagent was diluted 5-fold in 
MilliQ water. 1ml of this diluted reagent was then added to the 10µl of standards 
and samples, vortexed and incubated for 5 minutes at 25°C. Then the solutions 
were transferred to plastic cuvettes and spectrographically analysed at 595nm in 
a Cary UV Vis Spectrophotometer. From the standards, a calibration curve was 
calculated and used to determine the protein concentration of the samples.   
Also, the same assay was later performed using a micro-plate (96-well plate) 
using a plate reader (BMG FLUOstar Omega). 2µl of each of the standards and 
the samples were taken out and spread into the wells of the 96-well plate. 200µl 
of the diluted reagent was then added to each of the samples using a multi-
channel pipette and mixed well. Standards and samples were then incubated for 
5 minutes at 25°C. The plate was then put into the plate reader which was set up 
to measure absorbance at 595nm. A calibration curve was drawn automatically in 
the machine and unknown protein concentration was therefore determined. 
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b. UV Absorbance 
This method was also used to determine the concentration of recombinant 
protein. Protein samples (100µl) and appropriate buffer (900µl) were transferred 
to clean quartz cuvettes and mixed properly. The absorbance at 275nm was 
measured and in a Cary 50 Bio UV-Visible spectrophotometer (Varian), after it 
was zeroed using the same buffer. Protein concentration was calculated using 
C=A275 X dilution/ molar coefficient. Where, C: is concentration (M), A275: 
absorbance at 275nm. The extinction coefficient of the protein was determined 
based on its amino acid sequence (us.expasy.org/tools/protparam.html).  
 
 
2.2.7 Polyacrylamide Gel Electrophoresis 
 
12% separating gels were prepared and poured into the gap between ATTO 
glass plates and allowed to set. A 4% stacking layer was added to the top of the 
separating gel. For gradient gel preparation, a 5% acrylamide solution and a 20% 
acrylamide solution were prepared individually in the pouring stand before mixing 
them together and pouring them into the gap between the ATTO glass plates. A 
12-well comb was then set in the stacking layer to create wells to load the 
samples in. Protein samples for analysis were mixed with 4x loading dye (~10µl) 
and dH2O to make a total volume of 20µl. Protein samples were heated at 100ºC 
for 5min and then loaded into the wells along with a protein size marker and the 
gels were put into a tank containing running buffer. The gels were run for 40min 
at 35mA and 260V per gel. The electrophoresis was stopped when the dye 
reached the bottom of the gel. Under denaturing conditions, proteins were 
separated by molecular weight. Protein fractions were observed by either 
coomassie blue staining or western blotting using unstained protein ladder.  
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Densitometry analysis was performed using Image J programme where the same 
size shape was placed over the bands and the programme measured the pixel 
density which was then related to control, usually as percentage.  
 
 
Recipes for acrylamide gels are shown below: 
12% acrylamide gel: 2.3ml dH2O, 2.8ml 30% acrylamide, 2.6ml 1M Tris (pH8.8), 
80µl 10% SDS, 10µl TEMED, 50µl 20% APS. 
4% stacking gel: 3.6ml dH2O, 630µl 30% acrylamide, 1.3ml 1M Tris (pH6.8), 
100µl 10% SDS, 10µl TEMED, 50µl 20% APS. 
4X loading dye: For 10mls: 4ml glycerol, 2ml 1.5M Tris (pH 6.8), 0.4ml 0.5% 
Bromophenol blue, 0.4g (4% w/v) SDS, 200mM B-mercaptoethanol, dH2O to 
10mls. 
Running buffer: For 1L of 10X: 188g Glycine, 30.2g Tris, 100ml 10% SDS and up 
to 1L with dH2O. 
 
 
2.2.8 Coomassie Blue Staining 
 
The gel will be taken out of the plates and soaked in Coomassie stain (for 100ml: 
0.25g Coomassie brilliant blue, 45ml methanol, 45ml dH2O, 10ml acetic acid) for 
at least 1 hour. The dye will bind nonspecifically to all proteins and any dye that is 
not bound to the protein will diffuse out of the gel during destaining steps. Gels 
are destained in a destaining buffer (For 2L: 100ml methanol, 140ml glacial 
acetic acid and 1760ml dH2O) and gently rocked until the protein bands were 
visualised against a clear background.  
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2.2.9 Western Blotting  
 
Also referred to as immunoblotting, western blotting is a method used to detect 
specific protein in a given sample. After gel electrophoresis to separate 
denatured proteins by molecular weight, proteins were then transferred to a 
PVDF membrane (nitrocellulose membrane) by a semi-dry transfer method. 
Polyacrylamide gels and blotting paper were soaked in transfer buffer (for 1L: 
500ml 1X Running buffer, 200ml methanol and 300ml dH2O). PVDF membranes 
were soaked in methanol and placed on the top to pre-soaked blotting paper. The 
gel was then placed on top of them. Finally, blotting paper was used on top of the 
previous layers and care was taken to remove any bubbles while placing all the 
layers on top of each other. The transfer was performed in a Trans-Blot®Semi-
Dry transfer machine (Biorad). The transfer was run at 50mA per gel, 25V for 1.5 
hour or 33mA, 6V overnight for proteins of cell lysate transfer.  
 
 
The membrane was then blocked in 5% milk in PBS-0.1% Tween20 at room 
temperature (RT) for 30 minutes to 1 hour. The membrane was then incubated n 
primary antibody diluted at 1:2000 in 1% milk in PBS-0.1% Tween20 for 2 hours 
at RT or at 4°C shaking overnight. Next, the primary antibody solution was 
removed and the membrane was washed 3 times in PBS-0.1% Tween20 15 
minutes first and then 2X of 5 minutes. Horseradish peroxidise (HRP) conjugated 
secondary antibody diluted at 1:4000 in 1% milk in PBS-0.1% Tween20 was 
added to the membrane and incubated shaking at RT for 1 hour. The membrane 
was then washed 3 times, 5 minutes each and treated with ECL PLUS Western 
Blotting detection kit (Amersham Pharmacia Biotech) for 5 minutes and exposed 
to film. A compact X-ray processor was used to develop the film. Analysis of 
expression levels of α-Syn and tubulin were determined. Intensities of detected 
bands were analysed and compared using densitometry. Values obtained by 
densitometry analysis of the bands were normalised to tubulin levels.  
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α-Syn and its disease associated mutants and its N-terminal metal binding 
mutants were detected using a mouse primary antibody (Zymed Laboratories 
Inc.) directed against the C-terminus of α-Syn sequence. It was visualized with a 
secondary anti mouse antibody (Invitrogen). While α-Syn and its C-terminal 
mutant (Δ116-129) was detected using sheep primary α-Syn antibody (Abcam) 
directed against amino acids 11-26 of α-Syn sequences, and was visualized with 
a secondary anti sheep antibody (Molecular probes).  
 
 
2.2.10 Isothermal Titration Calorimetry (ITC) 
 
ITC experiments were carried out in a Microcal titration calorimeter (Microcal VP-
ITC). Metal solutions were prepared by dissolving the metal in chelex-treated 
MilliQ water. Protein samples and metal solutions for calorimetric analysis were 
diluted from concentrated stocks into 250µM and 12mM final concentration, 
respectively. Copper (CuSO4) was added to the protein prior to ITC experiments 
at 2:1 ratio (metal: protein). The pH of the working solutions, of both protein and 
metal, was adjusted to pH7 with 50mM MOPS buffer as final concentration. All 
reactions and measurements were conducted in an isolated cell chamber at 
maintained temperature of 25°C. A series of 60x 2µl injections of buffered metal 
solution were titrated into the well chamber containing 1.2ml of buffered protein 
solution. A time gap of 2 minutes was allowed between injections to allow system 
temperature to equilibrate between reactants before proceeding to the next 
injection. A small amount of sample buffer was simultaneously injected into a 
reference well, which services as a reference temperature for the machine to 
equilibrate after each injection. The chamber well was washed thoroughly 
between each run with up to 10 chamber volumes of MilliQ water using a clean 
syringe. The machine measured any heat changes generated in the experimental 
well during each injection as the metal reacted with the protein. The machine 
recorded the total heat change per second over time. Data was then fitted into a 
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binding isotherm, which represents the heat change per mole of injectant (metal 
solution) against metal to protein molar ratio. ITC experiments were repeated 
three times for each condition to ensure reproducibility. Each experimental 
condition had a blank run with buffer instead of protein in the chamber well. This 
data was subtracted from the protein run to account for heat dilution, which is the 
amount of energy released when metal is titrated into the buffer. The data was 
analysed using Origin 5.0 software from Microcal and fitted into a regression 
model to predict the number of binding sites on the protein, binding constants 
(Ka), and change in enthalpies (ΔH) and entropies (ΔS).   
 
 
2.2.11 Ferrireductase Assay 
 
This assay was performed using recombinant protein or cell lysate from cells 
over-expressing the protein. 100µM recombinant protein or protein solutions of 
standardised cell lysates were mixed with a final concentration of 100µM 
ferrozine ((3-(2-pyridyl)-5,6-bis(phenyl sulfonic acid)-1,2,4-triazine), 100µM 
NADH, 10mM MOPS pH7. Protein had been exposed to 2 equivalents of copper 
(II) sulphate and allowed to equilibrate. The reaction was started by the addition 
of iron (III) citrate to a final concentration between 1µM and 100µM. the reaction 
was set up in a final volume of 100µl. Samples were performed in triplicates and 
reactions were carried out in 96-well plates. Changes in absorbance were 
monitored at 562nm in the plate reader (BMG FLUOstar Omega). 
 
 
    2.2.12 Aggregation Assay 
 
A Thioflavin-T based fluorometric assay (ThT assay) was used to investigate 
synuclein aggregation and fibril formation in vitro. ThT assay is based on the 
ability of the fluorescent dye Thioflavin-T to bind to β-sheet rich amyloid 
structures and gives fluorescence at excitation and emission maxima of 450nm 
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and 480nm, respectively. The dye alone or in the presence of low content of β-
sheet structures will produce no fluorescence at these wavelengths. A stock 
solution of buffer (10mM Tris or 10mM MOPS at pH7.4, and 10mM NaP buffer in 
optimisation experiments) and metals were prepared in advance. Master mixes of 
dH2O, metals (up to the required final concentration), protein (up to the final 
concentration required), buffer and ThT (at 10µM final concentration) were added 
in order into 1.5ml tubes. Master mixes were gently mixed by inverting the tube 4-
6 times. Samples were prepared in triplicates or quadruplicates. A 100µl of each 
mix was then aliquoted into 96-well plate and incubated shaking at 37°C, 
600rpm. The fluorescence was measured with different time intervals, averaged 
and then plotted into a sigmoidal curve. Fluorescence measurements were 
performed using Fluroskan Ascent software version2.4 (with excitation at 444nm 
and emission at 485nm) and using BMG FLUOstar Omega plate reader. 
 
Data of ThT fluorescence intensities were processed using SigmaPlot software 
using nonlinear regression. The ThT fluorescence measurements were plotted as 
a function of time and fitted by a sigmoidal curve described by the following 
equation using SigmaPlot: 
 
                                                F= y0 + a/ 1 + e
-(x-x0/b)  
Y0 is minimum fluorescence, a: maxY- minY, X0: time to 50% maximum 
fluorescence. The apparent constant rate, kapp, for fibrils growth is given by 1/b. 
ThT values were normalised by subtracting the background fluorescence of the 
buffer, then calculating the fluorescence as a percentage to the maximum value 
in each set of experiments.  
 
 
2.2.13 Maintenance and Growth of Mammalian Cells 
 
SHSY-5Y (human neuroblastoma) cells were cultured in 50% (v/v) Dulbecco’s 
Modified Eagle media and 50% (v/v) Ham’s F12 supplemented with 10% (v/v) 
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fetal bovine serum (FBS), 100U/ml penicillin, 100µg/ml streptomycin and 2mM 
glutamine. Growth conditions were maintained at 37°C and 5% CO2 in a 
humidified incubator. Routine culture was performed as follows: 1ml trypsin was 
added per T25 flask after medium was aspirated and incubated at room 
temperature (RT) for 2-3 minutes with gentle tapping. 4ml medium was used to 
inactivate trypsin. Cells were counted using the hemocytometer and plated at 3 x 
105 in a new T25 with 5ml medium. This procedure was repeated every 5-6 days 
until cells are confluent with changing the media every 2 days. 
 
 
2.2.14 Transfection 
 
Transfections were performed using FuGene 6 transfection reagent (Roche) and 
genejuice transfection reagent. Both transient and stable transfections were 
performed.  
 
     2.2.14.1 Transient Transfection Prior to Luciferase Assay 
 
SHSY-5Y cells were trypsinised and counted using a hemocytometer in order to 
plate 8x 104 cells per well in a 24-well plate in 500µl media. Cells were grown 
overnight at 37°C with 5% CO2. The next day, cells were transfected with two 
individual reporter vectors at the same time. The first is the experimental vector, 
(pGL3basic), containing the insert of interest and a second plasmid that serves 
as internal control for the transfection (pRL-SV40 or pRL-TK). Either internal 
control plasmid serves to control transfection efficacy as results were normalised 
against it. Transfection was performed using 200ng of the pGL3basic plasmid 
and 10ng of the control plasmid. A master mix of 100µl serum-free media (DMEM 
containing no FBS, no antibiotics), 200ng DNA and 0.7µl transfecting reagent 
(FuGene 6) per well, were mixed in a 1.5ml sterile tube by gentle flicking. The 
mixture was incubated at RT for 15 minutes and then 100µl of the mix was added 
into each well of the 24-well plate containing 400µl fresh media. Cells were 
 60 
returned to the incubator and grown at 37°C with 5% CO2. After 48 hours of 
incubation, the media was removed and cells were washed using PBS prior to 
lysing. Cells were harvested using a Passive Lysis Buffer (PLB) provided in the 
Luciferase Kit (Promega). The buffer was diluted 5 times with dH2O and then 
100µl of the diluted buffer was added to each well. The plates were rocked for 20 
minutes on a shaker before storing at -80°C until analysis.  
 
     2.2.14.2 Stable Transfection 
 
SHSY-5Y cells were plated in 6-well plates at 50% confluency a day before 
transfection and were grown at 37°C with 5% CO2. The next day, cells were 
transfected as follows: 50µl serum-free media with 3µl transfecting reagent 
(FuGene 6) were added into a 1.5ml sterile tube and flicked gently and incubated 
at RT for 5 minutes. For each cell line, 1µg of DNA was then added to the mix 
and gently flicked again and further incubated for another 15 minutes at RT. After 
that the transfection mix was added to each well of the 6-well plate and the plate 
was returned to the incubator. Cells were selected by adding 400µg/ml G418 
sulfate (Calbiochem) 24 hours after transfection and maintained at 100µg/ml to 
keep the selection. Successful transfection was assessed by western blotting to 
ensure over-expression of the protein was observed.  
 
 
2.2.15 Luciferase Assay 
 
SHSY-5Y cells were transfected with two individual reporter vectors at the same 
time. The first is the experimental vector, (pGL3basic), in which the sequence of 
interest is cloned upstream of the Firefly Luciferase gene. The second is the 
control vector, Renilla Luciferase, which serves as internal control for the 
transfection. The activities of both luciferases were detected in the same sample 
using the Dual-Luciferase Reporter Assay System (Promega). Cells were 
defrosted shortly prior to the Luciferase assay. 10µl of cell lysate was aliquoted in 
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each well of a white 96-well plate. Samples were plated in triplicates. Firefly 
Luciferase activity was measured first by adding (LARII) reagent to generate a 
stabilized luminescent signal that will be detected and quantified. Then, the 
reaction was quenched and the Renilla Luciferase reaction was simultaneously 
initiated by adding (Stop&Glo) reagent to produce a stabilized signal from Renilla 
Luciferase that will also be detected and quantified. Finally, the activity of the 
experimental reporter was normalized to the activity of the control reporter to 
minimize experimental variability caused by differences in cell viability and 
transfection efficiency.  
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Chapter Three: Ferrireductase Activity of 
Alpha Synuclein 
 
 
    3.1 Introduction 
 
 
A key issue preventing the general understanding of the synucleinopathies is that 
the function of α-Syn remains unknown. Since 15% of α-Syn has been found to 
be membrane-bound (Lee, Choi et al. 2002), several different roles of α-Syn in 
membrane-associated processes have been proposed such as the regulation of 
synaptic neurotransmitter and dopamine release (Abeliovich, Schmitz et al. 
2000). α-Syn was shown to be a metal binding protein, although the precise role 
for metal binding and whether it has any effect on the protein’s function is not 
known yet.  
 
 
Metals, such as copper, iron and zinc, have been reported to exist at high 
concentrations in α-Syn fibrillar deposits, and were proposed to be important 
factors that cause α-Syn aggregation (Uversky, Li et al. 2001b). Research has 
focused mainly on copper and, to some extent, iron. Studies of the coordination 
of copper binding to α-Syn have failed to reach a consensus result. Initial studies 
showed α-Syn to bind 5 to 10 molecules of copper (Paik, Shin et al. 1999), while 
a later study showed α-Syn to bind copper at two high affinity binding sites with 
more copper able to bind at other lower affinity sites (Rasia, Bertoncini et al. 
2005). A more recent study found two, independent, non-interacting copper 
binding sites in the N-terminus of α-Syn (Binolfi, Lamberto et al. 2008). 
Therefore, there is significant evidence that α-Syn is a copper binding protein, 
even though the exact number of binding sites and affinities are still controversial. 
In a normal functioning organism, these metals are essential for various 
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constituents of the mitochondrial respiratory chain, as well as other parts of the 
organism (Ohgami, Campagna et al. 2006). Copper and iron metabolism has 
been shown to be interrelated as copper-dependant oxidases have been shown 
to be components of cellular uptake pathways of iron in both yeast (Spizzo, 
Byersdorfer et al. 1997) and mammals (Nittis and Gitlin 2002). Eukaryotes have 
evolved complex mechanisms to regulate organismal and cellular concentrations 
of each metal, as a deficiency or an excess in either copper or iron can lead to 
metabolic collapse or organ toxicity, respectively (Ohgami, Campagna et al. 
2006). Both metals exist primarily in the oxidised form in the environment. 
Therefore, it is an obligate step to reduce these metals and transport them 
efficiently across the plasma membrane by high affinity transporters. Several 
metal transporters and reductases, located in different body organs, have been 
discovered and studied, such as DMT1 and CTR1 found in the plasma 
membrane of epithelial cells of the intestine (Ohgami, Campagna et al. 2006). 
Another example is the Steap protein family, which have been shown to function 
as metalloreductases and to be expressed in different tissues such as pancreas, 
prostate and brain (Ohgami, Campagna et al. 2006). In general, 
metalloreductases have been shown to be highly expressed in tissues relevant to 
metal homeostasis (Ohgami, Campagna et al. 2006; Ghio 2009), and have also 
been demonstrated to be membrane-bound proteins (Ghio 2009).  
 
 
Dopamine depletion is considered to be the neurochemical feature that 
characterises PD; however, reductions in the level of other neurotransmitters in 
PD patients have also been detected, including noradrenaline, GABA and 
acetylcholine (Ach). A decline in noradrenaline levels in PD is the most 
consistently observed (Gesi, Soldani et al. 2000). The depletion in 
neurotransmitters in dopaminergic terminals, which is an early event in PD 
pathophysiology, has been proposed to increase susceptibility to neurotoxins. 
Tyrosine hydroxylase (TH) is an iron-containing rate-limiting enzyme that 
catalyses the hydroxylation of L-Tyrosine to dihydroxyphenylalanine (DOPA), 
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which represents an essential step in the biosynthesis of catecholamines (CA) 
such as dopamine, adrenaline and noradrenaline (Nakashima, Hayashi et al. 
2009). Research in this domain has revealed that the decrease in catecholamine 
levels observed in PD could occur through oxidative or nitrative damage to TH 
causing a decrease in its catalytic activity (Ara, Przedborski et al. 1998; Kuhn, 
Aretha et al. 1999). These studies also suggested that inactivation of TH may 
lead to the formation of insoluble α-Syn fibrils and aggregates that could induce 
toxicity. This emphasizes the importance of a normal TH function to maintain 
normal levels of neurotransmitters and therefore emphasizes the importance of 
iron (ferrous iron) being a critical part of the enzyme and required for its function. 
 
 
It has been shown that the levels of iron in PD brains undergo a shift in favour of 
ferric iron (Fe3+) which constitutes α-Syn’s substrate in work presented in this 
chapter. Hence, a defect in α-Syn activity as a ferrireductase could possibly 
contribute to the previously mentioned iron increase. Moreover, this could also 
affect the inactivation of the TH as iron is an important part of the enzyme 
structure, and lead to the dopamine depletion occurring in PD cases.  
This chapter proposes a possible role of α-Syn as cellular ferrireductase using 
copper as co-factor and ferric iron (Fe3+) as substrate, in both cell-free 
(recombinant protein) and cell-based (SHSY-5Y cells) systems.  
 
 
3.2 Purification of Recombinant α-Syn  
 
In this study, recombinant His-tagged and recombinant untagged α-Syn was 
over-expressed and purified. His-tagged protein was used at the early stages of 
the project to investigate aggregation properties of the protein. After that, 
untagged protein was over-expressed and purified to further investigate its 
aggregation properties and ferrireductase activity.  
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3.2.1 Protein Expression and Purification  
 
Plasmid vector pET11a encoding untagged α-Syn was transformed into E.Coli 
BL21 expression strain cells. Protein expression was successfully induced with 
1mM IPTG. Protein expression was then allowed to proceed for 3-4 hours. Up to 
3L of induced cell culture were harvested by centrifugation at 7000g for 7 
minutes. The cell pellet was lysed mechanically by sonication (on ice) in buffer A 
(50mM Tris buffer pH8) with 1mM PMSF, 50µg/ml DNase1 and 50µg/ml 
lysozyme. The cell lysate was spun for 20 minutes at 8000g, after adding 1% 
streptomycin sulphate. Protein in supernatant was precipitated using 30% (w/v) 
ammonium sulphate stirring over night at 4°C. A second centrifugation step at 
10000g for 20 minutes was applied and the resulted pellet was resuspended in 
buffer A and loaded onto the 50ml anion exchange Q sepharose column pre-
equilibrated with 2CV buffer A. The column was then washed with another 2CV 
of buffer A, followed with a broad gradient wash starting with 2CV of 0-20% buffer 
B (50mM Tris, 1M NaCl pH8), followed by a 2CV wash of 20% buffer B wash. α-
Syn was eluted by 20-100% buffer B wash (2CV). A broad range of low peaks 
appeared on the UV chromatogram of the purification when applying the low 
concentration washes of buffer B, while a distinct high peak representing the 
eluted fractions of α-Syn, appeared during the high concentration flow of buffer B 
(Figure 3.1, A). Eluted fractions, corresponding to the high peak, containing α-
Syn were size analysed by SDS-PAGE gel with coomassie staining (Figure 3.1, 
B). Same purification method was used for α-Syn metal binding mutants. 
Fractions containing the protein were pooled and filtered at least two times 
through a PM30 membrane (Millipore), where most of the high molecular weight 
contaminants were trapped above the membrane while α-Syn pass through the 
filter. α-Syn was then concentrated using a PM10 membrane (Figure 3.1, C) and 
then dialysed against chelex-treated MilliQ water pH7.   
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(A)     
(B)              
(C)                
Fig. 3.1 Purification of untagged synucleins by anion exchange chromatography.  
(A) UV chromatogram showing the process of protein loading and elution. (B) α-
Syn eluted fractions separated on a 14% SDS-PAGE gel and coomassie staining. 
Lane1: protein marker. Lanes 2-10: 10µl of each eluted fraction. (C) Purified 
untagged synuclein proteins with anion exchange chromatography. Lane1: 
Protein marker. Lane2: WT α-Syn. Lane3: H50A α-Syn. Lane4: Δ1-9 α-Syn. Lane5: 
Δ1-9 H50A α-Syn. Star represents the peak at which the protein was eluted. 
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    3.3 Thermodynamics of Iron Binding to α-Syn 
 
Isothermal titration calorimetry (ITC) was used to assess the affinity of iron 
binding to α-Syn. It is important for this work to show that α-Syn binds iron like it 
binds copper, as copper is required for the proposed α-Syn ferrireductase activity 
as a co-factor while ferric iron (Fe3+) is the substrate. Isothermal titration 
calorimetry (ITC), a calorimetric technique, was used to assess the dynamics of 
ferric iron (Fe3+) binding to α-Syn. α-Syn was expressed and purified as 
described previously (2.2.6). The concentration of α-Syn was maintained at 
250µM and titrated with Fe3+ 12mM into the chamber of the ITC machine. 
Experiments were performed by titrating Fe3+ into α-Syn in the absence and the 
presence of copper. In some of the experiments, α-Syn was loaded with two 
equivalents of copper (CuSO4) to show that copper-loaded α-Syn is able to bind 
Fe3+ with a similar affinity to monomeric α-Syn in the absence of copper. The use 
of 2:1 Cu2+: α-Syn stoichiometry was based on recent studies showing that α-Syn 
is a high affinity copper binding protein at nanomolar range 1:1 stoichiometry 
(Davies, Wang et al. 2011; Dudzik, Walter et al. 2011). Therefore, 2:1 ratio will 
enable binding of copper to α-Syn. Both the metal solution present in the injector 
and the protein sample present in the chamber were buffered using 50mM MOPS 
pH7 (2.2.10). A background titration was performed where the identical ferric iron 
(Fe3+) solution was titrated into the chamber that is containing only the buffer 
(50mM MOPS pH7), as used in the experiments. This background titration was 
subtracted from each experimental titration, where α-Syn is present, to account 
for the heat of dilution. The heat of dilution represents the amount of energy 
released from the occurring dilution when metal is titrated into buffer. The energy 
change against the molar ratio is indicated by dots in the ITC data plots where 
the buffer run has already been subtracted (Figure 3.2). The resultant isotherm of 
the ITC experiments representing the interaction between α-Syn and ferric iron in 
the absence of copper is shown in Figure 3.2 (a representative isotherm of one 
experiment). This experiment was repeated three times at 25°C.  
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Fig. 3.2 ITC analysis of ferric iron (Fe3+) binding to untagged α-Syn in the absence 
of copper. The curve represents the heat enthalpy changes after addition of metal 
as a function of total metal/protein molar ratio in the chamber well.  
 
 
The titration of Fe3+ to α-Syn produced an exothermic response. The data best fit 
with a two binding sites model using the Microcal Origin 5.0 software, until the 
least squares regression X2 value was obtained. Using regression to fit the 
isotherm of the ITC data, the two binding sites model assumed two sites for Fe3+ 
binding, with different binding affinities and enthalpies, where one of the sites has 
a higher affinity comparing to the other site. This is also supported by the binding 
isotherm shown earlier in figure 3.2, where two phases of binding can be 
observed. The binding constants of the two Fe3+ binding sites to α-Syn in the 
absence of copper are shown in Table 3.1.   
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A similar result was also obtained when copper-loaded α-Syn was titrated with 
Fe3+ at 25°C, pH7. The background titration was similarly subtracted from each 
experimental titration, where α-Syn is present, to account for the heat of dilution. 
The energy change as a function of the molar ratio of Fe3+ binding to α-Syn 
showed considerable binding and the resulted ITC isotherm is shown in the 
following figure (Figure 3.3) after subtracting the buffer run.   
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Fig. 3.3 ITC analysis of ferric iron (Fe3+) binding to untagged α-Syn in the presence 
of Cu2+. The curve represents the heat changes after addition of metal as a 
function of total metal/protein ration in the chamber well. α-Syn was preloaded 
with two equivalents of copper (CuSO4). This figure is of one representative 
experiment and experiments were repeated three times. 
 
 
The titration of Fe3+ to copper-loaded α-Syn resulted in a similar-pattern of an 
exothermic reaction. Using Microcal Origin 5.0 software, data was best-fitted with 
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a two binding sites model until the least square regression X2 value was 
obtained. In the presence of copper, the model similarly suggested two binding 
sites with different affinities and enthalpies, where one has a lower affinity 
comparing to the other. The ITC isotherm was similar in both cases where copper 
is present or absent. Table 3.1 shows the stoichiometry and binding constants of 
Fe3+ binding sites to α-Syn in the presence and the absence of copper. 
 
α-Syn+Fe3+           n1      K1 (M
-1)          n2       K2 (M
-1) 
No Cu2+ 0.142767±0.067      2.13x10
6  1.984±0.055       1.06x105 
With Cu2+ 0.182767±0.088      4.43x10
5   1.98 ±0.108       3.17x104   
Table 3.1 Comparison of binding constants and number of binding sites of ferric 
iron to α-Syn in the absence and the presence of copper. Experiments were 
performed using 250µM α-Syn and 12mM of Fe3+, when copper was added α-Syn 
was pre-loaded with 500µM Cu2+. Each set of experiments were repeated three 
times. n1 and n2 represent binding stoichiometry and indicate the number of sites 
detected within each group of sites. 
 
n1 and n2 refer to the stoichiometry of ferric iron binding to α-Syn. The sum of N 
values for different sets of sites indicated the number of sites. It shows that α-
Syn, in the presence or the absence of copper, binds two ferric iron molecules 
with an error of less than 10%. K values, which represent the binding constants, 
were calculated from the mean of three independent experiments with errors also 
less than 10%. The data suggested two binding sites of Fe3+ where one of them 
has lower affinity comparing to the other site. ITC also provided association 
constants values (Ka) from which dissociation constants values (Kd) can be 
obtained which represents the measure of how tightly a ligand binds to a 
particular protein (Table 3.2).  
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α-Syn+Fe3+      K1 (M
-1)      Kd1(µM)       K2 (M
-1)      Kd2(µM) 
No Cu2+       2.13x10
6         0.469        1.06x105        9.433 
With Cu2+       4.43x10
5         2.257        3.17x104       31.545 
Table 3.2 Calculations of dissociation constant values of WT α-Syn from Fe3+ in 
the presence and absence of copper, based on affinity constant values obtained 
from ITC data.  
 
Enthalpy changes (ΔH) as calculated by ITC binding experiments showed that 
ΔH values of the binding events of Fe3+ to α-Syn were relatively close, thus 
reflecting sites with similar level of energy capacities. In addition to that, 
assessment of the free energy changes in the binding reaction showed the 
following results (Table 3.3), where the Gibbs free energy states of the iron 
binding process would favour a forward reaction at physiological concentrations 
and conditions. 
 
αSyn+Fe3+      n1   K1 (M
-1)  ΔG1 (KJ)      n2    K2 (M
-1) ΔG2 (KJ)       
No Cu2+ 0.142767   2.13x106  -7899.37    1.984  1.06x105  -7067.24  
With Cu2+ 0.182767   4.43x105  -7618.85    1.98  3.17x104  -6245.33       
Table 3.3 Free energy changes of the binding events as shown by ITC experiments 
 
3.4 Ferrireductase Activity of α-Syn 
  
One way to assess whether α-Syn displays ferrireductase activity is to use 
recombinant protein. A ferrozine-based colorimetric assay, known for its potential 
to detect and even quantify iron, was used to assess α-Syn ferrireductase activity 
(Riemer, Hoepken et al. 2004). Ferrozine (3-(2-pyridyl)-5,6-bis(phenyl sulfonic 
acid)-1,2,4-triazine) forms a complex with ferrous iron (Fe2+) that strongly 
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absorbs light at 562nm. The first experiment was conducted to obtain a standard 
plot (calibration curve) of ferrous iron (Fe2+) concentrations against absorbance 
at 562nm. This calibration curve was used for the determination of ferrous iron 
(Fe3+) concentrations. A range of standard concentrations of equal volumes of 
Fe2+ (used as sulphate form), was added anaerobically and mixed with 100µl 
ferrozine solution prepared at 100µM final concentration. After applying the 
ferrozine solution into ferrous iron (Fe2+) standards, the absorbance at 562nm 
was measured and it was found to rapidly increase to maximal values within 10 
minutes and produce a linear plot (Figure 3.4).  
 
                   
Fig. 3.4 Absorbance of the Fe2+-ferrozine complex formed with increasing 
concentrations of the standard (ferrous sulphate). The amount of iron indicated 
was contained in 100µl in wells of a 96-well plate. The data represent means ±SD 
of triplicates of a representative experiment.  
 
 
3.4.1 Determination of α-Syn Ferrireductase Activity 
 
For the assessment of ferrireductase activity purified recombinant protein WT α-
Syn was used at 100µM final concentration. The ferrireductase activity of α-Syn 
was stimulated by the addition of 100µM NADH as an electron donor and in the 
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presence of copper (Cu2+) as a possible co-factor. Studies have shown that α-
Syn is a copper binding protein, however it is still controversial to how many 
copper molecules can α-Syn bind. Therefore, a ratio of 2:1 copper: α-Syn was 
used in ferrireductase assays described in this chapter to ensure that α-Syn is 
present in the copper-bound form. Controls in the absence of copper, protein or 
NADH were used to ensure any observed activity is due to the copper-loaded 
protein.  
 
 
The assay was carried out in 96-well plates at a total volume of 100µl per well. 
Samples representing each condition were performed in triplicate. 100µM α-Syn 
was loaded with 2-fold copper in the sulphate form. Protein solutions were 
buffered with 10mM MOPS, pH7. 100µM of each of NADH and ferrozine were 
added to the buffered copper-loaded protein. The final step was then to add the 
ferric iron (Fe3+), and start measuring and monitoring changes in the absorbance 
at 562nm in BMG Fluorstar plate reader.  
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Fig. 3.5 Changes in the absorbance of Fe2+-ferrozine complex at 562nm in the 
presence of α-Syn and two different ferric iron concentrations. The assay was 
performed in 96-well plate with 100µM α-Syn loaded with 2-fold copper, 100µM 
NADH, 100µM ferrozine and either 20µM or 30µM Fe3+ in the citrate form. The 
bottom three lines (white triangles, black triangles and black squares) represent 
controls used in the experiment (without protein, NADH or copper respectively).  
 
 
Ferric iron (Fe3+) at concentrations of 20µM and 30µM was reduced by copper-
loaded α-Syn in the presence of NADH. This is clear from the increase in the 
absorbance at 562nm, which represents an increase in the formation of Fe2+-
ferrozine complex. This catalytic activity of α-Syn was shown to be dependent on 
the protein being loaded with copper (Cu2+), as no increase on absorbance at 
562nm was observed when copper is absent in one of the controls (Figure 3.5). 
In addition, increasing the concentration of the substrate resulted in an increase 
in the rate of the reaction. This is further illustrated in the following figure (Figure 
3.6).  
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Fig. 3.6 Initial rates of activity based on substrate concentration. Increasing Fe3+ 
concentration resulted in an increase in reaction velocity to reach a maximum at 
around 50µM Fe3+. The data represent means ±SD of triplicate of a representative 
experiment.    
 
 
The rate of α-Syn activity in reducing ferric iron (Fe3+) to ferrous iron (Fe2+) is 
dependent on the substrate concentration. It is shown from figure 3.5 that the 
reaction is following first-order kinetics, because the reaction rate is directly 
proportional to substrate concentration. Therefore, the use of a range of 
increased substrate (Fe3+) concentrations from 1µM to 50µM led to an increase 
in the reduction reaction until the velocity of the reaction reached a maximum. 
The maximum velocity represents the stage at which the substrate concentration 
is high enough to saturate all available enzyme molecules. However, in this case 
of α-Syn , it is more common to measure the substrate concentration at which the 
reaction rate reaches half of its maximum value. This concentration is expressed 
as the Km, which describes the relationship between the reaction rate and the 
substrate concentration for a particular catalytic molecule (enzyme).  
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A more accurate determination may be made through a double-reciprocal plot 
which yields a straight line, based on the Michaelis-Menten equation of enzyme 
kinetics as shown in Figure 3.7. Vmax is difficult to be determined from plot in 
Figure 3.6, since enzymes may not function optimally in the presence of 
excessive amounts of substrate and Vmax may not be achieved in enzymatic 
reactions.  
 
                        
Fig. 3.7 Double-reciprocal plot for the calculation of Vmax and Km. Vmax is the 
reciprocal of the Y intercept of the straight line. Km is the negative reciprocal of the 
X intercept of the same line.  
 
 
The double-reciprocal plot of V0 against [S] yields a straight line. The reciprocal 
was taken for both substrate concentration and the velocity of α-Syn reduction 
activity. From these plots, the Vmax and Km were calculated for the reaction of the 
reduction of ferric iron to ferrous iron mediated by α-Syn, where Vmax (2.72 
nmol/min/mg) is the reciprocal of the Y intercept of the straight line. Km (23µM) is 
the negative reciprocal of the X intercept of the same line (Table 3.4).   
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3.4.2 Determination of Ferrireductase Activity of Disease-
Associated Mutants   
 
Disease-associated mutants of α-Syn (A30P, A53T, E46K) were assessed for 
ferrireductase activity using the same procedure used with WT α-Syn. 
Recombinant disease-mutant proteins were purified and used at final 
concentration of 100µM in the ferrireductase assay. The assay was carried out 
with copper-loaded protein, buffered to pH7 with 10mM MOPS. 100µM NADH 
and 100µM ferrozine were then added to the protein solution. Adding ferric iron 
was the last step before measuring changes in absorbance at 562nm due to the 
formation of Fe2+-ferrozine complex (Figure 3.8).  
 
                  
Fig. 3.8 Changes in the absorbance of Fe2+-ferrozine complex at 562nm in the 
presence of 100µM Fe3+. The assay was carried out in 96-well plate using 100µM 
final protein concentration loaded with 2-fold copper, with 100µM NADH, 100µM 
ferrozine. 
 
 
The disease mutants (A30P, A53T, E46K) share similar catalytic activity of WT α-
Syn in reducing ferric iron into ferrous iron, and this activity is also dependent on 
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the protein being loaded with copper. The absorbance increased with increasing 
substrate (Fe3+) concentrations, which also means an increase the rate of the 
reaction. Using a gradient in substrate concentrations from 5µM and up to 40µM 
led to increase in rate of the reaction for each of the mutant proteins (Figure 3.9).  
 
  
       (A)                                                                                                 (B) 
       (C)                
Fig. 3.9 Initial rates of activity of the disease mutants of α-Syn in relation to 
substrate concentration. Increasing Fe3+ concentrations resulted in an increase in 
the reaction velocity up till 50µM Fe3+ in the presence of A) A30P α-Syn, B) A53T α-
Syn and C) E46K α-Syn at 100µM final concentration. The data represent means 
±SD of triplicate of a representative experiment for each of the mutant proteins.  
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The rate of activity of the synuclein disease mutants in reducing Fe3+ into Fe2+ 
was dependent on the substrate concentration as shown in figure 3.9. When 
using a gradient of increased Fe3+ concentrations, the resultant rate was 
accordingly increasing. To better determine the velocity of the reaction and the 
Km, the data were plotted into a double-reciprocal plot, which gives a straight line 
from which a more accurate Vmax and Km values can be obtained (Figure 3.10).  
 
                    
Fig. 3.10 Double-reciprocal plot for the calculation of Vmax and Km. Vmax is the 
reciprocal of the Y intercept of the straight line. Km is the negative reciprocal of the 
X intercept of the same line.  
 
 
Values for Vmax and Km were calculated and listed in table 3.4 for comparison 
with WT α-Syn. 
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             Protein     Vmax (nmols/min/mg)               Km (µM) 
      Wild Type α-Syn              2.72                   23 
      E46K α-Syn              2.52                   23 
      A30P α-Syn              2.37                   19 
      A53T α-Syn              2.62                   25 
Table 3.4 Comparison of the kinetic parameters for the ferrireductase activity of 
wildtype α-Syn and its disease-associated mutants showing the calculated values 
for each of Vmax and Km as described above. 
 
 
    3.5 Discussion 
 
α-Syn fibrils have been recognised as hallmarks in brains of PD and other 
neurodegenerative diseases (Spillantini, Crowther et al. 1998b). Transition 
metals, such as copper and iron, have also attracted attention in the research of 
neurodegenerative diseases. Both metals have been found to accelerate α-Syn 
aggregation and to bind to it, where α-Syn is widely accepted as copper binding 
protein (Uversky, Li et al. 2001b; Binolfi, Rasia et al. 2006). Considering that one 
of the main unknown aspects about α-Syn is its function and whether metal 
binding to α-Syn contribute in one way or another to its function; work in this 
chapter represents an attempt to explore a possible aspect of α-Syn’s function as 
ferric-reductase and hence link this function to its ability to bind metals including 
iron. Studies of metal binding to α-Syn have centred more on copper than iron, 
although the exact features of that binding is not established yet. There has been 
some degree of variability in the proposed number of copper binding sites and 
their affinities. Up to 10 molecules of copper were suggested to bind to one 
molecule of α-Syn (Paik, Shin et al. 1999), while in later studies α-Syn was 
shown to bind two molecules of copper (Rasia, Bertoncini et al. 2005; Binolfi, 
Lamberto et al. 2008). However, based on recent work conducted in our 
laboratory, α-Syn was shown to be able to bind one equivalent of copper. 
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Although the number of copper molecules that bind to α-Syn is controversial, 
accumulative evidence has shown α-Syn as copper binding protein and this is 
important as α-Syn’s ability to reduce ferric iron (Fe3+) occurred only when copper 
was present (Figure 3.4). This implies that copper might be playing a co-factor 
role in the reaction. It is important to note that two equivalents of copper were 
used in ITC experiments as copper at higher concentrations caused instant α-
Syn aggregation and precipitation in the sample while repeating experiments. 
However, it was more crucial for this project to assess and demonstrate that 
ferric iron binds to α-Syn considering that it is the substrate in the reaction. 
Notably, the C-terminus of α-Syn has been referred to as a possible site to bind 
iron and other metals (Rasia, Bertoncini et al. 2005; Binolfi, Lamberto et al. 
2008), although the features of the iron binding are not yet studied thoroughly. 
Furthermore, it was equally important to show that α-Syn binds ferric iron in the 
presence of copper as both metals are part of the reaction. 
 
 
ITC is a method commonly used to study ligand-binding properties to proteins 
based on the assessment of the heat changes during the reaction. ITC was used 
to reveal binding properties of Fe3+ to α-Syn, as Fe3+ resembles the substrate in 
the reaction described in this chapter. ITC produces curves that reflect heat 
changes within the binding reaction and the shape of the curves is dependent on 
the binding mode. A previous study that has attempted to reveal Fe3+ binding 
properties to α-Syn (Bharathi and Rao 2007) has suggested a single Fe3+ binding 
site on α-Syn, utilising the same technique which is ITC. However, work done in 
this study suggested two binding sites of Fe3+ on α-Syn as ITC isotherms were 
best fitted with a two binding sites model and reflected two binding phases as 
well (Figure 3.2 and Figure 3.3). The affinity values (Ka) of the two binding groups 
(n1, n2), in the presence or the absence of copper lay within the same range. 
This suggests that the presence of copper did not change the binding affinity of 
ferric iron to α-Syn and reserved the main characteristics of iron binding. 
Therefore, α-Syn binds ferric iron (Fe3+) at two sites, with relatively similar affinity 
 82 
values (Ka). These binding affinity values (Ka) represent the association constant 
values which describes the affinity between Fe3+ and α-Syn at equilibrium. Ka is 
the inverse of the dissociation constant value (Kd), which is usually the propensity 
of a complex molecule to dissociate to its components. In other words, it is the 
concentration at which half Fe3+ molecules are not bound to α-Syn. This value is 
of a similar magnitude to the Km value obtained for α-Syn as a ferrireductase. Km 
describes the substrate concentration where the reaction of a certain catalytic 
molecule reaches half the maximum rate. Kd values were calculated for α-Syn 
based on Ka values obtained from ITC performed with and without copper as 
shown in table 3.2. It shows that, when α-Syn is loaded with copper, the affinity 
for Fe3+ decreases slightly in both sites. However, the main aspect is that the 
dissociation constant value (Kd) when α-Syn is pre-loaded with copper is 
comparable and close to the Km value (23µM) for α-Syn (Table 3.4). Also, the 
conditions used in ITC experiments were similar to the conditions in which 
ferrireductase assays were performed, therefore, the comparison between Kd 
values and Km values is valid in such case.    
 
 
Moreover, assessment of the ferrireductase activity of α-Syn using the ferrozine-
based assay showed that α-Syn activity follows first order kinetics, where the rate 
of the reaction was directly proportional to substrate concentration as shown in 
Figure 3.4. Figure 3.11 illustrates the classical Michaelis-menten enzyme kinetics 
where Km is the amount of substrate needed to reach half maximum velocity at 
which half substrate is bound to enzyme. In other words, Km is another 
representative of Kd (the dissociation constant) for α-Syn. Km values for the 
reaction between Fe3+ and α-Syn was calculated from the linear plot in Figure 3.7 
and Figure 3.10 and presented in Table 3.4.  
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Fig. 3.11 The curve of velocity versus substrate concentration as derived from the 
Michaelis-Menten theory of enzymatic activity.  
 
 
The difference between Kd values obtained from ITC binding studies and Km 
values obtained from ferrozine-based assay for α-Syn are relatively small, 
providing evidence that the process of iron binding pre-reduction is the same 
process as that observed in the ITC assays.  Therefore, it is possible to conclude 
that both methods confirm the proposed ability of α-Syn to bind and reduce ferric 
iron (Fe3+) in the presence of copper as co-factor.  
 
 
In terms of free energy changes, Table 3.3 showed that ΔG values did not 
change between the two binding sites and the presence of copper did not affect 
the change of energy pattern dramatically. ΔG value is lower for one of the 
binding sites comparing to the other site, which suggests that the binding is 
possible from energy point of view and is favorable. Fe3+ could bind to α-Syn on 
the first binding site (site1) and then move to the second binding site (site2) 
where copper is the redox centre and mediate the ferric iron (Fe3+) reduction into 
ferrous iron (Fe2+) (Figure 3.12).  
 
 84 
 
Fig. 3.12 Theoretical pathway of ferric iron reduction by α-Syn in the presence of 
copper as co-factor. Fe3+ binds to α-Syn at the first binding site with ΔG=-6245.33 
and then moves to the second binding site with ΔG=-7618.85 which is 
energetically favourable.  
 
 
The figure above represent a speculation pathway in which α-Syn reduces Fe3+ 
to Fe2+ using Cu2+ as co-factor and NADH as electron donor, based on data 
obtained from ITC and ferrireductase experiments performed with recombinant α-
Syn. In this model and in the presence of copper, α-Syn can bind two ferric iron 
(Fe3+) molecules, and reduce them in an energetically favourable route. The 
reduction of ferric iron to ferrous iron has been shown to be important process in 
the uptake of iron in many organisms such as Saccharomyces cerevisiae (Inman, 
Coughlan et al. 1994; Lesuisse, Casteras-Simon et al. 1996; McKie, Barrow et al. 
2001). This process of iron uptake to many cell types has been suggested to be 
mediated by transferrin (ferric iron carrier) and Dmt1 (ferrous iron selective 
carrier) (Ohgami, Campagna et al. 2005) where the presence of an NAD(P)H-
dependent, cell-surface and/or endosomal ferrireductase activity is required 
(Ohgami, Campagna et al. 2005). This supports the proposed role of α-Syn as 
ferrireductase, since it is a membrane bound protein and NADH was required for 
its activity. In addition, this further confirms the importance of balanced metal 
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content in the brain, which is altered in disease status and could be attributed to 
a change in α-Syn structure or function.  
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Chapter four: Aggregation of Alpha 
Synuclein 
 
 
4.1 Introduction 
 
 
Considerable evidence suggests that the aggregation of α-Syn represents a 
critical step in the aetiology of PD (Trojanowski and Lee 2003). This is supported 
by various observations such as over-expression of α-Syn in familial PD cases 
with multiplications in α-Syn gene (SNCA) (Kruger, Kuhn et al. 1998; Zarranz, 
Alegre et al. 2004). In some cases of early onset familial PD, the cause is linked 
to duplication or triplication in the α-Syn gene locus (Singleton, Farrer et al. 
2003). Additionally, α-Syn disease associated mutants (A30P, A53T) were shown 
to increase the propensity of α-Syn to aggregate (Polymeropoulos, Lavedan et al. 
1997; Kruger, Kuhn et al. 1998; Zarranz, Alegre et al. 2004). More importantly, α-
Syn fibrils are found within cells in the form of neuronal cytoplasmic inclusions 
(LBs and LNs) in the brains of PD patients (Jakes, Spillantini et al. 1994).  
 
 
α-Syn is known to be a natively unfolded protein, although it can adopt other 
structural conformations, such as α-helical in its lipid-bound state (Clayton and 
George 1998; Chandra, Chen et al. 2003). In the fibril form α-Syn has been 
shown to adopt a cross-β structure of unknown function (Conway, Harper et al. 
2000; Serpell, Berriman et al. 2000). It is essential to highlight this structural 
transformation of α-Syn into β-sheet rich fibrils that is found in LBs (Serpell, 
Berriman et al. 2000), and the possible role of α-Syn aggregates in the specific 
loss of dopaminergic neurons in PD brains (Winner, Jappelli et al. 2011). This 
conformational change to β-sheet structure has been previously noted for the Aβ-
peptide of Alzheimer’s disease (Barrow and Zagorski 1991) and prion protein 
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(Pan, Baldwin et al. 1993). This structural change is believed to be an essential 
step in the pathogenesis of neurodegenerative amyloid diseases. Several factors 
and conditions have been identified to promote α-Syn aggregation, fibril 
formation and the likelihood of inclusion formation. These factors include mass 
crowding (Uversky, Cooper et al. 2002), point mutations (Li, Uversky et al. 2001), 
the level of phosphorylation (Chen and Feany 2005), and the presence of metals 
(Paik, Shin et al. 1999; Uversky, Li et al. 2001b). It has been demonstrated that 
fibrils of recombinant α-Syn formed in vitro resemble those derived from disease 
affected brains (Conway, Harper et al. 1998; Hashimoto, Hsu et al. 1998; 
Giasson, Uryu et al. 1999).  
 
 
Research of α-Syn and neurodegeneration has revealed that α-Syn structural 
change can also lead to aggregated forms other than fibrils, such as amorphous 
aggregates and oligomers (Uversky, Li et al. 2001a; Bharathi and Rao 2007). 
However, since fibrillar α-Syn is seen in the surviving neurons in the brain, this 
has prompted a lot of research into revealing the reasons behind α-Syn 
transformation into an abnormal form and the consequences of this aggregation. 
α-Syn fibrils have been reported to have typical morphology to amyloid fibrils with 
β-sheet structure (Conway, Harper et al. 2000). Several methods have been 
used to assess and detect this fibrillar protein structure such as Circular 
Dichorism (CD), electron microscopy (EM) and more simply Thioflavin-T (ThT) 
fluorescence (Uversky, Lee et al. 2001; Rasia, Bertoncini et al. 2005; Binolfi, 
Rasia et al. 2006). ThT is a fluorescent dye that has the ability to bind to β-sheet 
rich amyloid fibrils and gives fluorescence at excitation and emission maxima of 
450nm and 480nm, respectively. The dye alone or in the presence of proteins 
with low β-sheet content gives no fluorescence at these wavelengths. α-Syn 
aggregation kinetics exhibit sigmoidal curves, defined by an initial lag phase, 
followed by exponential phase (growth phase) and final plateau after fibrils are 
completely formed (Uversky, Li et al. 2001a).   
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Metals have been identified as epidemiological risk factors for PD (Gorell, 
Johnson et al. 1999) and found to accelerate the fibrillation rate of α-Syn in vitro 
as assessed by laddering on SDS-PAGE gel (Paik, Shin et al. 1999) and by 
Thioflavin-T (ThT) assay (Uversky, Li et al. 2001b). However, research on the 
interaction between α-Syn and metals has reported variable information about 
how metals influence the aggregation process of α-Syn. Several studies have 
suggested metal binding to α-Syn, thus inducing its aggregation (Paik, Shin et al. 
1999; Rasia, Bertoncini et al. 2005; Binolfi, Rasia et al. 2006). The N-terminal 
domain of α-Syn (residues 1-9 and residues 48-52) including His50 as anchoring 
reside, as well as residues within the C-terminus (121-123) have been suggested 
as primarily metal binding sites for metals such as copper and iron. Given that α-
Syn has been shown to be a copper and iron binding protein (Bharathi and Rao 
2007; Binolfi, Lamberto et al. 2008), metal binding could be the mechanism by 
which metals induce α-Syn aggregation. Moreover, metals such as copper and 
iron (redox-active metals) were proposed to play a role in the aggregation of α-
Syn via catalysis of oxidative oligomerization in the presence of hydrogen 
peroxide leading to neurodegeneration (Hashimoto, Hsu et al. 1999; Paik, Shin et 
al. 2000). This is supported by observations of disturbed metal homeostasis such 
as increased iron levels and the presence of iron deposits in PD brains 
(Castellani, Siedlak et al. 2000; Sayre, Moreira et al. 2005). In addition, elevated 
levels of copper have been reported in the cerebrospinal fluid of PD patients 
(Pall, Williams et al. 1987). Also, levels of hydrogen peroxide have been shown 
to be increased with the stimulation of dopamine turnover by monoamine oxidase 
(Spina and Cohen 1989; Paik, Shin et al. 2000). Redox-active metals and 
hydrogen peroxide, hydroxyl radicals could be generated in PD and lead to 
neurodegeneration by affecting various biomolecules including brain proteins 
(such as α-Syn) and thus contributing to their aggregation (Paik, Shin et al. 
2000). 
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Along with the broad assessment of α-Syn aggregation in vitro using recombinant 
protein, cell culture and animal models have also been used to better understand 
the mechanism of aggregation and its consequences. This has proved important 
especially with the accumulating evidence that fibrils may not be the pathogenic 
species in PD. However, many studies have shown that α-Syn is toxic to neurons 
in an oligomeric or aggregated form (Dedmon, Christodoulou et al. 2005; Danzer, 
Haasen et al. 2007; Wright, Wang et al. 2009). The presence of highly soluble 
oligomers of α-Syn has been reported in cell culture, animal models and in brains 
with PD and DLB (Volles and Lansbury 2002; Sharon, Bar-Joseph et al. 2003). 
These oligomeric species of α-Syn have been shown to be able to form pores in 
the membrane (Volles and Lansbury 2002), which may alter the balance of ions 
within cells and trigger apoptosis. In addition, linking that to metals, injecting iron 
to the substantia nigra of adult rats has been shown to cause dopaminergic 
neurodegeneration in PD (Youdim, Ben-Shachar et al. 1991). Copper has also 
been shown to participate in the extracellular toxicity of α-Syn due to the 
formation of a unique oligomeric species (Wright, Wang et al. 2009). 
 
 
The following work presents an attempt to examine whether α-Syn aggregation is 
mediated by metal binding. With the recognition of potential sites for metal 
binding in α-Syn, mutants lacking amino acids proposed to comprise the metal 
binding sites were created. Both WT α-Syn and its metal-binding mutants were 
used as recombinant proteins in ThT assays to detect any differences in 
aggregation kinetics in response to metal treatment. Recombinant α-Syn was 
purified initially as His-tagged and then untagged protein. To support the 
assessment of α-Syn metal-binding induced aggregation with recombinant 
protein, α-Syn and its metal-binding mutants were expressed in neuroblastoma 
cell line SHSY-5Y and treated with metals, and the extent of aggregation was 
analysed using western blotting.   
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    4.2 Purification of Recombinant Alpha Synuclein 
 
In this study, recombinant His-tagged and recombinant untagged α-Syn was 
over-expressed in bacteria and purified by chromatographic techniques. His-
tagged protein was used at early stages of the work to investigate general 
aggregation properties of the protein. The use of His-tagged protein was due to 
the availability of the purification protocol of His-tagged and not untagged protein. 
After that, untagged protein was over-expressed and purified, to further 
investigate its aggregation properties.  
 
 
4.2.1 Expression and Purification of His-tagged α-Syn 
 
Plasmid vector pET15b-α-Syn was transformed into BL21 cells and α-Syn 
expression was induced with 1mM IPTG. Due to the presence of the Histidine tag 
(His-tag), the protein was purified using nickel affinity column (IMAC column). 
The column was first washed with MilliQ water pH7 and equilibrated with 8M urea 
buffer pH7.5, and then the protein was loaded onto the column and washed with 
50ml of 8M urea buffer pH7.5, 180ml of 25mM imidazole in urea buffer and 30ml 
of 40mM imidazole in urea buffer. The protein was finally eluted with 300mM 
imidazole in urea buffer.  
The purity of the eluted protein was assessed by SDS-PAGE gel. The eluted 
fractions contained the protein as a single band, corresponding to the appropriate 
molecular weight, after staining with coomassie stain (Figure 4.1). 
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Fig. 4.1 Purified His-tagged WT α-Syn separated on a 14 % SDS-PAGE gel and 
coomassie stained. Lanes 1-12 represents: (1) protein marker (M), (2) un-induced 
sample (UI), (3) induced sample (I), (4) lysate (L), (5) filtrate (F), (6) flow-through 
(FT), (7) urea wash (Urea), (8) 25mM imidazole wash, (9) 40mM imidazole wash, 
(10-11-12) 300mM imidazole. Noting that majority of α-Syn is eluted in the second 
elution fraction (Lane 11). 
 
 
The resultant His-tagged α-Syn was 95% pure after purification with almost no 
impurities. However, SDS gels occasionally revealed small bands alongside α-
Syn band. Western blotting analysis was performed using α-Syn specific 
antibodies (Mouse anti-α-Syn, monoclonal antibody, Invitrogen) to detect the 
nature of these bands and whether they represent aggregates of α-Syn (Figure 
4.2).   
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Fig. 4.2 Western blot analysis of purified his-tagged α-Syn after purification. 
 
 
Western blotting showed only one band comprising his-tagged α-Syn. Other His-
tagged α-Syn mutants, which lack the potential metal binding sites (H50A α-Syn 
and Δ1-9 α-Syn), were also inserted into pTrc plasmid and purified similarly to 
His-tagged WT α-Syn (Figure 4.3). Protein identity was also performed routinely 
in the laboratory by western blotting. Protein concentration was determined by 
Bradford assay using a series of BSA standards, and measuring absorbance at 
595nm. Prior to aggregation assays, the protein was dialysed in chelex-treated 
MilliQ water pH7, to remove any metal traces, at 4°C overnight. 
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 (A) 
 
 (B)  
Fig. 4.3 Purified His-tagged α-Syn metal binding mutants separated on a 14 % 
SDS-PAGE gel and coomassie stained (A) His-tagged H50A α-Syn (B) His-tagged 
Δ1-9 α-Syn. Lanes 1-12 represents: (1) protein marker (M), (2) un-induced sample 
(UI), (3) induced sample (I), (4) lysate (L), (5) filtrate (F), (6) flow-through (FT), (7) 
urea wash (Urea), (8) 25mM imidazole wash, (9) 40mM imidazole wash, (10-11-12) 
300mM imidazole. Noting that majority of α-Syn is eluted in the first elution 
fraction (Lane 10). Proteins were dialysed against chelex-treated MilliQ water pH7 
before using it in assays. 
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4.3 Aggregation Assay Optimisation 
 
Primary aggregation experiments were conducted to assess the best conditions 
to be used for further experiments with metals. Optimisation experiments were all 
conducted using His-tagged α-Syn. WT α-Syn was prepared using the pET15b 
vector while both mutants H50A α-Syn and Δ1-9 α-Syn were prepared using the 
pTrc vector.    
 
 
4.3.1 Buffer and pH 
 
Buffers were chosen based on those used in previous published studies 
(Uversky, Li et al. 2001b; Uversky, Li et al. 2002b; Rasia, Bertoncini et al. 2005; 
Bharathi and Rao 2007). There was a great variability in conditions as reported. 
However, two different buffers, Sodium Phosphate (NaPO4) buffer and Tris-HCl 
buffer, were chosen. Both buffers were tested at pH6.5 and pH7.4. 10µM purified 
recombinant α-Syn was used with 10µM ThT in either buffer and then incubated 
with shaking at 37°C, 600rpm to induce aggregation. Fluorescence 
measurements were performed at different time intervals using a Fluoroskan 
Ascent Software version2.4. α-Syn aggregation occurred faster in the lower pH 
value and with enhanced level of ThT fluorescence. This is exhibited by higher 
fluorescence values reached by the blue line representative of the low pH value, 
as well as the less time taken for the fluorescence values to increase. ThT 
fluorescence values were normalized by subtracting the background 
fluorescence (buffer with ThT) and then as percentage against the highest value 
of each condition.  
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     (A)       
     (B)        
Fig. 4.4 Effect of buffer and pH on α-Syn aggregation kinetics. (A) 10µM α-Syn with 
10µM ThT in sodium phosphate (NaPO4) buffer at pH6.5 and pH7.4. (B) 10µM α-Syn 
with 10µM ThT in Tris buffer at pH6.5 and pH7.4. Measurements were performed 
with excitation at 444nm and emission at 485nm. Experiment solutions were 
incubated at 37°C with agitation at 600rpm. Values represent average of replicates 
in one experiment. 
 
 
Figure 4.4 represents curves from an individual experiment. Time point values 
represent average of replicate within one experiment (wells replicate of each 
condition). Choosing buffer and pH value was important as α-Syn has a pI value 
of 4.7, therefore the lower the pH the faster it will aggregate. Also, different pH 
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values were reported to result in different aggregation kinetics and morphologies 
(Hoyer, Antony et al. 2002) where low pH values led to amorphous aggregates, 
rather than fibrils, to which ThT dye does not bind. Since faster aggregation was 
accompanied by lower pH value; therefore, pH7.4 was more favourable in 
addition to being more physiologically relevant. Comparing both buffers, it 
seemed that the aggregation pattern seen in Tris buffer pH7.4 represent a 
desirable kinetics to the type of experiments to be performed later in this work, as 
the rate was low to moderate and suitable to observe any occurring changes 
when adding metals. In addition, pH7.4 is more physiologically relevant than 
pH6.5. 
 
 
4.3.2 Protein Concentration 
 
This set of experiments was performed to confirm that α-Syn aggregation is a 
concentration dependent process (Uversky, Li et al. 2001b) and to enable the 
determination of an appropriate α-Syn concentration to be used in the following 
aggregation experiments. A range of α-Syn concentrations were used in ThT 
assays in both 10mM Tris buffer pH7.4 and 10mM Sodium Phosphate buffer 
pH7.4. As the aim was to look for protein concentration that enables the 
aggregation to occur at relatively slow yet detectable rate, α-Syn concentrations 
used started at 1µM up to 10µM (Figure 4.5). Protein concentration was 
assessed using Bradford assay. α-Syn at 1µM had minimal aggregation as 
shown by hardly detectable ThT fluorescence with very low ThT fluorescence 
intensity values. α-Syn aggregation showed a long lag phase occurring over an 
observable amount of time with 5µM and 10µM concentration but with better 
fluorescence, pre-normalized values, with the higher concentration. Therefore, 
10µM was chosen to be the protein concentration used in aggregation assays. 
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     (A)      
     (B)      
Fig. 4.5 The effect of protein concentration on α-Syn aggregation kinetics. Purified 
α-Syn was diluted with either 10mM NaPO4 pH7.4 (A) or with 10mM Tris pH7.4 (B) 
to obtain a range of final protein concentrations of 1µM and 5µM in a 100µl final 
volume and liquated into 96-well plate. Kinetics of aggregation was monitored by 
ThT Fluorescence. Measurements were performed with excitation at 444nm and 
emission at 485nm. Experimental plate was incubated at 37°C, shaking at 600rpm. 
Curves shown in this figure represent one experiment. Values represent average 
of replicates in one experiment.  
 
 
Also, the figure above shows that α-Syn aggregation occurred faster in Sodium 
Phosphate buffer pH7.4 comparing to Tris buffer at 5µM and 10µM final 
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concentration, which emphasizes the result shown in figure 4.4, that Tris buffer at 
pH7.4 provides favourable conditions for later experimental work.   
 
 
4.4 Effect of Metals on His-tagged α-Syn Aggregation 
 
Aggregation experiments assessing the effect of metals on His-tagged proteins 
were conducted using WT α-Syn, H50A α-Syn and its N-terminal mutant (Δ1-9 
His-tagged α-Syn). Each protein was used at 10µM final concentration in 10mM 
Tris pH7.4, incubating at 37°C, and shaking constantly at 600rpm with or without 
metals (Cu2+, Fe3+, and Al3+) at 100µM final concentration. After purification and 
dialysis, protein concentration used in these experiments was measured using 
Bradford assay. Samples were run in quadruplicates and ThT fluorescence 
intensities were recorded at different time points. Quadruplicates were averaged 
and plotted as a function of time. Similar to previous reports (Uversky, Li et al. 
2001a), α-Syn aggregation kinetics were found to be sigmoidal (Figure 4.4 and 
4.5), defined by an initial lag phase where no changes in ThT intensities are 
observed, a subsequent growth phase in which ThT intensities increase and a 
final equilibrium phase in which ThT fluorescence reaches a plateau indicating 
the end of β-sheet rich fibril formation.  
 
 
4.4.1 Effect of metals on His-tagged WT α-Syn 
 
Aggregation assays were performed using 10µM final protein concentration in 
10mM Tris buffer pH7.4 mixed with 10µM ThT, incubated at 37°C and shaking 
constantly at 600rpm with and without metals at 100µM final concentration. 
Copper was the most effective metal ion in terms of inducing the aggregation of 
His-tagged WT α-Syn. This is illustrated in the following figure by having the 
highest ThT fluorescence values and the least time taken to initiate aggregation 
comparing to iron and aluminium. Less effect was observed with iron and 
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aluminium, represented by orange and green lines respectively, as demonstrated 
by lower ThT Fluorescence intensities measured during the course of experiment 
and longer lag phase (Figure 4.6).  
 
                                
Fig. 4.6 Effect of metals on His-tagged WT α-Syn aggregation kinetics. 10µM WT α-
Syn with or without 100µM metals was incubated at 37°C, shaking constantly at 
600rpm. ThT measurements were recorded at designated time points. Values 
represent average of replicates in one experiment.  
 
 
Fluorescence intensity of 10uMα-Syn in the absence of metals (Figure 4.5) was 
~80%, while less 20% in Figure 4.6 where metals were present. This is due to 
the use of the highest fluorescence intensity value obtained in each experiment 
individually to normalise the rest of the ThT fluorescence values as a percentage 
of that high value. This value differed between both experiments and was much 
higher when copper was present with α-Syn. 
  
 
Acceleration of α-Syn aggregation induced by metals exceeded that arising from 
α-Syn with no metals shown by the blue dots and the blue line in Figure 4.6. 
Copper came first and caused the highest level of acceleration. Iron and 
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aluminium came second and third respectively and also resulted in higher ThT 
intensities and shorter lag time compared to the case where no metals were 
present with α-Syn.  
 
 
Both his-tagged α-Syn mutants, which lack the potential metal binding sites 
(H50A α-Syn and Δ1-9 α-Syn), were inserted into a different his-tag vector (pTrc 
plasmid vector) to WT α-Syn and purified in the same way. Protein concentration 
was determined by Bradford assay using a series of BSA standards, and 
measuring absorbance at 595nm. Prior to aggregation assays, the protein was 
dialysed in chelex-treated MilliQ water pH7, to remove any metal traces, at 4°C 
overnight. In order to validate the use of the mutant proteins in a different plasmid 
vector, an aggregation experiment was run to compare WT α-Syn purified from 
both plasmid vectors (pET15b and pTrc) and another comparing WT α-Syn with 
its his-tagged mutants (Figure 4.7).  
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   (A)      
   (B)      
Fig. 4.7 (A) His-tagged α-Syn aggregation kinetics in relation to the plasmid vector 
inserted in. His-tagged WT α-Syn inserted into either pET15b or pTric vector. (B) 
Comparison of the aggregation pattern of WT α-Syn and metal binding mutants all 
in pTric vector. Values represent average of replicates in one experiment.  
 
 
Results shown in Figure 4.7 above demonstrate that α-Syn in pTrc plasmid 
vector has slightly slower aggregation to α-Syn in pET15b vector as shown by 
lower fluorescence intensities and longer lag time (A). Yet it can be seen that α-
Syn in both plasmids reached its maximum fluorescence levels around the same 
time. In addition, the second graph (B) shows that the eventual extent of 
aggregation of WT α-Syn is fairly similar to metal binding mutants (H50A and Δ1-
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9 α-Syn) as shown by maximal ThT fluorescence. Although the figure indicates 
that WT α-Syn reaches the maximum fluorescence relatively faster than the 
mutant proteins. However, the longer lag phase of mutants shown in the above 
figure represents an anolamous single experiment which was not present in all 
the repeats and such a difference when present does not influence any potential 
effect metals can have when added to each of the tested proteins.  
 
 
4.4.2 Effect of metals on His-tagged Mutants of α-Syn 
 
Aggregation assays of α-Syn mutants were performed similar to His-tagged WT 
α-Syn, using 10µM final concentration of His-tagged mutant protein in 10mM Tris 
buffer pH7.4 mixed with 10µM ThT, incubated at 37°C and shaking constantly at 
600rpm with and without adding metals at 100µM final concentration. As copper 
was the most effective metal in inducing WT α-Syn aggregation, it was solely 
tested with His-tagged H50A α-Syn and Δ1-9 α-Syn. Samples were assayed in 
quadruplicates. ThT measurements were recorded at designated time point, 
averaged and plotted as function of time (Figure 4.8).  
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     (A)     
     (B)     
Fig. 4.8 Effect of copper on the aggregation kinetics of α-Syn His-tagged metal 
binding mutants (A) His-tagged H50A α-Syn, (B) His-tagged Δ1-9 α-Syn. 10µM 
protein was mixed with 10µM ThT and incubated with and without 100µM Cu2+ at 
37°C, shaking constantly at 600rpm. ThT measurements were recorded at 
designated time points. Values are average of replicates in one experiment.  
 
 
Copper resulted in considerable and comparable acceleration of the aggregation 
kinetics of both α-Syn metal binding mutants compared to the case where no 
copper is present. This is shown from the lag time where ThT fluorescence of 
both proteins reached maximum values at about 40hr. Both mutants are his-
tagged protein and lack a number of amino acids at potentially copper binding 
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sites (H50A or amino acids 1-9). Lacking either of the potential copper binding 
sites resulted in no major difference on the observed aggregation when copper 
was added to each protein.   
 
 
4.5 Effect of Metals on Untagged α-Syn Aggregation 
 
After the purification method of untagged proteins had been designed, untagged 
α-Syn was purified according to the protocol described in the materials and 
methods chapter. Untagged proteins purified included WT α-Syn and mutants 
lacking the potential metal binding sites such as H50A α-Syn, Δ1-9 α-Syn, and 
Δ1-9 H50A α-Syn (double mutant). Ahead of conducting aggregation 
experiments of untagged α-Syn with metals, the protein was used in a primary 
aggregation experiment against His-tagged α-Syn to compare their aggregation 
patterns. Samples were run in quadruplicates and incubated in 96-well plates 
shaking constantly at 37°C, 600rpm. ThT fluorescence intensities were measured 
at different time points. Quadruplicates were averaged, plotted as a function of 
time. The aggregation of His-tagged α-Syn occurs faster than untagged α-Syn as 
indicated by the higher fluorescence intensities and shorter lag time shown in 
Figure 4.9. 
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Fig. 4.9 Comparison of the aggregation patterns of His-tagged and untagged α-
Syn. 30µM α-Syn was incubated in 10mM Tris pH7.4 at 37°C, shaking constantly at 
600rpm. Samples were run in quadruplicates. ThT fluorescence intensities were 
recorded at different time points and plotted as a function of time. Values are 
average of replicate wells in one experiment.  
 
 
The result in Figure 4.9 comes from an individual experiment where values of 
ThT intensities at each time point represent the average of wells replicate. The 
pattern of faster aggregation of His-tagged α-Syn compared to untagged α-Syn 
was also observed when repeating the experiment. In addition to the higher ThT 
intensities, the slope of the curve is steeper with His-tagged α-Syn. Moreover, 
calculating the rate of both forms of the protein showed higher rate of 0.884 (h-1) 
for His-tagged α-Syn, comparing to 0.357 (h-1) of untagged α-Syn which is 
consistent with what the Figure 4.9 shows of faster aggregation of His-tagged α-
Syn.  
 
 
4.5.1 Effect of Metals on Untagged WT α-Syn 
 
Untagged WT α-Syn was used at a final concentration of 10µM, similar to 
experiments performed with His-tagged proteins, with and without 100µM final 
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concentration of each metal. The three metals tested (Cu2+,Fe3+ and Al3+) 
resulted in acceleration of the aggregation of untagged WT α-Syn, with ferric iron 
and copper being slightly more effective comparing to aluminium (Figure 4.10). 
This is due to observation that α-Syn aggregation and increased ThT 
fluorescence started to occur faster when copper and iron were present and to 
less extent with aluminium. 
 
               
Fig. 4.10 Effect of metals on the aggregation kinetics of WT α-Syn. 10µM WT α-Syn 
was incubated in 10mM Tris pH7.4 with or without 100µM metals at 37°C, shaking 
constantly at 600rpm. Samples were run in quadruplicates and aliquoted in 96-well 
plate at a total volume of 100µl in each well. ThT fluorescence intensities were 
recorded at different time points and plotted as a function of time. Values 
represent average of replicates in one experiment. 
 
 
Higher ThT fluorescence intensities and faster occurrence of aggregation were 
obtained in the presence of metals as ThT fluorescence started to increase at 
around 40hrs. This is further analysed by calculating the apparent rate constant 
(kapp) of α-Syn when incubated alone and with metals (Figure 4.11).  
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Fig. 4.11 Plot of the aggregation rate (kapp) (h
-1) obtained for untagged WT α-Syn in 
the presence of 100µM metals. Data presented in this figure represent one 
experiment.   
 
 
Figure 4.11 shows that ferric iron and copper caused more than 2-fold increase in 
the aggregation rate of untagged WT α-Syn which emphasizes the results 
observed with ThT assays. Aggregation rate (kapp) was calculated using 
SigmaPlot from data obtained from one experiment (Section 2.2.11 Materials and 
Methods). This trend was confirmed with subsequent experiments. Copper, in 
four other experiments, showed similar acceleration of α-Syn aggregation. The 
rate was calculated in each experiment and resulted in an average of 1.6 fold 
increases with a standard deviation of 0.123 caused by copper.  
 
 
However, it was difficult to get more successful repeats of the experiment. There 
is no single reason for the failure in achieving more working repeats. It may result 
from various causes such as protein preparation and process with its 
accompanied different stages that could affect protein produce in terms of action 
and folding. The following figure (Figure 4.12) shows a representative experiment 
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where no aggregation was observed with WT α-Syn in the absence and the 
presence of metals. Over time, no increase in ThT fluorescence occurred.  
 
                
Fig. 4.12 Untagged WT α-Syn aggregation in the presence of metals where no 
effect was observed. 10µM WT α-Syn with or without 100µM metals was incubated 
at 37°C, shaking constantly at 600rpm. ThT measurements were recorded at 
designated time points. Values represent average of replicates in one experiment.  
 
 
There was no producibility of results when assessing WT α-Syn aggregation 
despite more than 10 attempts undertaken to correct this condition and overcome 
problems associated with this assay. All except one aggregation experiment 
showed no increased ThT fluorescence. Although the number of negative 
experiments was high, the positive results shown in the single experiment would 
be valid since similar results were published in the literature (Uversky, Li et al. 
2001b). Hence, data were shown as only one representative experiment for each 
protein. 
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4.5.2 Effect of Metals on Untagged α-Syn Mutants 
 
To further assess the role of metals in inducing the aggregation of α-Syn, 
mutants of the protein lacking the potential metal binding sites were created and 
purified similarly to WT α-Syn and used in aggregation assays. These mutants 
included the H50A α-Syn, the N-terminal mutant (Δ1-9 α-Syn), and a second N-
terminal mutant (Δ1-9 H50A α-Syn). Both N-terminal mutant proteins were used 
at 10µM final concentration in 10mM Tris pH7.4, and mixed with 10µM ThT. 
100µM of each metal was then added and samples were incubated at 37°C, 
shaking constantly at 600rpm (Figure 4.13). Both ferric iron and copper 
accelerated the aggregation of both α-Syn mutants at 100µM final metal 
concentration and aluminium to a lesser degree as illustrated by the shorter time 
taken to reach the maximum fluorescence. Iron being the most potent 
accelerator. This is shown in the following figure by the orange and red lines 
representing the aggregation of α-Syn mutants in the presence of iron and 
copper, respectively.  
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(A)     
   (B)          
Fig. 4.13 Effect of metals on the aggregation kinetics of the untagged metal 
binding mutants of α-Syn (A) Δ1-9 α-Syn and (B) Δ1-9 H50A α-Syn. 10µM protein 
was incubated in 10mM Tris pH7.4 with or without 100µM metal at 37°C, shaking 
constantly at 600rpm. ThT fluorescence was recorded at different time points and 
plotted as function of time. Values represent average of replicates in one 
experiment.     
 
 
The result observed with the mutant proteins resembles that of WT α-Syn with 
ferric iron being the most effective metal in enhancing the aggregation of the 
protein. Similarly to WT α-Syn, the result was confirmed by calculating the 
aggregation rate (kapp) using SigmaPlot (Figure 4.14). 
 
-20
0
20
40
60
80
100
0 20 40 60 80 100 120
time (hr)
N
o
rm
a
li
s
e
d
 T
h
T
 I
n
te
n
s
it
ie
s
 (
%
)
10µM Δ1-9 α-Syn
w ith 100µM Cu2+
w ith 100µM Fe3+
w ith 100µM Al3+
-20
0
20
40
60
80
100
0 20 40 60 80 100
time (hr)
N
o
rm
a
li
s
e
d
 T
h
T
 I
n
te
n
s
it
ie
s
 (
%
)
10µM Δ1-9 H50A α-Syn
w ith 100µM Cu2+
w ith 100µM Fe3+
w ith 100µM Al3+
 111 
   (A)       
   (B)       
Fig. 4.14 Plot of the aggregation rate (kapp) obtained for untagged metals binding 
mutants of α-Syn (A) Δ1-9 α-Syn and (B) Δ1-9 H50A α-Syn, in the presence of 
100µM metals. Data presented in this figure represent one experiment.  
 
 
Some level of variability was present while conducting the aggregation 
experiments. While the trends were reproducible, the rates of aggregation varied. 
Different untagged protein batches were tested for their ability to aggregate. At 
this stage, inaccuracies were discovered in the Bradford assay for protein 
quantification when applied to α-Syn. Bradford assay was found to underestimate 
α-Syn concentration by approximately 10 fold when comparing resultant 
concentration to that of A275. Therefore, aggregation experiments of H50A α-Syn 
were carried out at 100µM final protein concentration which resembles the 
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content of 10µM protein estimated at previous work stages via Bradford assay. 
The concentrations of metals were kept at 100µM to keep it relevant to previous 
experiments. This was accompanied by the change into the use of MOPS buffer 
instead of Tris buffer mainly since Tris buffer can interact with copper (Smith and 
Martell 1987). Other experimental conditions were similar such as dialyse the 
protein in chelex-treated MilliQ water pH7 prior to utilising it in aggregation assay. 
Protein samples with or without metals were aliquoted into 96-well plates in a 
final volume of 100µl. Samples were run in triplicates and incubated at 37°C, 
shaking constantly at 600rpm. Results of H50A α-Syn ThT assay are shown in 
the following (Figure 4.15). Copper had the largest effect on accelerating the 
aggregation of H50A α-Syn. Fluorescence intensities obtained with copper were 
much higher compared to iron, in addition to where no metal was present. Also 
less time was taken to get increased ThT fluorescence.  
 
                 
Fig. 4.15 Effect of metals on the aggregation kinetics of H50A α-Syn. 100µM 
protein was incubated in 10mM MOPS pH7.4 with or without 100µM metal at 37°C, 
shaking constantly at 600rpm. ThT fluorescence intensities were recorded at 
different time points and plotted as function of time. Values represent average of 
replicates in one experiment.  
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Both metals (Cu2+ and Fe3+) caused enhancement in H50A α-Syn aggregation, 
but at much higher level with Cu2+ comparing to Fe3+. This was shown in terms of 
maximum fluorescence intensities reached and time taken to achieve it.  
 
 
4.6 Alpha Synuclein Aggregation in Cell Culture   
 
Cell culture and animal models have been used to study the aggregation of α-
Syn and its consequences on cell viability including the identification of the 
possible toxic species. α-Syn in an oligomeric or aggregated form was shown to 
be toxic (Danzer, Haasen et al. 2007; Wright, Wang et al. 2009). Here in this 
work, neuroblastoma cells (SHSY-5Y cells) were utilised to assess the 
aggregation and oligomer formation of α-Syn in response to metals treatment. 
Stable cell lines of SHSY-5Y over-expressing WT α-Syn, metal binding mutants 
(Δ1-9 α-Syn, H50A α-Syn, and Δ119-126 α-Syn) and disease associated mutants 
(A30P, A53T and E46K) were generated. SHSY-5Y cells were individually 
transfected with each of those proteins to over-express them and produce stable 
cell lines, in a way to verify that aggregates increase upon exposure to metals 
(Figure 4.16). 
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Fig. 4.16 Analysis of stably transfected SHSY-5Y cells for the level of protein 
expression. SHSY-5Y cells were transfected with pcDNA3.1 or the plasmid with the 
ORF of WT α-Syn or its mutants. Protein extracts were prepared from cells and 
electrophoresed on 12% acrylamide PAGE gels followed by western blotting. 
Protein bands corresponding to α-Syn were shown using immunodetection via a 
specific antibody for α-Syn. Cont. refers to pcDNA3.1 plasmid and Triple refers to 
Δ2-9 H50A Δ119-126 α-Syn.  
 
 
Figure 4.16 shows increased level of expression of the proteins compared to 
pcDNA3.1 transfected cells (control) using two anti- α-Syn antibodies. The first 
line represent cells immunodetected with an antibody directed against the C-
terminus of α-Syn, while the second line represents cells immunodetected with 
an antibody directed against amino acids 11-26. Control cell lines are cells 
transfected with pcDNA3.1 with no protein expressing insert in it. α-Syn 
corresponding band was found in all cell lines including the control which 
represent endogenous α-Syn in cells. Cells were grown in 6-well plates in either 
normal media or chelex-treated media prior to metal treatment (10µM, 100µM or 
300µM). After 48hr cells were harvested, lysed and equal amounts of total 
protein were then loaded onto a reducing gradient gel as estimated by Bradford 
assay. Protein bands corresponding to monomeric or oligomeric α-Syn were 
revealed using western blotting immunodetection using α-Syn specific antibodies. 
 115 
The same procedure was applied for the different proteins tested. Equal protein 
loading was confirmed using an antibody for tubulin (Sigma).  
 
 
Oligomers (~150kD) were seen in all cell extracts regardless of the treatment, 
which could also represent endogenous level of α-Syn oligomers. In the case of 
WT α-Syn, there were significantly increased levels of oligomers in cells treated 
with copper but not iron (Figure 4.17). Intensities of aggregate bands were 
compared between different conditions using densitometry (Figure 4.18). 
 
        
Fig. 4.17 SHSY-5Y cells stably transfected with WT α-Syn were grown in normal 
media(Con), chelex-treated media (CM) and with metals added. Representative 
experiment of protein separated in 5-20% gradient gel. Western analysis was 
performed using α-Syn or tubulin antibodies. Lanes on gradient gel shows the 
different conditions starting with: normal media (Con), chelex-treated media 
(CM), 10µM Cu2+, 100µM Cu2+, 300µM Cu2+, 10µM Fe3+, 100µM Fe3+, 300µM Fe3+. 
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Fig. 4.18 Integrated density measurements of higher molecular weight α-Syn 
aggregates in SHSY-5Y cells stably transfected with WT α-Syn and grown in 
normal media, chelex-treated media and with metals added. Density 
measurements were related to the untreated control (normal media) as metals 
were added to cells grown in chelex-treated media. Data from three independent 
experiments were pooled and is represented as mean ± standard error. Statistical 
analysis was performed using Student-t test. P<0.05 chelex-treated versus 10µM 
Cu2+, 100µM Cu2+ and 300µM Cu2+.  
 
 
Similar experiments were performed with SHSY-5Y cells expressing each of α-
Syn mutants. Cells were grown in 6-well plates and treated with different 
concentrations of Cu2+ and Fe3+, and harvested 48hrs later for analysis. A similar 
pattern was noted in the case of α-Syn disease-associated mutants (A30P, A53T 
and E46K); to that obtained with WT α-Syn (Figure 4.19). Each of the disease-
associated mutants resulted in an increase in oligomeric aggregates particularly 
with 100µM Cu2+ treatment, but not greater than that seen with WT α-Syn. On the 
other hand, no such increase in the level of oligomers was observed with cells 
expressing α-Syn copper binding mutants in response to copper (Figure 4.19).  
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Fig. 4.19 The effect of 100µM Cu2+ on aggregates formation of α-Syn mutants. 
SHSY-5Y cells expressing each of the proteins were grown in 6-well plates and 
treated with 100µM Cu2+ for 48hrs. Western blot analysis was performed using 
specific α-Syn and α-tubulin antibodies. Higher molecular weight oligomeric 
species of α-Syn were quantified densitometrically and compared to the untreated 
control. Data from three independent experiments were pooled and presented as 
mean ± standard error. The presence of Cu2+ caused significant increase in the 
level of oligomeric aggregates of WT α-Syn and its disease-associated mutants 
using Student’s t test (p<0.05). Black bars represent cells over-expressing protein 
in chelex-treated medial. Grey bars represent cells over-expressing protein in 
chelex-treated media in the presence of 100µM Cu2+. 
 
 
The results shown in both figures (Figure 4.17, Figure 4.18 and Figure 4.19) 
confirm that deletion of copper binding domains in α-Syn prevented copper from 
stimulating aggregation of the protein within cells. 
  
 
4.7 Discussion 
 
α-Syn aggregation has been recognized as a pathological feature of PD and 
other neurodegenerative diseases (Spillantini, Schmidt et al. 1997). Since it has 
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been discovered, it gained a lot of interest as to reveal causative factors and the 
mechanism by which it occurs. In this regard metals have attracted increased 
attention given that iron deposits have been discovered in Lewy bodies 
(Castellani, Siedlak et al. 2000) and elevated concentrations of copper have been 
reported in PD patients (Pall, Williams et al. 1987). Metals have been shown to 
enhance protein aggregation in other neurodegenerative diseases such as PrP in 
prion disease (Brown, Guantieri et al. 2004) and Aβ in Alzheimer’s disease 
(Bush, Masters et al. 2003). Both proteins have also been identified as metal-
binding proteins especially to Cu2+ (Hesse, Beher et al. 1994; Viles, Cohen et al. 
1999; Thompsett, Abdelraheim et al. 2005), which directed research to 
investigate the ability of α-Syn to bind metals. As such, copper binding to α-Syn 
was widely assessed, and α-Syn was identified as a copper binding protein 
(Rasia, Bertoncini et al. 2005). In addition to copper, α-Syn was found to bind 
iron and other divalent metal ions such as Fe2+ and Mn2+ (Binolfi, Rasia et al. 
2006). Furthermore, this study has shown ferric iron (Fe3+) binding properties to 
α-Syn. Copper and iron, have not only been shown to bind to α-Syn, but also to 
accelerate its aggregation (Uversky, Li et al. 2001b), even though the mechanism 
is not yet known. A direct interaction between α-Syn and the metals has been 
proposed to be the underlying mechanism of the aggregation (Rasia, Bertoncini 
et al. 2005). Also, metal binding has been proposed to strongly influence the 
fibrillation process as it could lead to electrostatic masking of the negative 
charges at the C-terminus of α-Syn (Bharathi and Rao 2007), and could cause 
perturbation of the N-terminus long range interactions (Rasia, Bertoncini et al. 
2005; Binolfi, Lamberto et al. 2008), since the main metal binding takes place at 
the N-terminus. Based on that, mutants of α-Syn lacking the potential metal 
binding sites at the N-terminus (residues 1-9) and His-50 individually and 
combined (Δ1-9H 50A α-Syn) were created. α-Syn was assessed as either His-
tagged or untagged forms. Thioflavin-T (ThT) assay was used to assess α-Syn 
aggregation and fibril formation as previously reported for the same purpose 
(Uversky, Li et al. 2001b; Uversky, Li et al. 2002b; Khan, Ashcroft et al. 2005; 
Rasia, Bertoncini et al. 2005; Binolfi, Rasia et al. 2006).   
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While the method of purification of untagged protein was still being developed in 
our laboratory, aggregation experiments (ThT assays) were performed to give a 
preliminary assessment using His-tagged protein. His-tagged α-Syn was 
produced via two different vectors, pET15b and pTrc vectors. Either vector 
generates α-Syn with histidine tag attached to its N-terminal end. The only 
difference between the two His-tagged proteins is the number of amino acids in 
the leading sequence located between the histidine tag and the protein 
sequence, which are 10 amino acids longer for pTrc His-tagged α-Syn. 
Differences in the length and composition of this intermediate sequence may 
alter protein structure and may interfere with protein-protein interaction required 
for aggregation. Hence, this difference could underlie the relatively faster 
aggregation of WT α-Syn produced via pET15b vector compared to WT α-Syn of 
pTrc vector. Nevertheless, the use of His-tagged protein was one of the 
limitations in this study. The presence of the histidine tag in α-Syn sequence may 
cause a change in the way the protein folds to form aggregates or fibrils, which 
may also explain the faster aggregation observed for His-tagged α-Syn 
compared to untagged α-Syn. Therefore, this presumed structural change might 
be responsible for the faster aggregation observed for His-tagged α-Syn 
compared to untagged α-Syn. In addition, the presence of the histidine tag may 
result in some level of metal binding during different steps of purification. 
However, care was taken to use chelex-treated buffers and solutions during the 
course of experiment to eliminate the presence of any metal traces.  
 
 
Optimisation of assay conditions was one of the main aims to start with. Since α-
Syn is an acidic protein with a pI value of 4.7, therefore the lower the pH the 
more prone α-Syn will be to aggregate (Hoyer, Antony et al. 2002). Optimisation 
tests demonstrated that pH 7.4 fitted a preferable aggregation pattern than pH 
6.5 did. Both Tris and Sodium phosphate (Na2PO4) were used in pH tests and 
other optimisation experiments. Although, Tris buffer was reported to be able to 
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interact with copper (Smith and Martell 1987), data was still considered as a 
control was always present and used in all experiments. In addition, other 
published studies have presented related work of α-Syn interaction with metals 
using Tris buffer (Uversky, Li et al. 2001b; Bharathi and Rao 2007). Various 
factors can affect the reproducibility of the results. Protein concentration is a 
critical factor that can significantly affect assay results. Variability seen with 
protein concentrations may originate from the different stages of protein 
preparation process, since it can influence the final protein concentration 
obtained at the end of the process. Some examples can be addressed such as 
freezing or not freezing bacterial cell pellets prior to purification. This could affect 
how well the bacterial cell wall is broken to release proteins. Also, it is important 
to consider the freshness of chemicals used throughout the process and 
maintaining the desired temperature when appropriate. In addition, protein 
concentration estimation method was another source of confusion that could 
effectively influence results. α-Syn concentration was estimated using Bradford 
assay throughout the project. When comparing values to those obtained by 
measuring concentration using absorbance at 275 nm, Bradford assay was found 
to underestimate protein concentration by approximately 10-fold. This is due to 
the lack of tertiary structure of α-Syn and the lack of enough ionisable amino 
acids on α-Syn to bind non-covalently to the dye via van der Waals forces. Thus, 
forming fewer complexes that are needed to measure the protein concentration. 
Estimating α-Syn concentration with absorbance at 275nm is reliable since the 
protein has aromatic amino acids (Tyrosine and Phynealanine). However, this 
variation was not of an issue regarding to measuring protein concentration since 
it was taken into account while performing ThT assays. In addition, during 
experimental course, a different plate reader was used to perform assays and 
measure ThT fluorescence. Therefore, a sensitivity factor in detecting the 
fluorescence could add more into the differences obtained in the aggregation 
pattern when plotting the recorded ThT intensity values. ThT dye binding to the 
protein and the β-sheet structures can also contribute to the effectiveness of the 
results and assay accuracy. Yet, it is still a less controllable factor. Some of this 
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variability could be eliminated via the production of α-Syn batch that is enough to 
perform three repeats of the experiment. The next step then could be producing 
another batch of the protein and use it for the same purpose and compare 
results. This procedure may reduce the interference of protein preparation factor 
in assay results.  
 
 
Metals in this study were used at 100µM which is low compared to other studies 
that have reported a similar effect of metals in accelerating α-Syn aggregation 
using concentrations of up to 2mM (Paik, Shin et al. 1999; Uversky, Li et al. 
2001b). ThT assays focused mainly on three metals including copper, iron and 
aluminium. Results generated through this work regarding metals’ effect on WT 
α-Syn brought no new findings. Copper, iron and aluminium to some extent all 
showed acceleration of α-Syn aggregation in ThT assays. While experiments 
performed with His-tagged α-Syn pointed to copper as the most effective metal in 
inducing α-Syn aggregation, experiments with untagged α-Syn demonstrated a 
higher effect for ferric iron. Such variation was present and has been reported in 
published studies where copper was most effective at enhancing α-Syn 
aggregation (Uversky, Li et al. 2001b; Rasia, Bertoncini et al. 2005; Binolfi, Rasia 
et al. 2006). On the other hand, previously aluminium was shown to cause rapid 
aggregation and high level of fluorescence of α-Syn compared to copper 
(Uversky, Li et al. 2001b). This variation could be a result of the different 
experimental conditions between these studies since different protein (35µM to 
100µM) and metal concentration (100µM to 2mM), buffer and pH values (Mes 
buffer pH6.5 or NaP pH7.5) were used.  
 
 
Importantly, potential metal binding sites in α-Syn were deleted in an attempt to 
assess the role of metal binding in α-Syn aggregation. All metals enhanced the 
aggregation of α-Syn metal binding mutants. Both N-terminal mutants (Δ1-9 α-
Syn, Δ1-9 H50A α-Syn) showed similar results to WT α-Syn with regard to 
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accelerated aggregation with metals, mainly copper and iron. Moreover, copper 
was effective in inducing acceleration of the aggregation of H50A α-Syn. This 
could be explained by a possible coordination of copper by other sites, even in 
the absence of His 50 which reduces the competition to bind copper, and makes 
the protein prone to aggregate. In addition, mutating His 50 (being a copper 
interacting residue) to alanine was shown not to affect copper binding to the 
protein (Sung, Rospigliosi et al. 2006) indicating that copper binding sites are not 
dependent on each other. The effect observed of metals on α-Syn aggregation 
could be a result of metal binding to the C-terminus or the presence of the 
histidine tag within the N-terminal domain of his-tagged proteins. In addition, 
imidazole moieties of histidine residues represent a target for direct interaction 
with copper because they represent a high affinity copper binding element. 
Moreover, as ThT fluorescence indicates the presence of β-sheet rich fibrillar 
structures, therefore, WT α-Syn and its N-terminal mutants resulted in fibril 
formation, and metals accelerated the process. This was reported for WT α-Syn 
but no such data has previously been established for metal binding mutants 
(Uversky, Li et al. 2001b; Binolfi, Rasia et al. 2006). All proteins used in ThT 
assays aggregated and had increased ThT fluorescence. As ThT fluorescence 
was suggested to be a result of the interaction of ThT molecules within grooves 
between solvent-exposed side-chains of the amyloid fibrils (Hawe, Sutter et al. 
2008) and to be enhanced by its specific binding to amyloid fibrils (Krebs, 
Bromley et al. 2005). Structurally, all proteins used in this study have the NAC 
domain, specifically residues 71-82, which was shown to be essential for protein 
aggregation (Uversky and Fink 2002). It has been shown in another study that 
fibrils formed by a truncated form of α-Syn (30-140) are similar in morphology 
and core size to those formed by the full length α-Syn (Qin, Hu et al. 2007). They 
reported that residues 32-102 constitute the core of α-Syn fibrils, which are 
present in WT, Δ1-9 α-Syn, Δ1-9 H50A α-Syn and H50A α-Syn used in this work. 
Hence, all mutants have the ability to aggregate and form fibrils. 
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The ability of copper to induce α-Syn aggregated was further supported by the 
cell culture model, where increased protein aggregates and not fibrils were 
detected via western blotting analysis. However, this method is capable of 
detecting large aggregates but not fibrils that are resistant to the denaturing 
conditions of the gel, since they would not pass through the polyacrylamide 
matrix pores which are not more than 200nm in diameter (Stellwagen 1998). 
Oligomeric aggregates of α-Syn were seen in samples representing all 
conditions, which imply the presence of a background level of oligomeric α-Syn in 
all cells over-expressing any form of α-Syn. It also could be related to the 
technique used to prepare the samples from cell lysates, which necessarily 
concentrate the protein and therefore generating some amount of α-Syn 
oligomers not present in cells. Even though, the latter can not be ruled out, it 
does not detract from or diminish the effect observed with copper where it altered 
the level of aggregates as demonstrated with western blotting. No role for iron in 
increasing aggregation was found in this work which is in disagreement of a 
previous study (Ostrerova-Golts, Petrucelli et al. 2000). In addition, intracellular 
aggregation of α-Syn in response to copper was shown to require both the N- 
and C-terminals, and deletion of either resulted in a clear loss of aggregation. It 
has been previously suggested (Brown 2009) that copper binding to α-Syn 
involves interaction between both domains; hence deletion of one domain would 
disturb copper binding especially that binding copper could occur via interaction 
of both domains of one α-Syn molecule. Moreover, results shown in this work did 
not include a comparison of the relative level of oligomer formation between cells 
expressing WT α-Syn and its disease-associated mutants in the absence of 
copper treatment which could be different. However, it has been reported that 
these mutants cause an increase formation of aggregated including fibrils (Li, 
Uversky et al. 2001). 
 
In summary, all synucleins used in this study aggregated in the presence and the 
absence of metals. Metals at low, physiologically relevant concentrations induced 
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faster aggregation as demonstrated by ThT assay. Different assay conditions 
such as protein concentration, pH and even protein purification method and 
fluorescence detection method contribute to the final result. Mutating α-Syn at the 
N-terminal did not affect protein aggregation or prevent metal effect as shown by 
ThT assays. While deleting the C-terminus affected protein aggregation and 
blocked any obvious effect of copper on the protein aggregate formation as 
demonstrated by cell model but not in vitro. Copper increased α-Syn oligomers 
formation in a cell model. However, more repeats of these experiments under the 
same conditions are required to state a more clear result. Moreover, electron 
microscopy (EM) analysis would be of great beneficial to add more information 
about aggregation and fibrillation process of α-Syn metal binding mutants. 
Further ITC experiments of metal binding mutants of α-Syn would be beneficial to 
assess iron binding to these different mutant proteins. Also, it is important to 
consider complications accompanied with the method used to assess α-Syn 
aggregation. As well as the lack of reproducibility found while conducting the 
experiments. 
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Chapter Five: Regulation of Synuclein 
Expression 
 
 
5.1 Introduction 
 
 
The majority of Parkinson’s disease (PD) cases are sporadic; however a subset 
of PD cases is inherited as a familial trait (autosomal-dominant trait). The α-Syn 
gene (SNCA) was one of the first genes implicated in PD aetiology, as the 
causative gene in familial PD, with the identification of point mutations in cases of 
early onset familial PD (Polymeropoulos, Lavedan et al. 1997; Kruger, Kuhn et al. 
1998). Additionally, α-Syn was shown to be the main component in LBs and LNs 
(Spillantini, Schmidt et al. 1997), even in brains of patients who do not carry α-
Syn mutations (Mezey, Dehejia et al. 1998). Therefore, other mechanisms 
underlie the contribution of α-Syn in PD. Such mechanisms might include post-
translational modifications, damage to the protein (oxidation), altered regulation 
of protein expression or protein degradation (Chiba-Falek and Nussbaum 2001). 
The importance of assessing the regulation of α-Syn expression comes from 
other findings, such as mice over-expressing α-Syn have been found to display 
neuronal inclusions similar to LBs, increased degradation of dopaminergic 
neurons and motor deficits (Masliah, Rockenstein et al. 2000). Moreover, 
genomic multiplications in SNCA were considered to be risk factors for PD 
(Singleton, Farrer et al. 2003) and polymorphic alleles in synuclein promoter were 
found to be associated with sporadic PD (Kruger, Vieira-Saecker et al. 1999).  
 
 
Little is known about the regulation of α-Syn expression. Many studies have 
suggested that the genomic multiplications in SNCA lead to increased gene 
expression (Singleton, Farrer et al. 2003; Miller, Hague et al. 2004; Pals, Lincoln 
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et al. 2004) and cause excess amounts of α-Syn, which might be sufficient to 
increase susceptibility to familial PD (Chiba-Falek, Kowalak et al. 2005). In 
addition, increased levels of α-Syn mRNA in substantia nigra (SNpc) neurons 
from patients with idiopathic PD compared to controls have been reported, which 
emphasizes the importance of normal regulation of α-Syn expression (Chiba-
Falek, Lopez et al. 2006; Grundemann, Schlaudraff et al. 2008). Many studies 
have aimed to characterize the promoter (enhancer) elements in SNCA gene and 
to analyse the potential sites for transcription factors, particularly in the region 
upstream of SNCA gene (Chiba-Falek and Nussbaum 2001). Others attempted 
to investigate the association between promoter polymorphisms of SNCA gene 
and sporadic PD (Pals, Lincoln et al. 2004; Mueller, Fuchs et al. 2005). The most 
studied genetic variation was the REP1 polymorphism, which has been shown to 
have a direct relevance to PD by affecting gene expression and age of disease 
onset based on the allele size (Chiba-Falek and Nussbaum 2001; Maraganore, 
de Andrade et al. 2006; Kay, Factor et al. 2008). Polymorphisms at this complex 
dinucleotide repeat NACP-REP1, located ~10kb upstream of the SNCA 
transcriptional start site, have gained attention as they have been associated with 
sporadic PD (Kruger, Vieira-Saecker et al. 1999; Linnertz, Saucier et al. 2009). 
This region has been suggested to likely contain the gene promoter and putative 
regulatory sequences, and to influence the expression of α-Syn (Touchman, 
Dehejia et al. 2001). Moreover, the ~10kb sequence upstream of SNCA gene, 
including the NACP-REP1, has been shown to be necessary for normal 
expression (Chiba-Falek and Nussbaum 2001; Touchman, Dehejia et al. 2001) 
and for regulating the transcriptional activity of SNCA gene. SNCA activity has 
also been found to be modulated by the length of the REP1 allele (Chiba-Falek, 
Touchman et al. 2003). Assessment of promoter activity of deletion constructs of 
that sequence confirmed its importance in controlling α-Syn expression. It has 
been shown that the absence of an 880bp segment containing the NACP-REP1 
repeat led to total elimination of the promoter activity in neuroblastoma cell line 
(SHSY-5Y) (Chiba-Falek and Nussbaum 2001).  
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A role for β-Syn, which shares structural homology and sub-cellular localisation 
pattern similar to α-Syn, in modulating the pathology of α-Syn has been 
suggested. It has been shown that β-Syn can inhibit the aggregation process of 
α-Syn in vitro (Uversky, Li et al. 2002b) and can reduce its toxicity in animal 
models in vivo (Hashimoto, Rockenstein et al. 2001). Importantly, it has been 
reported that levels of α-Syn mRNA increases and β-Syn mRNA decreases in 
SNpc of PD brains compared to controls (Rockenstein, Hansen et al. 2001) 
which is the opposite to normal brains aging (Li, Lesuisse et al. 2004). Decreased 
levels of β-Syn mRNA, as demonstrated by RT-PCR, have also been reported in 
brains of patients of dementia with Lewy bodies (Beyer, Domingo-Sabat et al. 
2010). These observations emphasize the importance of a balanced regulation of 
both α-Syn and β-Syn, and suggest that β-Syn might be a natural negative 
regulator of α-Syn. Information about regulators of β-Syn expression had not 
been reported at the start of this study.  
 
 
Metals, as repeatedly mentioned, were linked to PD as risk-increasing factors 
and were shown to induce α-Syn aggregation in vitro (Uversky, Li et al. 2001b). 
Although the cellular function of α-Syn is not known, however, giving that α-Syn 
binds metals (Cu2+ and Fe3+) (Binolfi, Rasia et al. 2006) and the increased iron 
content in PD brains (Dexter, Wells et al. 1989; Dexter, Carayon et al. 1991) 
where aggregated α-Syn constitutes a major component of Lewy bodies 
(Spillantini, Schmidt et al. 1997), it all emphasizes the role played by metals in 
PD. It has been shown that expression of prion protein (PrP), involved in Prion 
disease pathology, was shown to be regulated by copper (Toni, Massimino et al. 
2005; Varela-Nallar, Toledo et al. 2006b) via metal response element (MRE’s) 
sequences, and mediated by metal-responsive transcription factors such as 
MTF-1 (Bellingham, Coleman et al. 2009). Metal responsive transcription factor-1 
(MTF-1) can bind to MRE sequences and regulate metallothionein genes in 
response to metals such as zinc (Stuart, Searle et al. 1984; Radtke, Heuchel et 
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al. 1993). Moreover, SP1, a general activator of transcription, can also bind to 
putative MRE sites (Ogra, Suzuki et al. 2001) and was shown to mediate copper 
regulation of PrP expression with MTF-1 (Bellingham, Coleman et al. 2009). 
Therefore, it could be hypothesized that metals, among different factors and 
conditions, could cause altered regulation of α-Syn expression.  
 
 
In this study, human neuroblastoma cells SHSY-5Y, were used. Promoter 
analysis was performed largely based on the finding of MRE’s in α-Syn promoter, 
as well as β-Syn promoter. Therefore, it is essential to determine the potential 
involvement of MRE’s in α-Syn promoter activity and to assess any changes in 
expression in response to metal exposure. A reporter assay, utilizing plasmid 
vector (pGL3basic) containing synuclein promoter fragments, was used in the 
following experiments to assess synuclein’s promoter activity. Quantitative real 
time PCR is a widely used method to assess transcriptional activation of genes in 
response to different treatments or conditions, however, a reporter based assay 
was chosen as a start point in this work. 
 
 
5.2 Synuclein Promoter Analyses 
 
For the assessment of synuclein promoter activity, synuclein promoter fragments 
were cloned into Luciferase reporter constructs and transfected into SHSY-5Y 
cells. The 10.8kb region upstream of the synuclein transcriptional start site was 
divided into smaller DNA segments and cloned into the reporter assay plasmid 
vector (pGL3basic). Promoter fragments were gradually shortened to further 
identify the regulatory regions of the synuclein promoters with and without metal 
exposure. 
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5.2.1 Luciferase Based Analysis of Synuclein Promoter 
 
Fragments of both human α-Syn and β-Syn promoters were cloned and inserted 
into pGL3basic reporter vector to enable assessment of their activities. SHSY-5Y 
cells were transfected with two individual reporter vectors at the same time. The 
first is the experimental vector (pGL3basic) in which the promoter sequence of 
interest is cloned upstream of the Firefly Luciferase gene. The second is the 
control vector, Renilla Luciferase, which serves as internal control for the 
transfection. The activity of both Luciferases was detected in the same sample 
using the Dual-Luciferase Reporter Assay System (Promega). The activity of the 
experimental reporter was normalized to the activity of the control reporter to 
minimize experimental variability caused by differences in cell viability and 
transfection efficiency. During the course of experiments, assessing synucleins 
promoter’s activity, two internal control vectors were used pRL-SV40 and pRL-
TK. The difference between both vectors is that pRL-SV40 contains the SV40 
enhancer and early promoter elements which provides a high level of expression 
of Renilla Luciferase in the co-transfected mammalian cells, while pRL-TK 
contains the herpes simplex virus thymidine kinase (HSV-TK) promoter which 
produces a low to moderate expression level. Results obtained using both 
vectors were similar.  
 
 
5.2.1.1 Alpha Synuclein Promoter Activity Assessment 
 
To evaluate the promoter activity of α-Syn, the -10.8kb region was divided into 
smaller segments and cloned into pGL3basic reporter plasmid. Numbers such as 
(-10.8/-6) refer to kilobases upstream of the transcriptional start site. Initial 
analysis was performed on fragments (α-Syn-10.8/-6, α-Syn-6/-1.3, α-Syn-3.6/-
1.3, α-Syn-1.3/1 and α-Syn-4.1/1). Selection of promoter fragments for potential 
activity was based on the presence of MRE’s in their sequence to which 
transcription factors such as MTF-1 and SP1 can bind.  
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Figure 5.1 shows that intron1 sequence of α-Syn is included as it has been 
reported to be an important regulatory region and cooperates with region 5’ to 
exon1 in order to mediate gene transcription (Clough and Stefanis 2007; Clough, 
Dermentzaki et al. 2011).  
 
 
Fig. 5.1 Schematic illustration of the 10.8kb region upstream of α-Syn 
transcriptional start site. Stars represent transcription factor binding sites (MTF-
1), metal response elements MRE’s, as identified using Transcriptional Element 
Search Software (TESS) (http://www.cbil.upenn.edu/cgi-bin/tess/tess). 
 
 
α-Syn promoter analysis revealed two MRE’s, (TGCGCTC and GTGTGCA), 
contained in α-Syn-3.6/-1.3, α-Syn-1.3/1 and α-Syn-4.1/1 fragments tested in this 
project, and located at -1182bp and -2517bp upstream of the transcriptional start 
site.   
 
 
Results showed an increase in the activity of promoter fragment α-Syn-6/-1.3 
compared to α-Syn-10.8/-6. Higher activity was observed with α-Syn-3.6/-1.3 
fragment and α-Syn-4.1/1 compared to other fragments (Figure 5.2). 
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(A)  
(B)  
Fig. 5.2 Relative Luciferase activity of different α-Syn promoter fragments in the 
absence of metals. SHSY-5Y cells were grown in normal media and transfected 
with 200ng of pGL3basic vector containing one of the promoter fragments with 
10ng of the control vector (A) pRL-SV40 and (B) pRL-TK. Error bars represent 
standard error of four and three independent experiments, repectively. RLU 
stands for: Relative Luciferase Units.  
 
 
α-Syn-3.6/-1.3 and α-Syn-4.1/1 showed more activity than other fragments tested 
when co-transfected with either pRL-SV40 or pRL-TK controls. On the other 
hand, α-Syn-10.8/-6 showed no activity comparing to the other fragments and it 
was as low as the control (pGL3basic vector) that has no DNA insert in it. Results 
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shown in Figure 5.2 reflect transfections performed on cells grown in normal 
growth media (DMEM + Ham’s F-12). 
 
 
      5.2.1.2 Effect of Metals on Alpha Synuclein Promoter Activity 
 
SHSY-5Y cells were grown in normal media (DMEM + Ham’s F-12) until they 
reached 60-80% density and then transfected with 200ng of each of the promoter 
fragments along with 10ng of the control vector (pRL-TK). Metal treatment was 
performed ~16 hours past transfection with fresh media. Metal (Cu2+ and Fe3+) 
were added at either 10µM or 100µM final concentrations and cells were 
incubated further for ~30 hours (Figure 5.3).  
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(A)                                                           (B)  
 
(C)                                                          (D) 
Fig. 5.3 Relative Luciferase activity of different α-Syn promoter fragments in the 
presence of metals. The effect of the presence of 10µM or 100µM of Cu2+ or Fe3+ 
on α-Syn promoter fragments (A) α-Syn-3.6/-1.3 (B) α-Syn-6/-1.3 (C) α-Syn-4.1/1 
and (D) α-Syn-2.3/-1.3. SHSY-5Y cells were grown in normal media and co-
transfected with pRL-TK as control vector. Error bars represent standard error of 
the mean of three experiments. Statistical analysis was performed using Student-t 
test and was found to be above the p<0.05 threshold.  
 
 
Results in Figure 5.3 show that metals have little to no effect on increasing the 
activity of α-Syn promoter fragments tested either containing MRE’s (α-Syn-3.6/-
1.3, α-Syn-1.3/1 and α-Syn-4.1/1) or not containing any MRE’s (α-Syn-2.3/-1.3). 
This could be due to performing this set of experiments in normal media (DMEM 
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+ Ham’s F-12) which contains trace levels of metals that could make observing 
any differences in metal regulation of promoter activity difficult. Promoter 
fragment α-Syn-10/-6 was not assessed with metals as it showed no activity 
comparing to other fragments. Therefore, it was important to assess whether the 
presence of metals in the media would influence promoter activity. This is an 
important precursor to experiments which continue to assess the effect of metals 
on promoter activity, whereby metal treatment was performed after removing the 
normal media and replacing it with chelex-treated media. Therefore, after 
transfecting cells in normal media (DMEM + Ham’s F-12), basal activity of α-Syn 
promoter fragments was not affected by adding fresh chelex-treated media. 
Basal activity of α-Syn-3.6/-1.3 fragment shown in Figure 5.4 is an example of 
the effect of changing the media after transfection (Figure 5.4).  
 
                 
Fig. 5.4 Relative Luciferase activity of α-Syn-3.6/-1.3 fragment in two different 
conditions. α-Syn-3.6/-1.3 was transfected into SHSY-5Y cells grown in two 
different conditions, normal and chelex-treated media, after being transfected in 
normal media. Cells transfected with pGL3basic vector with no α-Syn fragment 
was used as a control. Error bars represent standard error of the mean of three 
experiments.  
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Figure 5.4 above shows that activity of α-Syn-3.6/-1.3 fragment was slightly 
higher when SHSY-5Y cells were cultured in chelex-treated media, from which 
metal traces has been removed, compared to those left in normal media. No 
activity was shown in both conditions with cells transfected with pGL3basic 
control with no insert in it. This result suggests that changing the media in which 
cells were grown after transfection into a media from which metals are removed 
could affect promoter activity. A similar result was obtained when such 
assessment was repeated and accompanied with metal (copper) treatment. The 
promoter fragment chosen for this experiment was α-Syn-1.9/1 because it 
showed activity considerably higher than the control and because it was available 
at time of the experiment. SHSY-5Y cells were grown in normal media until 
reaching 60-80% density, and then cells were transfected with a promoter 
fragment (α-Syn-1.9/1). Copper treatment and changing the media was 
performed together, ~16hr after transfection, keeping half the cells in normal 
media and changing the media into chelex-treated media for the other half. Both 
groups of cells were harvested ~30hrs after metal treatment, lysed and analysed 
(Figure 5.5, A). In addition, a third set of SHSY-5Y cells were grown in normal 
media until the proper density (60-80%), then the media was changed into 
chelex-treated media prior to transfection and metals were added to the cells in 
the same media (chelex-treated). Transfecting cells with the later condition 
showed major effect on transfection efficiency and much less activity compared 
to other condition used and described above (Figure 5.5, B).  
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    [A]        
    [B]        
Fig. 5.5 Relative Luciferase activity of α-Syn-1.9/1 promoter fragment under 
different conditions where [A] SHSY-5Y cells were transfected in normal media 
and treated with Cu2+ in (A) normal media, and (B) after changing the media into 
chelex-treated media. [B] SHSY-5Y cells were transfected in (A) normal media (C) 
chelex-treated media and then treated with Cu2+ in the same media. Error bars 
represent standard error of the mean of three experiments.  
 
 
Results in Figure 5.5 above show and confirm that the effect of metal treatment 
on promoter activity was not influenced by changing the media in which the cells 
are incubated after transfection, when cells were transfected in normal media. 
Also results in Figure 5.5, B shows considerable decrease in the activity of α-Syn 
promoter fragment when transfection was performed in chelex-treated media and 
0
20
40
60
80
100
No Cu2+ w ith Cu2+ No Cu2+ w ith Cu2+ No Cu2+ w ith Cu2+
pGL3basic α-Syn-1.9/1 (A) α-Syn-1.9/1 (B)
R
L
U
0
20
40
60
80
100
No Cu2+ w ith Cu2+ No Cu2+ w ith Cu2+ No Cu2+ w ith Cu2+
pGL3basic α-Syn-1.9/1 (A) α-Syn-1.9/1 (C) 
R
L
U
 137 
followed by metal treatment. Therefore, the conditions utilised in Figure 5.5 A, 
rather than 5.5 B were used in the assessment of metals’ effect on α-Syn and β-
Syn promoter activity such as that presented in Figure 5.6, as well as the 
subsequent assessments.  
 
 
A further set of experiments was conducted to assess activity of α-Syn promoter 
fragments utilising the procedure described earlier, with pRL-SV40 as the internal 
control vector and metals were added to transfected cells in chelex-treated 
media. SHSY-5Y cells were grown in normal media until 60-80% density was 
reached and then transfected with 200ng of each of the promoter fragments with 
10ng of the control vector (pRL-SV40). Metal treatment was performed ~16hrs 
after transfection just after the media was changed into fresh chelex-treated 
media. Metals were added at 1, 10, 100µM final concentrations and cells were 
incubated for further ~30hrs. Similar to metals treatment in normal media (Figure 
5.6), metals showed no statistically significant effects on α-Syn promoter activity.  
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     (A)      
     (B)      
     (C)      
Fig. 5.6 Relative Luciferase activity showing the effect of metals on α-Syn 
promoter fragments. 1, 10, 100µM of metals (Cu2+, Fe3+, Al3+) were added on 
SHSY-5Y cells transfected with α-Syn promoter fragments (A) α-Syn-3.6/-1.3 (B) α-
Syn-1.3/1 and (C) α-Syn-4.1/1. SHSY-5Y cells were grown in normal media and co-
transfected with pRL-SV40 as internal control vector. Metal treatment was 
performed in chelex-treated media. Error bars represent standard error of the 
mean of four experiments.  
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Results presented in Figure 5.6 show little effect of metals tested on increasing 
activity of α-Syn promoter fragments. The effect shown with 1µM Fe3+ on α-Syn-
1.3/1 and with 100µM Cu2+ on α-Syn-4.1/1 was not significant as demonstrated 
by Student’s t-test. Additionally, there was little difference between results shown 
with α-Syn fragments (α-Syn-3.1/-1.3, α-Syn-4.1/1) when treated with metals in 
either normal or chelex-treated media.  
 
 
5.2.1.3 Beta Synuclein Promoter Activity Assessment 
 
Similar to α-Syn, the β-Syn promoter was cloned into pGL3basic plasmid vector 
to be assessed for its potential activity (Figure 5.7). 
 
Fig. 5.7 Schematic illustration of the 10.8kb region upstream of β-Syn 
transcriptional start site. Stars represent transcription factor binding site (MTF-1), 
metal response elements MRE’s, as identified using Transcriptional Element 
Search Software (TESS) (http://www.cbil.upenn.edu/cgi-bin/tess/tess). 
 
 
Basal activity of selected β-Syn fragments were assessed using the Luciferase 
based assay. The selection of β-Syn fragments was based on location similarity 
to those of α-Syn fragments and taking in consideration the presence of MRE’s in 
that region. Analysis of the β-Syn promoter fragments using Transcriptional 
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Element Search Software (TESS) (McHugh, Wright et al. 2011; Schug 2008) 
revealed the presence of more MRE’s in β-Syn promoter compared to α-Syn 
promoter (Figure 5.1). SHSY-5Y cells were grown in normal media (DMEM + 
Ham’s F-12) until they reached 60-80% density and then transfected with 200ng 
of each of the promoter fragments inserted in pGL3basic vector along with 10ng 
of the internal control vector (pRL-TK). Cells were then incubated for ~48hr after 
transfection and then harvested for analysis (Figure 5.8).  
 
          
Fig. 5.8 Relative Luciferase activity of different β-Syn promoter fragments in the 
absence of metals. SHSY-5Y cells were grown in normal media and transfected 
with 200ng of pGL3basic vector containing one of the promoter fragments with 
10ng of the control vector (pRL-TK). Error bars represent standard error of the 
mean of three experiments.  
 
 
β-Syn promoter fragments showed much lower activity compared to α-Syn and 
also close to the background activity shown by the empty vector (pGL3basic with 
no promoter insert in it) when either internal control is present (pRL-SV40 or pRL-
TK). β-Syn-1.1/-0.6 fragment showed the highest activity level among all 
fragments tested which was recently reported (McHugh, Wright et al. 2011).  
 
 
 
0
1
2
3
4
5
6
pGL3basic β-Syn-3.7/-
0.9
β-Syn-10/-6 β-Syn-6/-
0.9
β-Syn-3.7/1 β-Syn-1.1/-
0.6
R
L
U
 141 
5.2.1.4 Effect of Metals on Beta Synuclein Promoter Activity  
 
Similar to the previously conducted assessment of α-Syn promoter fragments, 
SHSY-5Y cells transfected with a β-Syn promoter fragment, were treated with 
metals (Cu2+, Fe3+ and Al3+) to assess whether metals cause any changes to 
their activities. SHSY-5Y Cells were grown in normal media until 60-80% density 
and then transfected with 200ng pGL3basic with a β-Syn promoter fragment 
inserted in it along with 10ng pRL-TK as an internal control for transfection. 
Metals (Cu2+, Fe3+ and Al3+) were added at 10µM and 100µM as final 
concentration ~16hrs after transfection. Cells were then incubated for another 
30hrs and then harvested for analysis. This experiment was performed for two 
fragments of the β-Syn promoter (β-Syn-3.7/-0.9 and β-Syn-0.9/1) shown in 
Figure 5.9.  
 
 
 
 
 
 
 
 
 
 
 
 142 
(A)      
(B)      
Fig. 5.9 Relative Luciferase activity of different β-Syn promoter fragments in the 
presence of metals. The effect of adding 10µM and 100µM of metals (Cu2+, Fe3+ and 
Al3+) on SHSY-5Y cells transfected with β-Syn promoter fragments (A) β-Syn-3.7/-
0.9 and (B) β-Syn-0.9/1. SHSY-5Y cells were grown in normal media and co-
transfected with pRL-TK as internal control. Error bars represent standard error of 
the mean of three experiments.  
 
 
Metals resulted in no effect on the activity of β-Syn-0.9/1 fragment (Figure 5.9, 
B). However, copper at 10µM and 100µM showed a significant increase in 
prompter driven activity of β-Syn-3.7/-0.9 (as shown by Figure 5.9, A; Student-t 
test p<0.05).  
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5.3 Discussion 
 
The importance of understanding the regulation of α-Syn expression is clear from 
studies showing increased levels of α-Syn mRNA and protein in PD brains, in 
addition to the identification of several genomic multiplications of the α-Syn gene 
in families with PD and DLBD (Singleton, Farrer et al. 2003; Pals, Lincoln et al. 
2004; Nishioka, Hayashi et al. 2006). Moreover, β-Syn has been presented as a 
negative regulator of α-Syn due to its ability to inhibit its aggregation and reduce 
its toxicity (Hashimoto, Rockenstein et al. 2001; Uversky, Li et al. 2002b; 
Hashimoto, Bar-On et al. 2004). This emphasized the need to have a strict 
regulation of both α-Syn and β-Syn and to identify regulators of their expression 
to assist avoiding disease progression. The assessment of the regulation of 
synuclein expression as reported throughout this project aimed to identify the 
regulatory regions in both α-Syn and β-Syn promoters, and to assess how 
factors, such as metals, can affect synuclein’s expression. This consideration of 
metals as regulatory factors was supported by the in vitro findings of metals’ 
enhancement of α-Syn aggregation (Uversky, Li et al. 2001b) and by copper’s 
regulatory role reported for PrP in Prion disease (Toni, Massimino et al. 2005; 
Varela-Nallar, Toledo et al. 2006b).  
 
 
The 10.8kb region upstream of SNCA transcriptional start site has been the main 
focus in research of the regulation of SNCA gene expression (Chiba-Falek and 
Nussbaum 2001). This is mainly due to the presence of polymorphisms at a 
complex repeat site approximately ~10kb upstream of SNCA gene which was 
accompanied with increased expression levels of α-Syn (Fuchs et al. 2008), even 
though the region -10/-6 fragment was shown to have low promoter activity 
(Chiba-Falek and Nussbaum 2001). Several constructs, covering varying 
distances from the transcriptional start site of SNCA gene, were created to 
perform a deletion analysis to this region in order to facilitate observing the ones 
with enhancer activity. These constructs included the first intronic sequence of 
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SNCA gene based on reports highlighting the importance of that region in 
regulating α-Syn transcription (Clough and Stefanis 2007; Jowaed, Schmitt et al. 
2010). Response elements mediating α-Syn transcriptional regulation by growth 
factors have been characterized in intron1 of SNCA gene (Clough and Stefanis 
2007). Moreover, expression-relevant GATA TF binding sites have been 
identified in intron1, and therefore they can play a role in regulating SNCA gene 
expression (Scherzer, Grass et al. 2008). In addition, promoter analyses and 
prediction software identified several transcription factor binding sites upstream 
from ATG in human SNCA gene (Jowaed, Schmitt et al. 2010). Thus including 
intron1 of SNCA gene was relevant to transcriptional regulation studies.  
 
 
Assessment of short DNA segments of that promoter region (α-Syn-3.6/-1.3 and 
α-Syn-4.1/1) resulted in high enhancer activity (Figure 5.2). This result is 
consistent with another study indicating that this part (-6/-1.3kb) of the promoter 
conserves the enhancer ability to drive the expression (Chiba-Falek and 
Nussbaum 2001), especially that the part (-10.8/-6kb) showed no activity. It is 
also in agreement of their work as they referred to the importance of a 400pb 
segment upstream of exon1, being sufficient to drive the expression, as 
demonstrated via similar deletion analysis and Luciferase assay. This 400bp is 
contained within both constructs referred to earlier (α-Syn-3.6/-1.3 and α-Syn-
4.1/1) but not in α-Syn-1.3/1 which showed less activity (Figure 5.2, A). On the 
other hand, analysis of β-Syn promoter size-matching fragments to those of α-
Syn had activity that was either lower or slightly higher than that of the 
background which was different to activity levels seen with α-Syn. Although both 
α-Syn and β-Syn promoters possess a similar range of transcription factor 
binding sites in the region comprising (-6/Ex1) such as Sp1 and AP2 which would 
imply that they would have a similar activity, however the effect on regulation of 
transcription might be different. One fragment, β-Syn-1.1/-0.6, had a considerably 
high activity comparing to other closely located promoter fragments such as β-
Syn-3.7/1 or β-Syn-3.7/-0.9, in human dopaminergic SHSY-5Y cells (Figure 5.8). 
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This could be due to the absence of repressors from this small fragment while 
present in others, and could suggest that promoter sequence of β-Syn might be 
overlapped with exon1.  
 
 
The change in conditions reported throughout the assessment of synucleins 
promoter activity did not affect results and activity pattern. Such a change was 
the use of two different internal control vectors, pRL-SV40 or pRL-TK, and the 
level of activity of tested fragments was alike when either internal control plasmid 
was used. This established that the main purpose of using those controls was 
fulfilled which is to control transfection. Due to the low level of Firefly Luciferase 
expression driven by synuclein promoter fragments comparing to the high level of 
Renilla Luciferase expression driven by pRL-SV40 plasmid used initially, 
experiments were carried out afterwards using pRL-TK plasmid which has a 
moderate Luciferase expression and makes it more relevant. Putting transfected 
cells into chelex-treated media prior to metal treatment was another change in 
conditions which did not inhibit promoter activity. However, transfecting the cells 
in chelex-treated media resulted in a notable decrease in activity level (Figure 
5.5, B). Chelex-treated media is the normal growth media (DMEM + Ham’s F-12) 
treated with chelex beads for few hours to remove metal traces present in the 
media, as metal concentrations as low as 1µM were aimed to be tested. This 
could imply that metals are essential and their removal could cause decrease in 
transfection efficiency.  
 
 
Metals have been linked to PD aetiology and were found to accelerate α-Syn 
aggregation in vitro (Uversky, Li et al. 2001b). Disturbed metal homeostasis has 
also been recognized in brain of patients with PD (Dexter, Wells et al. 1989). 
Moreover, analysis of α-Syn and β-Syn promoter sequence revealed the 
presence of MRE’s, which are highly conserved motifs found in other genes’ 
promoters that are regulated in response to metal exposure to enable metals 
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metabolism and detoxification (Lichtlen, Wang et al. 2001). This suggests that 
synuclein’s may be regulated by transcription factors such as MTF-1. Thus, it 
was important to evaluate the role of metals and MRE’s present in synuclein’s 
promoter and whether they participate in regulating their expression. 
Transfections directed to assess metals’ effect on promoter activity were not 
performed in chelex-treated media, hence maintaining transfection efficiency as 
high as possible. The use of either internal control plasmid vector (pRL-SV40 or 
pRL-TK) did not influence the tested effect of metals on promoter activity. Metals 
showed neither decrease nor a major increase of synucleins promoter activity as 
demonstrated by Luciferase expression. Results however carried some 
variability, where adding Fe3+ at 10µM concentration resulted in a noteworthy 
increase in α-Syn-2.3/-1.3 activity which is a construct with no MRE’s. Moreover, 
adding Cu2+ at 10µM and 100µM concentration caused considerable increase in 
β-Syn-3.7/-0.9 activity (Figure 5.9, A). Bearing in mind that standard error for that 
set of experiments is small, in addition to the presence of MRE’s within this 
fragment β-Syn-3.7/-0.9 as shown using Transcriptional Element Search 
Software (TESS); hence it is be possible that this effect is not false. However, 
this does not imply that MRE’s present in this construct are responsible for the 
observed effect, as this need to be confirmed by other methods such as EMSA 
(Electrophoretic Mobility Sift Assay) which determine the binding of a 
transcription factor to DNA (MRE’s). In addition, copper’s effect on regulating PrP 
expression was mediated by MLS sites that does not bind MTF-1 TF (Varela-
Nallar, Toledo et al. 2006b), hence more work and assessments are required to 
confirm any seen effects. Recently, it has been shown that among β-Syn 
constructs reported throughout the chapter, β-Syn-1.1/-0.6 which possesses the 
highest basal promoter activity and an MRE binding site is up-regulated in 
response to MTF-1 TF (McHugh, Wright et al. 2011).  
 
 
The highest concentration of metals used in Luciferase assays was 100µM which 
was found to cause no damage to the cells. It was reported that 200µM Cu2+ is 
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the concentration required for induction of a stress response in cells (Murata, 
Gong et al. 1999; Varela-Nallar, Toledo et al. 2006b). The results obtained from 
the Luciferase assays are preliminary, since such assessment was not performed 
on a wide range and even on smaller constructs of synuclein promoters. 
Therefore, a link supporting a role for metals (such as Cu2+) in regulating 
synuclein expression was not fully established resembling that of Cu2+ and Prp, 
APP or at the recently identified for β-Syn (McHugh, Wright et al. 2011). 
However, it appears that removing metals from the growth media leads to 
alterations in α-Syn expression (Figure 5.4) separate from being a result of a 
modification in transfection efficiency. In addition to the enhancing effect of Cu2+ 
observed on β-Syn-3.7/-0.9 fragment, it can be assumed that metals participate 
to some level in regulating synuclein expression. The Luciferase assays require 
more optimisation and further repeat, as results obtained had variability and were 
not sufficient to precisely determine metals’ effect on synuclein regulation.  
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Chapter Six: General Discussion 
 
 
Interaction between metals, such as copper and iron, with α-Syn was the main 
focus of this thesis. This interaction was addressed in three main aspects in 
which metals were relevant to the activity, aggregation and expression of α-Syn. 
Metals were required for α-Syn proposed ferrireductase activity and were also 
looked at as enhancers of α-Syn aggregation. In addition, an aspect of exploring 
whether metal exposure enhanced α-Syn expression was addressed.  
 
 
A metal dependent activity for α-Syn was determined which is reducing iron using 
copper as a co-factor. Establishing the ability of α-Syn as ferrireductase required 
a series of complementary experiments. The start point was ITC experiments to 
demonstrate that α-Syn is able to bind iron. ITC experiments were focused on 
iron binding to α-Syn because α-Syn is widely accepted as a copper binding 
protein. In addition, copper binding to α-Syn had previously been shown in our 
laboratory. In order to support the proposed function of α-Syn, it was important to 
show that α-Syn binds iron in the presence of copper. α-Syn was able to bind iron 
when pre-loaded with copper and with only slightly reduced affinity values. Then 
ferrozine based experiments were the second step to demonstrate the reduction 
ability of copper-loaded α-Syn of ferric iron. The core factor of both ITC and 
ferrozine based assay was the use of freshly purified monomeric α-Syn. There is 
no clear link between α-Syn structure and its proposed function. ITC showed that 
α-Syn requires being at monomeric state to bind iron and perform as 
ferrireductase, which means using the protein after purification before it becomes 
precipitated or aggregated. Moreover, the ferrozine based assay depends on 
absorbance measurements, thus any level of aggregation of the protein prior to 
the experiment would interfere with the out coming results. In addition, such 
activity of α-Syn might be disturbed by aggregation as it can cause α-Syn to lose 
its ability to reduce iron. One possibility is that α-Syn aggregation might lead to 
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changes in the binding sites configuration and therefore losing its ability to bind 
metals. As a result, metals will accumulate in the brain and become more 
available for redox activities by producing radicals capable of causing oxidative 
damage in the brain. On the other hand, conditions which cause copper and iron 
to increase or accumulate in the brain, have the potential to induce α-Syn 
aggregation leading to the formation of proteinacious inclusions and iron 
deposits. Hence, it could be speculated that the presence of α-Syn in a non-
aggregated form is important for its activity, especially with the continuous 
implication of α-Syn aggregation in PD pathogenesis.  
 
 
It is well known and reported in the literature that metals, such as copper and 
iron, can induce α-Syn aggregation. This effect was proposed to occur by 
masking negative charges located at the C-terminus. However, it was essential to 
demonstrate this effect of metals on WT α-Syn as an initial step in this project 
using recombinant protein. The second step was then to move on and reveal 
metals’ effect on aggregation of α-Syn mutants which lack the potential metal 
binding sites. Mutants lacking the potential metal binding sites on α-Syn, were 
previously created in our laboratory. In order to study the role of metals in protein 
aggregation it was first necessary to develop a reliable assay to measure α-Syn 
aggregation. Although ThT assay is a considered to be a simple and commonly 
used method to study protein aggregation, the lack of reproducibility experienced 
with the assay did not enable the study to go beyond few repeats. Therefore, it 
was not enough to obtain information about the mechanism of α-Syn aggregation 
since metals, in the resultant experiments, induced the aggregation of both WT 
and mutant α-Syn. This assay uses a Thioflavin-T dye to detect the presence of 
β-sheet rich fibrils. Electron Microscopy (EM) would be a good additional way to 
confirm the proposed fibril formation.  
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Looking into aggregation work, and considering there was only one 
representative experiment of most studied cases it was not enough to draw any 
conclusions about this work. However, the performed experiments showed the 
same effect of metals on both WT α-Syn and its metal binding mutants. Metals 
could be acting by mediating the early stages of aggregation, presumably via 
metal binding to the protein which is the main core of the project. Particularly, 
since α-Syn was demonstrated to bind either copper and iron. Nevertheless, 
deleting amino acids which resemble the metal binding sites did not eliminate the 
proposed effect on aggregation. Metals can still bind to other sites such as the C-
terminus when the N-terminus residues were deleted and thus induce the protein 
aggregation. The aggregation study was further supported using our cell culture 
model (SHSY-5Y cells) and western analysis. Copper caused increased 
formation of high molecular weight aggregates of α-Syn when applied onto 
SHSY-5Y cells over-expressing WT α-Syn. Formation of such aggregates were 
present at less degree with cells over-expressing metal binding mutants. 
However, this is still not enough evidence to propose that induction of 
aggregation of α-Syn, caused by metals, occur via metal binding to the protein. 
Each of ThT and western analysis were used for the same goal. They differ in 
principle but each method identifies a different form of aggregates in response to 
metal exposure. The former looked into β-sheet rich fibrils, while western blotting 
provided information about formation of oligomeric aggregates. Therefore, work 
conducted on assessing α-Syn aggregation can be described as not complete till 
this point. Further ITC experiments are required for both WT α-Syn and its 
mutants to clarify the binding mode of metals to these proteins. More importantly 
is to extend ThT assays with more control over conditions and procedure. The 
reason why this is important is due to variable factors which were observed to 
interfere with assay’s results. Such factors include possible inaccuracy in protein 
concentration coming from the method of measurement as well as 
inconsistencies between protein batches. This is important since protein 
concentration chosen to be used in the assay could affect protein’s structure in 
solution, therefore the way it folds and aggregates. Also, ThT binding to the β-
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sheet structures formed when the protein aggregates is another uncontrollable 
factor that could vitally influence the assay results. Regarding ThT assay, it is 
essential to perform further similar experiments using α-Syn mutant in which both 
N- and C-terminal metal binding sites are deleted. In addition, the use of the cell 
model as described in aggregation chapter resembles the case where high metal 
concentrations are present in the brain such as neurodegenerative diseases 
(Sayre, Moreira et al. 2005). The known threat arising from elevated levels of free 
copper and iron in PD brains is associated with their ability to promote the 
formation of reactive oxygen radicals. Such radicals can oxidize proteins and 
lead to cell death (Sayre, Moreira et al. 2005; Perez and Franz 2010) since 
oxidized proteins may tend to be insoluble and more prone to aggregate. 
 
 
My study also presented an attempt to address whether increased metals 
concentrations would influence the level of α-Syn expression by affecting its 
promoter activity. However, no new findings were produced in this regard as 
results varied between no changes to some increase in the promoter activity. 
Also, our approach was limited to adding metals onto cells and evaluating 
changes in α-Syn promoter activity using Luciferase assay. Luciferase assay 
demonstrated a reproducible and a good tool in assessing promoter’s activity. It 
has been reported to be the method of choice in such studies (Chiba-Falek and 
Nussbaum 2001). It was recently published (McHugh, Wright et al. 2011) that 
MTF-1, metal transcription factor-1, differentially regulated β-Syn expression and 
not α-Syn. Such a result links metals with the regulation of synucleins’ expression 
and confirms the importance of a balanced regulation between both α-Syn and β-
Syn. β-Syn has been suggested to be a negative regulator of α-Syn (Uversky, Li 
et al. 2002b), even though it has not been reported to be present in LBs (Biere, 
Wood et al. 2000). Hence, β-Syn could also represent a therapeutic target in the 
treatment of synucleinopathies. Furthermore, maintaining metals’ levels is crucial 
for normal brain state and targeting metals, by using metal chelators, is one of 
the potential approaches in the treatment of PD (Perez and Franz 2010). Mainly 
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since metals represent a danger when present in increased concentrations due 
to their ability to oxidise proteins. Copper and iron have been given a central role 
in PD and other neurodegenerative diseases as well as throughout this thesis. α-
Syn binding ability to both metals is essential and might hold other roles besides 
the one discussed during this work. Sequestering copper by α-Syn may be a part 
of its natural function as a ferrireductase since α-Syn has no reduction activity in 
the absence of copper. It is well known that α-Syn has a high affinity to copper 
(II) at nanomolar range 1:1 stoichiometry (Davies, Wang et al. 2011; Dudzik, 
Walter et al. 2011). This verifies the use of two equivalents of copper when 
performing ITC experiments, as it will ensure that copper will bind to α-Syn, yet 
not very high copper to cause α-Syn aggregation. Moreover, metals such as 
copper and iron when incubated with α-Syn were shown to form spherical 
oligomers similar to those formed by α-Syn in the absence of metals (Yamin, 
Glaser et al. 2003; Lowe, Pountney et al. 2004). Such spherical oligomers were 
found to be present in α-Syn protofibrils (Ding, Lee et al. 2002). Consequently, 
this is further evidence that metals have the potential to cause α-Syn 
transformation from its native state into oligomeric protofibrils, hence make it 
more prone to aggregate.  
 
 
Metals were suggested to play a role in the normal brain function since they are 
involved in CNS metabolism as catalysts, second messengers and gene 
expression regulators (Minicozzi, Morante et al. 2008). Therefore, metals even at 
normal levels in the brain may influence α-Syn expression. This is important 
because it might represent an additional path by which metals induce α-Syn 
aggregation. Metals could upregulate α-Syn expression; hence increase its 
accumulation and aggregation. Iron amongst other metals involved in 
neurodegenerative disorders is known to be the most abundant metal in the 
human body and brain (Gerlach, Ben-Shachar et al. 1994), and is distributed in 
an uneven pattern among different brain regions with high levels in the SNpc. 
Such high content of iron in the brain is essential during development for 
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functions such as learning and memory. The majority of brain iron is in a bound 
form and very little is found free in the tissues (Gallagher, Finnegan et al. 2011). 
However, it represents a hidden danger as injuries to brain cells can release iron 
ions and cause oxidative stress. Increased iron concentrations can arise from 
defects in iron metabolism, uptake and storage in the brain (Lieu, Heiskala et al. 
2001). Overall, whether metals are related to alterations in α-Syn expression and 
aggregation, the aggregation process itself can lead to changes in tissue 
composition in the brain thus altering the normal functional environment. α-Syn 
aggregation may interrupt its ability to reduce ferric iron (Fe3+) due to possible 
resultant structural changes of the protein. Therefore, this might suspend ferric 
iron reduction and increase its level leading to possible oxidative damage and 
cell death. Such proposal can be proved throughout experimental work covering 
ferrireductase assay with pre-aggregated α-Syn. The function of other 
ferrireductases in the brain might also be affected with elevated iron 
concentrations, while on the other hand any damage to these proteins can cause 
iron levels to increase. It is ferric iron that increases in such cases. 
Ferrireductases are important as they enable the reduction of ferric iron into 
ferrous form that is ready for the cell to use. Iron is delivered to the brain as ferric 
form mediated by transferrin. Along with aggregated α-Syn, iron deposits were 
found in Lewy bodies (LBs) (Dexter, Carayon et al. 1991; Hirsch, Brandel et al. 
1991; Castellani, Siedlak et al. 2000). Histochemical and biochemical studies 
have shown an increase in total iron in brains of PD patients in favour of ferric 
iron (Sofic, Paulus et al. 1991). These findings together prompt thinking that 
metals are tightly linked to α-Syn role in PD and other neurodegenerative 
diseases. Transition metals such as copper, iron and zinc were shown to be 
common dominators in their pathology (Lovell, Robertson et al. 1998; Brown, 
Guantieri et al. 2004) via interacting with protein targets such as amyloid beta in 
AD (Selkoe 2001). This interaction was suggested to be mediated by metal-
protein association leading to protein aggregation or by metal catalyzed protein 
oxidation causing protein damage (Bush 2000).  
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Neurodegenerative diseases represent serious and life-threatening conditions 
and most of them have no cure. Since such diseases cause neuronal death in 
the brain, they affect and worsen many of the body’s activities such as 
movement, balance and talking. Clinical symptoms of PD include resting tremor, 
rigidity and bradykinesia (slowness of movement). With disease progression, 
other L-dopa responsive motor symptoms evolve such as gait and balance 
problems, dysarthria and dysphagia (Muller, Wenning et al. 2001; Hely, Morris et 
al. 2005). With longer disease durations, patients may also develop various non-
motor symptoms such as cognitive decline and dementia, depression and 
psychosis, sleep-wake cycle dysregulation; in addition to pain and sensory 
symptoms (Poewe and Mahlknecht 2009). Treatment usually focuses on 
improving symptoms and life quality of the patients. The most commonly used 
medications are levodopa, dopamine agonists and monoamino oxidase-B 
inhibitors. In addition, treatment also covers physiotherapy and speech and 
language therapy. However, treatment targeting the disease symptoms can not 
cover all needs of late-stage patients. Therefore, slowing disease progression is 
considered to be a main unachieved requirement in the treatment of PD. Findings 
in this thesis demonstrated further evidence that interaction between α-Syn and 
metals has a major implication in PD and cutting off this interaction could 
represent a potential target into developing therapies. Further research of α-Syn 
activity as ferrireductase is important. The future work can determine whether this 
activity could be affected by protein aggregation. In addition, it would be worth to 
assess the aggregation of α-Syn mutant lacking all potential metal binding sites 
(at both N- and C-terminals) to evaluate whether observed aggregation is related 
to metal binding. Capturing images of the end products of aggregation of such 
mutant will be useful, and then compare them with ones of full length α-Syn. 
There is currently no precise knowledge about what regulates synucleins, even in 
disease state. In order to obtain more information about the effect of metals on 
synuclein expression, it would be useful to use PCR to detect changes in α-Syn 
levels in cells upon metals addition. It is also beneficial to investigate other 
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transcription factors related to synuclein expression, since this could represent 
target for disease therapy.  
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